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ABSTRACT 
Results of explanatory research are recorded in the thesis. 
This thesis consists-of two parts: The Part A has one chapter dealing with the positional 
distribution of fatty acids in triacylglycerolsof four seed oils and Part B comprises of six 
chapters depicting the synthesis and characterization of selected fatty acids derivatives 
and their antimicrobial screening. 
PART A ANALYSIS OF SEED FATS/OILS 
Chapter 1: Pancreatic Lipase Hydrolysis of Triacylglycerols 
The fatty acids distribution pattern in triacylglycerols of four seed oils viz. 
Mimusops elengi, Parkinsonia aculeate, Brassica rapa, Brassica oleracea var. botrytis 
were determined using pancreatic lipase hydrolysis method. All the four seed oils contain 
high percentage of unsaturated acids. (M elengi 64.8%, P. aculeate 82.7%, B. rapa 
84.8%, B. oleracea var. botrytis 73.4%). M elengi contains relatively greater amount of 
saturated acids 35.2% than the other seeds. The lipolytic data revealed that linoleic acid 
dominates at 2-position of triacylglycerols of all seed oils. Among four oils, three contain 
erucic acid M elengi (0.3%), B. rapa (17.7%), B. oleracea var. botrytis (1.6%). 
PART B SYNTHESIS OF FATTY ACID DERIVATIVES 
Chapter 2: 3,5-Disubstituted-l^-l,2,4-triazoles* 
Rapid and efficient one-pot condensation reaction of long-chain alkyl and alkenyl 
acid hydrazides la-e and nitriles 2a-c was carried out to afford 3,5-disubstituted-l//-
1,2,4-triazoles (Scheme 1). The compounds 3a-o were characterized on the basis of 
elemental analysis and spectral data. 
*Research paper entitled "Synthesis, antibacterial and antifungal activity of some novel 3,5-
disubstituted-lH-l,2,4-triazoles" is published (S. Sharma, S. Gangal, A. Rauf, M. Zahin, 
Archiv de Pharmazie, 2008, 341,11, 714-720). 
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Scheme 1 Synthesis of3,5-disubstUuted-lH-l,2,4-triazoles 
The triazoles 3a-o were screened for in vitro antibacterial activity against the 
representative panel of two Gram-positive and two Gram-negative bacteria. All the 
synthesized compounds were also tested for their inhibitory action against five strains of 
fungus. The various compounds show potent inhibitory action against test organisms. 
Chapter 3: 2,5-Disubstituted-l^,4-oxadiazoles* 
A series of novel 2,5-disubstituted-l,3,4-oxadiazoles 4a-f have been synthesized 
from long-chain alkanoic and alkenoic acids (Scheme 2). Furthermore, compounds were 
screened for in vitro antibacterial activity against the representative panel of two Gram-
positive and two Gram negative bacteria. All the synthesized compounds were also tested 
for their inhibitory action against five strains of fimgus. The various compounds show 
potent inhibitory action against test organisms. 
•Research paper entitled ''One-pot synthesis, antibacterial and antifungal activities of novel 2,5-
disubstituted-l,3,4-oxadiazoles" is published. (A. Rauf, S. Sharma, S. Gangal, Chin. Chem. 
Lett., 2008, 19, 5-8). 
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Scheme 2 Synthesis of2,5-disubstituted-l,3,4-oxadiazoles. 
Chapter 4: 3,5-Disubstituted-l^,4-oxadiazoIes 
A series of novel 3,5-disubstituted-l,2,4-oxadiazoles have been synthesized from 
alkenyl long-chain esters and acid chlorides. The derivatives of acids have been 
employed for the synthesis under conventional and solvent free microwave conditions. 
The synthesis under different reaction conditions has been discussed. The structures of 
the synthesized compounds were elucidated by IR, ' H N M R , ' ^C N M R , MS data and 
elemental analysis. 
At first one-pot synthesis of 3,5-disubstituted-I,2,4-oxadiazoles 3a-t from easily 
synthesized fatty esters la-d and amidoximes 2a-e was carried out. The one-pot 
procedure provided 3a-t in 50-58% yield (Scheme 3). 
OMe NHj toluene, reflux / ^ 
(9-13h) ^ 
la-d 2a-e 3a-t 
Scheme 3 Synthesis of3,S-dhubstituted-l,2,4-oxadizolesfrom long-chain esters 
and amidoximes 
In another method, I'a-d was added dropwise to a stirred solution of the 
amidoxime 2a-e in pyridine (Scheme 4) and reaction was refluxed for 1-2.5 hours. In 
most of the cases the yield of product was 60-62%. 
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Scheme 4 Synthesis of3,5-disubsiituted-l,2,4-oxadizolesfrom long-chain acid 
chlorides and amidoximes 
To get the pharmacophoric important moiety in higher yields and in shorter reaction time 
the synthesis of 3a- t was carried out under microwave irradiation (Scheme 5). 
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Scheme 5 Synthesis of3,5-disubstituted-l,2,4-oxadiazoles under microwave 
irradiation 
C h a p t e r 5 : 2-Substituted-benzimidazoles, te t rahydrobenzimidazoles a n d 
imidazoles* 
A series of novel 2-substituted benzimidazoles 4a-p and imidazoles 4q-t have been 
synthesized from long-chain alkenoic acids. The reactions occurred under relatively mild 
conditions and afforded the desired product in good yields (Scheme 6-8). The structures of 
these compounds have been elucidated by elemental and spectral (IR, ' H N M R , ' ^ C N M R , 
Mass) analyses. 
•Research paper entitled "•Convenient one-pot synthesis of novel 2-substituted benzimidazoles, 
tetrahydrobenzimidazoles and imidazoles and evaluation of their in vitro antibacterial and 
antifungal activities" is in press. (S. Sharma, S. Gangal, A. Rauf, Eur. J. Med. Chem., (2008) 
doi:10.1016/j.ejmech.2008.03.026. 
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Furthermore, compounds were screened for in vitro antibacterial activity against the 
representative panel of two Gram-positive and two Gram-negative bacteria. All the 
synthesized compounds were also tested for their inhibitory action against five strains of 
fungus. The various compounds show potent inhibitory action against test organisms. 
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Scheme 6 Synthesis of 2-substituted-benzimidazoles 
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Chapter 6: 3,5,6-Trisubstituted-l,2,4-triazines* 
The use of microwave irradiation has been an established tool in organic synthesis 
for achieving better selectivity, rate enhancement and reduction of thermally degradative 
by product. Rapid and efficient solvent-free synthesis of 3,5,6-trisubstituted-l,2,4-
triazines 3a-l from fatty acid hydrazides la-f under microwave irradiation is described 
(Scheme 9). The one-pot synthesis on solid inorganic support provides the products in 
good yields. The newly synthesized compounds were screened for antimicrobial activity. 
The structural features of the synthesized 1,2,4-triazines were characterized by IR, ' H 
NMR, '^ C NMR, mass and elemental analysis. 
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Scheme 9 Synthesis of3,5,6-trisubstituted-l,2,4-triaunes 
3 
•Research paper entitled "Microwave assisted efficient one-pot synthesis of 3,S,6-trisubstituted-
1,2,4-triaunes from fatty acid hydrazides under solvent-free conditions and their antimicrobial 
activity" is published. (A. Rauf, S. Sharma, S. Gangal, ARKIVOC 2007, (xvi) 137-147). 
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Chapter 7: Isoxazoles and triazoies 
The efficient cycloaddition reactions were carried out to afford the novel 3,5-
disubstituted-dihydroisoxazoles, isoxazoles, triazole and triazolo-tetrazole from methyl 
undec-10-enoate 1 and methyl undec-10-ynoate 4. In this chapter, the straightforward 
synthesis of 3,5-disubstituted-4,5-dihydroisoxazoles 3a-c and bis-4,5-dihydroisoxazole 
3d possessing ester moiety by one-pot process is reported. The reactions occurred under 
relatively mild conditions and afforded the desired product in good yields. 
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' Sc "R 
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Scheme 10 Synthesis of3,5-disubstituted-dihydroisoxazoles and bis-isoxazole 
In similar reactions using methyl undec-10-ynoate (4) and Cerium (IV) 
ammonium nitrate in various acetones, the corresponding isoxazoles 5a-c and bis-
isoxazoles 5d were obtained (Scheme 11). 
0 
Scheme 11 Synthesis of3,5-disubstituted-isoxazoles and bis-isoxazole 
ABSTRACT 
The cycloaddition of azidoacetonitrile (6) with terminal alkyne gave 
corresponding triazole (7) which on further reaction with sodium azide and ammonium 
chloride in DMF gave tetrazole (8) (Scheme 12). 
HCiv^ 
"CH3 + N3CH2CN 
Scheme 12 Synthesis ofl-Cyanomethyl-4-(carbomethoxyoctyl))-l,2,3-triazole and 
fl-(lH-Tetrazol-S-yl-methyl)-4-carbonteihoxyoctylJ-(l,2,3)-iriazole 
One more representative of 1,2,3-triazole (10) was synthesized in appreciable 
yield by utilizing dipolarophile (4), benzyl chloride (9), sodium azide in DMF (Scheme 
13). 
HC.&. CH 
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10 
Scheme 13 Synthesis ofl-Benzyl-4-(carbomethoxyoctyi)-l,2,3-triazole 
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Introduction 
Oils and fats, main constituent of lipids, are significant physiologically as well as 
chemically. The calorie density for dietary fats is more than twice than that of proteins 
and carbohydrates. Fatty acids are essential dietary requirements for their link with the 
prostaglandins and their involvement in cell membrane formation. Recently the 
importance of oils and fats is continuously increasing in biochemical and biomedical 
sciences. 
All multi-cellular organisms, use chemical messengers to send information 
betv^ e^en organelles and into other cells and as relatively small hydrophobic molecules, 
lipids are excellent candidates for signaling purposes. The fatty acid constituents have 
well-defined structural features, such as cw-double bonds in particular positions, which 
can carry information by binding selectively to specific receptors. In esterified form, they 
can infiltrate membranes or be translocated across them to carry signals to other cells. 
During transport, they are usually bound to proteins so their effective solution 
concentrations are very low, and they can be considered to be inactive until they reach the 
site of action and encounter the appropriate receptor. 
India, predomiilantly an agricultural country flourishes in forest flora. There is a 
wide potential of agrichemicals derived from minor seed oils plentiful in specific kind of 
fat);y acids. In recent years the deployment of fatty acids as agrichemicals finds their way 
into a variety of industrial uses and most of them primarily through derivatization. 
The mounting costs of petrochemicals have attracted the attention of chemists to 
find new sources of oils containing unusual fatty acids and also to modify fatty acids for 
promising industrial uses. In nature large numbers of fatty acids are widely distributed in 
plants. The fatty acids with unusual structural features in seed oils have manifold 
industrial significance as they are utilized in dispersants, cosmetics, lubricants, protective 
coatings, plastics, urethane derivatives surfactants, varieties of synthetic intermediates, 
stabilizers in plastic formulations and in synthesis of other long-chain compounds. Such 
fatty acids with unusual structures are vital for the collection of oleochemicals (fat 
derived chemicals). The ethoxylated hydroxyl fatty acids-containing seed oils are used as 
stabilizers of hydrophobic substances in industries such as perfumes and cosmetics. The 
polyethoxylated hydroxy fatty acids are non-ionic surfactants and are included in the 
formulations for cleaning clothes, dishes, hand surfaces and metals, textile processing. 
The hydroxyolefmic fatty acids are known to occur in a number of seed oils and are 
highly important to the chemical and pharmaceutical industry. The importance of organic 
acids such as sorbic, cinnamic, ricinoleic, myristic as antimicrobial drugs is well 
established in pharmaceutical industry. 
Thus fatty acids have increasingly being found utilizable as explicit raw material 
for the upcoming chemical industry. They have also found applications in metal 
catalyzed metathesis and ring-opening reactions, polymerization, oxidation etc. Fatty 
esters are used as antifogging agents and found very useful for plasticizer in 
biodegradables plastic materials and also known to be good alternative fuel (biodiesel). 
Fatty acid monoesters are widely used in industry due to their lubricating and softening 
agents. Some fatty esters are found very effective for the treatment of dermatitis, 
cardiovascular, hepatic and renal diseases. 
The heterocyclic derivatives of fatty acids account for utility in variety of 
applications. The fatty acid derivatives are used in various industrial applications such as 
coatings, cosmetics, perfumes, pharmaceuticals, pesticides, insecticides and polymers. 
The presences of heterocyclic rings in fatty acids are rare in nature. 
For more than a century, heterocycles have constituted one of the largest areas of 
research in organic chemistry. They have contributed to the development of society from 
a biological and industrial point of view as well as to the understanding of life processes 
and to the efforts to improve the quality of life. Heterocycles play an important role in 
biochemical processes because the side groups of the most typical and essential 
constituents of living cells, DNA and RNA, are based on aromatic heterocycles. The 
remarkable ability of heterocyclic to serve both as biomimetics and active 
pharmacophores has largely contributed to their unique value as traditional key elements 
of numerous drugs. Among the approximately 20 million chemical compounds identified 
by the end of the second millennium, more than two-thirds are fully or partially aromatic, 
and approximately half are heterocyclic. The heterocycles are present in all kinds of 
organic compounds such as in biology, pharmacology, optics, electronics, material 
sciences, and so on. 
A number of cyclic derivatives of fatty acids containing nitrogen, sulfur, oxygen 
and phosphorus as heteroatoms have revealed fungi-static and bactericidal agents. Such 
oleochemicals are innate component in the manufacture of fungicides, insecticides, 
pharmaceuticals, lubricants, additives, greases, cosmetics etc. The fatty epoxy esters are 
utilized in the synthesis of PVC plasticizers and stabilizers. 
Fatty acids are privileged class of organic chemistry having distinctive feature of 
undergoing classical and non-classical reactions. Fatty acids have two dynamic sites 
which can be employed in chemical reactions for the synthesis of derivatives displaying 
diverse activities: (i) double bond (terminal and internal) (ii) carboxylic acid end. Along 
with classical reactions of organic chemistry, fatty acids also exhibited as potential 
substrate to undergo microwave assisted reactions. Microwave assisted organic synthesis 
(MAOS) continues to affect synthetic chemistry significantly by enabling rapid, 
reproducible and scalable chemistry development. Microwave heating has attracted the 
attention of investigators in that it makes it possible to shorten the length of reactions 
siignificantly, to increase their selectivity, and to increase the product yields, which is 
particularly important in the case of high-temperature processes that take a long time. 
One of the most fascinating aspects of olefinic long-chain carboxylic acids is 
conversion of double bond to triple bond which served as potential dipolarophile for the 
synthesis of diverse heterocycles. 
The development of synthetic routes for the synthesis of long-alkyi and alkenyl chain 
heyerocyclic moieties is highly desirable and advantageous as very few papers supports 
the synthesis of heterocyclic derived from fatty acids. These aspects created an active 
interest to undertake the present work which comprises of two parts: 
(i) analysis of seed oils especially to investigate the positional distribution of fatty 
acids in neutral triacylglycerols. 
(ii) to synthesize the fatty acid derivatives having biological importance. 
IV 

Cftapter 1 
Pancreatic Cipase fiydroCysis 
of triacyfgCyceroCs 
Pancreatic lipase hydrolysis of triacylglycerols 
1.1 Theoretical 
The seed oils consist predominantly of triacylglycerols (TAGs), which are esters 
of fatty acids with glycerol. Triacylglycerols are complex molecules present in all oils 
and fats. The wide variety of fatty acids that may attach to the glycerol backbone 
generates the large diversity of TAGs that share very similar physiochemical properties, 
thus making their separation and analysis difficult. Therefore one must employ a 
consecutive series of separation and characterization techniques to define TAGs 
composition of fat. 
TAGs on hydrolysis produce fatty acids. The common fatty acids of TAGs 
contain even number of carbon atoms (4-24) in straight chain with a terminal carboxyl 
group; which may be fiilly saturated (SFA) or unsaturated (UFA). In the diene and triene 
derivatives, respectively, the double bonds are interrupted by a methylene group. Of the 
most commonly occurring acids are: lauric (€120), myristic (Ci4:o), palmitic (Cieo), 
palmitoleic (C16.1), stearic (Ci8;o), oleic (Cjg 0, linoleic (C18.2), linolenic (Cig;3) and erucic 
(C22:i) acid. Smith' classified these ubiquitous compounds as usual fatty acids. 
Consequently, all fatty acids with different structure features are considered as unusual. 
Smith' has classified fatty acids into three major groups: 
(i) usual 
(ii) unusual non-oxygenated 
(iii) unusual oxygenated 
In nature large number of other fatty acids has been discovered possessing 
unusual structural features. They include allenic, cyclopropane, cyclopropene, 
cyclpentene, furan, hydroxyl, epoxy, keto groups^ " .^ 
For the chemist, the isolation and elucidation of rare fatty acid structures has 
always been a challenge, and nowadays the number of known fatty acids exceeds 
Pancreatic lipase hydrolysis of triacylglycerols 
thousands'". The interest in fatty acids with unusual structure features and in oils, that can 
provide a high concentration of a single fatty acid, has increased as they can be of high 
value for the chemical and pharmaceutical industry'°''^. Global screening programs for 
the search of new plant oils as renewable sources have been initiated. This is also a 
preventive research as it is estimated that there is approximately only 50-100 years 
supply left in readily accessible fossil oil resources, which are actually the most important 
basis of the petrochemical industry. In contrast to fossil oil resources, the vegetable oils 
are renewable and have the ecological advantage to be C02-neutral'^. The complexity in 
the analysis of fatty acids has created many problems in their detection, isolation and 
structure determination. This picture was changed with the advances in the methodology 
of lipid analysis. The chromatographic techniques used in the analysis of oils are: thin 
layer chromatography (TLC), high performance liquid chromatography (HPLC), column 
chromatography, liquid column chromatography'''', partition adsorption, ion-exchange 
and complexation chromatography and gas liquid chromatography (GLC) . Gas 
chromatography has been employed successfiilly in the isolation of pure fractions from 
complex mixtures. Although gas chromatography is the dominant technique for the fatty 
acid analysis, high-performance liquid chromatography (HPLC)^''^° has expanded 
dramatically into almost every area of chemical and biochemical research as well as food 
analysis^'. Likewise, various spectroscopic techniques, such as UV, IR, high resolution 
'H NMR, '^C NMR^^ liquid chromatography mass spectrometry (LCMS)" gas 
chromatography mass spectrometry (GCMS)^ ''"^ ^ and chemical ionization mass 
spectrometry (CIMS)^ ^ offer remarkable solutions and unexpected advantages for the 
analysis of unknown fatty compounds. 
The wealthy vegetation growth of India is abundant in medicinally important seed 
oils. To study the biological or medicinal aspects of seed oils it is indispensable to study 
the chemistry of that particular oil as the two branches are interrelated. The fatty acids 
constitute the TAGs. The chemistry of oils and fats is basically the chemistry of 
2 
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constituent fatty acids present in triacylglycerols (TAGs). The most important aspect of 
lipid analysis is to study the positional distribution of fatty acids in TAGs. It is of great 
importance to know the composition at all the three positions (i.e. sn-\, sn-2 and sn-2)) of 
TAGs. 
It is well established through literature that various methods like crystallization, 
Grignard procedure, enzymatic hydrolysis etc. are used for stereospecific TAGs analysis 
of fatty acids. Ester bonds to all three positions of the glycerol molecule are so similar in 
chemical reactivity that there is no simple chemical procedure for hydrolyzing one or 
other of them selectively. Most of the living organisms have developed lipolytic enzyme 
systems that are able to distinguish between various positions of glycerol or certain type 
of bonds in specific lipids and in many cases these enzymes can be isolated and used in 
simple in vitro incubations as an aid in structural analyses of lipids. Hence enzymatic 
hydrolysis is one of the most widely used methods. Enzymes used for this purpose are 
lipases. Lipases are enzymes that catalyze the hydrolysis of acylglycerols. In addition 
lipases are widely used in a variety of other reactions that include esterifications of acids 
with alcohols, oils and fats transesterifications as well as reactions leading to the 
synthesis of products such as sugars, esters, fatty amides etc. Lipases are ubiquitous in 
nature, being present in the animal, microbial and plant kingdoms. Enzymology of these 
lipases is well documented •^ '. Several scientists and companies have studied enzymatic 
hydrolysis extensively*^''''. Besides these, there are various other reports on enzymatic 
hydrolysis'**-''. 
One of the most important aspects of lipase mediated hydrolysis is that it requires 
a mild reaction condition which makes it a superior method over other classical processes 
which involves high temperature and pressure resulting in high energy consumption. 
Lipase catalyzed hydrolysis reactions require less energy causing essentially no thermal 
damage to reactants and products for example in color and formation of oxidation 
products. Also, certain important functionalities of fatty acids such as double bond 
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remains protected. Literature reports^* on the enzymatic fat-splitting show that rate of 
lipolysis reaction to be optimal in a pH range of 4.8-7.2 at 37°C. Therefore, despite 
relatively high price of the bio-catalysts, lipase catalyzed hydrolysis could be 
economically attractive for the preparation of thermally sensitive products of good 
commercial values, such as polyunsaturated fatty acid (PUFA), hydroxyl fatty acids etc. 
The lipases are position specific and their specifications have classically been 
divided into five major types: 
(i) lipid class 
(ii) positional 
(iii) fatty acids 
(iv) stereochemical 
(v) combinations 
Lipases obtained from natural sources can be positionally non-specific or display 
one of the two kinds of positional specificity sn-\,2) specific or sn-1 specific. Non-
specific lipases hydrolyze all three ester bonds of TAGs equally well. 
None the less, from time to time various enzymes have been studied for 
determining the composition of position sn-\, sn-2 and sn-3 yet no lipolytic enzyme has 
been isolated that is capable of distinguishing position between 1 and 3 of triacyl-5rt-
glycerols. 
A lipase that is completely specific for the primary ester bonds of TAGs is 
present in crude pig (and other animal) pancreas extract which is a sn-2 specific enzyme. 
0 
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Pig pancreatin, a powder obtained by dehydrating pig pancreas with acetone and 
diethylether, is the most widely used source of the enzyme, it is stable for long period of 
time and is available commercially. A series of animals and vegetable fats has been 
subjected to hydrolysis with pancreatic lipase. A considerable amount of data has been 
obtained by means of pancreatic lipase hydrolysis on the composition of position sn-2 of 
the triacyl-jn-glycerols of seed oils, and this has been enhanced in recent years by stereo-
specific analysis. These investigations have shown that all straight-chain saturated fatty 
acids of whatever chain lengths are hydrolyzed from the primary positions at the same 
rate, but the ester bonds of long-chain PUFA are hydrolyzed more slowly, possibly as a 
result of steric hindrance caused by the proximity of functional groups to the ester bonds. 
It is well established from studies involving with pancreatic lipase, position sn-2 
of the TAGs of seed oils is abundant in the PUFA (specifically linoleic and linolenic 
acids), while saturated fatty acids are concentrated in the primary positions and 
monoenoic acids are relatively evenly distributed^ .^ 
Besides being used for analyzing the distribution pattern of TAGs in seed oils 
pancreatic lipase is also used for the detection of adulteration in fats, preparation of 
TAGs with desired composition (structured lipids), and preparation of interesterified 
blends and in lipid bioconversions. 
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1.2 Pancreatic Lipase Hydrolysis Four Selected Triacylglycerols 
The genus Mimusops belongs to the family Sapotaceae and comprises 30 species 
including M. elengi L. It is cultivated in North and Peninsular India and Andaman 
Islands. It is grown as an avenue tree in many parts of India. M elengi is an ornamental 
tree with sweet-scented flowers. Seeds are 1-2 per fruit, ovoid, compressed, greyish 
brown and shiny*'. The bark and fruit of this plant are used in the treatment of diarrhea 
and dysentery, and a decoction of the bark is used as a gargle*°. The pounded seeds 
pasted with oil are used for the treatment of obstinate constipation. Pillow stuffing made 
from the dried flowers induces nasal discharge and relieves headache*''. Tree is an 
evergreen tree with sweet scented flowers having ancient glamour. Garlands made of its 
flowers are ever in good demand due to its long lasting scent. Its bark is used as a gargle 
for odontopathy, ulitis and ulemorrhagia. Tender stems are used as tooth brushes. It is 
also useful in urethrorrhoea, cystorrhoea, diarrhoea and dysentery. Flowers are used for 
preparing a lotion for wounds and ulcers. Powder of dried flowers is a brain tonic and is 
useful as a snuff to relieve cephalgia. Unripe fruit is used as a masticatory and will help 
to fix loose teeth. Seeds are used for preparing suppositories in cases of constipation 
Q I 
especially in children . The bark and seed coat are used for strengthening the gum and 
enter into the composition of various herbal tooth powders, under the name of 
"Vajradanti", where they may be used along with tannin-containing substances like 
catechu (Acacia catechu), pomegranate (Punica granatum) bark, etc. The bark is used as 
snuff for high fever accompanied by pains in various parts of the body. The flowers are 
considered expectorant and smoked in asthma. A lotion prepared from unripe fruits and 
flowers is used for smearing on sores and wounds. In Ayurveda, the important 
preparation of Mimusops is "Bakuladya Taila", applied on gum and teeth for 
strengthening them, whereas in Unani system, the bark is used for the diseases of 
genitourinary system of males . M. elengi has recorded highly significant antifungal 
J3 activity against Fusarium proliferatum . 
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In order to search for antimicrobial phytochemicals, two antibacterial compounds 
were detected from the seeds of M elengi Linn. After characterization, the compounds 
were identified as 2,3-dihyro-3,3'4'5,7- pentahydroxyflavone and 3,3',4',5,7 
pentahydroxyflavone. The compounds showed strong inhibitory activity against Gram 
positive and Gram negative bacteria*''. 
Parkinsonia aculeata belongs to Leguminosae. It is reported to be highly 
medicinal, whole plant is used as antipyretic, and leaves are considered to be diaphoretic 
and abortifacient*^. The leaves, stems and flowers contain alkaloids and steroids. The 
seeds are edible and contain albumin and glutelin as principal proteins. Seeds are 
Qz on 
mucilaginous and reported to contain golden colored fatty oil and neutral sugars . Leite 
et al. investigated the antidiabetic effect of water soluble fraction made of aerial parts 
(leaves and flowers) of the P. aculeata in alloxan diabetic rats. 
Brassica rapa belongs to family Brassicaceae. Leaves are used raw or 
cooked*'''°. The cooked leaves make an acceptable vegetable, though they are coarser 
than the related cabbage. They are more often used as a spring greens, sowing the plants 
in the autumn and allowing them to overwinter. Young leaves can also be added in small 
quantities to salads, they have a slightly hot cabbage-like flavor and some people find 
them indigestible. A nutritional analysis is available. Often used as a cooked vegetable, 
the young roots can also be grated and eaten in salads, they have a slightly hot flavor like 
a mild radish. A nutritional analysis is available^'. A decoction of the leaves or stems is 
used in the treatment of cancer^'. The powdered seed is said to be a folk remedy for 
cancer^'. The root when boiled with lard is used for breast tumours^^. A salve derived 
from the flowers is said to help skin cancer . The crushed ripe seeds are used as a 
poultice on burns'^. B. rapa root peelings contain a natural insecticide. The chopped roots 
can be brewed into a tea with flaked soap, this is then strained before use. It is effective 
against aphids, red spider mites and flies'^ 
Pancreatic lipase hydrolysis of triacylglycerols 
Thiols, polysulfides, isothiocyanates, nitriles, carbonyl compounds and terepenes 
were isolated from the head space of Brassica oleracea var. botrytis. Dimethyltrisulfide, 
prop-2-enyHsothiocyanate, pentanal, hexanal, heptanal, pentanol and octanol were 
identified. The oil is suitable for domestic consumption '^*. 
1.3 Results and discussion 
The oils from all the seed samples were isolated using Soxhlet apparatus and their 
analytical values are given in Table 1.1. Neutral TAGs were then isolated from the seed 
oils using column chromatographic technique. The isolated TAGs was transesterified for 
fatty acid methyl esters (FAMEs) analysis. The TAGs composition based on lipolytic 
data, which includes the molar percent of different acids at 2-position along with 
enrichment factor is given in Table 1.2. The total TAGs composition is given in Table 
1.3. 
Table 1.1 Analytical data of seed oils 
S.No. Source Oil content (%) Properties 
IV^ SV^ ^ Ref. Index' 
n 30 
Mimusops elengi 32.34 
(Sapotaceae) 
Parkinsonia aculeata 29.13 
(Leguminosae) 
Brassica rapa 38.57 
(Brassicaceae) 
Brassica oleracea 41.23 
var. botrytis 
(Brassicaceae) 
87.8 221.7 1.4829 
120.8 120.8 1.4845 
107.9 210.1 1.4826 
102.8 216.8 1.4833 
a- Iodine value b= Saponification value c= Refractive index 
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The neutral TAGs of M. elengi composed of oleic (27.9%), linoleic (35.7%), 
linolenic (0.9%) and erucic (0.3%) acids as unsaturated components. The myristic 
(8.1%), palmitic (10.2%) and stearic (16.9%) acids are also present in appreciable 
amount. The combined percentage of unsaturated acids (64.8%) shows that degree of 
unsaturation is quite higher in M elengi neutral TAGs with linoleic acid as major 
component. The fatty acids present at 2-position are myristic (4.2%), palmitic (7.3%), 
stearic (11.1%), oleic (33.7%), linoleic (40.9%), linolenic (2.2%) and erucic (0.6%). The 
composition at 1,3-position is depicted in Table 1.2. It was linoleic (33.1%) acid, which 
dominates at 1,3-position followed by oleic acid (25%). Another major component 
present at 1,3-position was stearic acid (19.8%). Compositions of other fatty acids present 
in TAGs, 2-position and 1,3-position are listed in Table 1.2. Molar present (M) of 
linolenic acid at 2-position in M. elengi is listed in Table 1.2 was greater as compared to 
other acids i.e. myristic, palmitic, stearic, oleic, linoleic, erucic acids. The enrichment 
factor (E, Table 1.2) shows that it was maximum for linolenic acid (E value 2.44). Table 
1.3 is further strengthening the calculated composition of saturated and unsaturated 
acylglycerols of M elengi. It was triunsaturated acylglycerols that were found in majority 
40.44%. 
The fatty acid profile of P. aculeate (Table 1.2) revealed by GLC indicated that 
the oil has requisite amount of unsaturated fatty acids (74.1%) with linoleic acid (40.5%) 
as major component. The other unsaturated acid present in major quantity was oleic acid 
(33.6%). Among saturated acids, stearic acid dominates (11.2%) over myristic (0.8%) 
and palmitic acid (5.3%). The lipolytic data oiP. aculeata (Table 1.2) clearly indicates 
that within the limits of experimental error oleic (Cigi), linoleic (Cig:2) and linolenic 
(C183) were preferentially acylated at 2-position of glycerol. Linoleic and linolenic acids 
were also present at 1,3-position in major amount. Major components at 2-position 
(43.7%) as well as 1,3-position (38.9%) was linoleic. The molar percentage at 2-position 
was maximum for oleic acid (34.22). The enrichment factor E was within the reported 
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range and Table 1.2 shows that it was maximum for erucic acid (E value 1.25). Table 1.3 
indicates that monosaturated acylglycerols (GSU2) were found in majority, 66.34 %. 
10 
Pancreatic lipase hydrolysis of triacylglycerols 
s. 
1. 
2. 
3. 
4. 
1,3-
M 
Table 1.2 Fatty acid composition based on 
No. Source 
M. elengi 
TAG' 
2-MAG'' 
1,3-position 
E^  
M" 
P. aculeata 
TAG' 
2-MAG'' 
1,3-position 
E^  
M'' 
B. rapa 
TAG' 
2-MAG'' 
1,3-position 
E^  
M'' 
B. oleracea 
var. botrytis 
TAG' 
2-MAG'' 
1,3-position 
E^  
M'' 
14:0 
8.1 
4.2 
10.1 
0.51 
17.28 
0.8 
0.6 
0.9 
0.75 
25 
0.6 
0.3 
0.75 
0.5 
16.66 
0.5 
0.3 
0.6 
0.6 
20 
position = OxTAG) - ('2-MAG) 
2 
= mole percent ofacid in 2-MAG 
3 X mole percent of same in TAG 
Methyl Ester Compositior 
16:0 
10.2 
7.3 
11.6 
0.71 
23.85 
5.3 
2.3 
6.8 
0.43 
14.46 
7.9 
4.6 
9.6 
0.58 
19.41 
10.9 
6.3 
13.2 
0.58 
19.26 
x l O O 
18:0 
16.9 
11.1 
19.8 
0.65 
20.19 
11.2 
8.1 
12.8 
0.72 
24.11 
6.7 
3.8 
8.2 
0.57 
18.90 
15.2 
9.6 
18 
0.63 
21.05 
18:1 
27.9 
33.7 
25 
1.21 
40.26 
33.6 
34.5 
33.2 
1.03 
34.22 
26.9 
30.1 
25.3 
1.11 
37.29 
33.8 
38.4 
31.5 
1.13 
37.86 
lipolytic data 
I by GLC 
18:2 
35.7 
40.9 
33.1 
1.14 
38.18 
40.5 
43.7 
38.9 
1.07 
30.89 
39.7 
41.1 
39 
1.04 
34.51 
37.7 
42.5 
35.3 
1.12 
37.57 
as mol' 
18:3 
0.9 
2.2 
0.25 
2.44 
81.48 
8.6 
10.8 
7.5 
1.25 
26.54 
0.5 
1.3 
o.\ 
2.6 
86.66 
0.3 
0.6 
0.2 
2 
66.66 
'/o 
22:1 
0.3 
0.6 
0.15 
2 
66.66 
— 
— 
— 
17.7 
18.8 
17.2 
1.06 
35.40 
1.6 
2.3 
1.3 
1.44 
47.91 
E = mole percent acid at 2-position of TAG 
mole percent of same in total TAG 
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The fatty acid composition of neutral TAGs of B. rapa as by GLC analysis 
indicated that the oil was composed of myristic (0.6%), palmitic (7.9%), stearic (6.7%), 
oleic (26.9%), linoleic (39.7%), linolenic (0.5%), erucic acid (17.7%). The GLC analysis 
of lipolytic product of B. rapa (Table 1.2) shows that linoleic acid dominates at 2-
position (41.1%) and 1,3-position (39%). Among saturated acids the major component at 
2-position were myristic (0.3%), palmitic (4.6%)) and stearic (3.8%) acids. The percent 
composition of fatty acids at 1,3-position were myristic (0.75%)), palmitic (9.6%)), stearic 
(8.2%), oleic (25.3%), linoleic (39%), linolenic (0.1%), erucic acid (17.2%). E values of 
B. rapa for different acids (Table 1.2) show that linolenic acid has the highest enrichment 
factor value (E value 2.6). M value was found maximum for linolenic acid (86.66). TAGs 
composition of B. rapa (Table 1.3) indicated that triunsaturated acylglycerols (GU3) 
were the most abundant (72.34 %) in the seed oil. 
Table 1.3 Triacylglycerol composition* of seed oils 
S.No. Source 
M elengi 
Trisaturated Disaturated Monosaturated Triunsaturated 
acylglycerols acylglycerols acylglycerols acylglycerols 
(GS3) (GS2U) (GSU2) (GU3) 
6.18 19.25 34.13 40.44 
2. P. aculeate 0.03 1.40 66.34 33.23 
3. B. rapa 0.51 1.61 25.54 72.34 
4. B. oleracea 
var. botrytis 
1.3 19.25 33.64 56.46 
Composition of minor TAGs are not included 
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GLC analysis of methyl esters of neutral TAG of B. oleracea var. botrytis showed that 
linoieic acid (37.7%) was present in maximum amount. Other than iinoleic acid, the oil composed 
of myristic (0.5%), palmitic (10.9%), stearic (15.2%), oleic (33.8%), linolenic (0.3%), erucic acid 
(1.6%). The GLC analysis of 2-MG of 5. oleracea var. botrytis showed that at 2-position was 
predominantly occupied by linoieic acid (42.5%). Composition of other components present at 2-
MG are myristic (0.3%), palmitic (6.3%), stearic (9.6%), oleic (38.4%), linoieic (42.5%), 
linolenic (0.6%>) and erucic acid (2.3%). The fatty acid present in maximum amount at 1,3-
position is linoieic (35.3%»). The molar percent of linolenic acid (66.66) was found to be 
maximum at 2-position. E factor was found to be maximum for erucic acid (E value 1.44). 
According to data given in Table 1.3, the molar percent of triunsaturated acylglyerols (GU3) was 
quite high 56.46 % with a very little amount of trisaturated acylglycerols (GS3,1.3 %>). 
According to Gunstone et al.^^, among the unsaturated C18 acids, oleic and 
linolenic acids show a slight preference for the 1-position while linoieic acid shows 
preference for the 2-position. The results in this chapter though not entirely but closely 
consent with this theory. Under the mentioned conditions of lipase digestion, because of 
incredibly fast hydrolysis and a prompt handling of the products no substantial acyl 
shifting took place in either mono-or diacylglycerols. From the present work it is 
concluded that the order of major unsaturated acids for 2-position in M. elengi is C^a > 
C181 > Cisoand in P. aculeata the order is Ci8;2> Cigi > Ciss- In B. rapa it was linolenic 
acid which was acylated at 2-position preferentially and the order of preference in this oil 
is Ci8:3 > Ci8:2 > C22:i whercas in B. oleracea var. botrytis the order of preference is C18:2 
> C18: I > C|8:0. 
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1.4 Experimental 
Dried samples of seeds were purchased from Pratap Nursery, Dehradun (INDIA). 
Analytical grades reagents and adsorbent (silica gel G) used for thin layer 
chromatography (TLC) and column chromatography (silica gel, 60-120 mesh) were 
Merck Ltd., Mumbai (INDIA). Distilled solvents were used throughout. Porcine 
pancreatic lipase was purchased from Sigma Chemicals Co. Centrifugation was carried 
out at 2000rpm on R-23, Remi centrifuge. 
Lipid Extraction 
Cleaned and dried samples of seeds were ground in a disintegrator. The powered seeds 
were extracted repeatedly with light petroleum ether (40-60 "C) in a Soxhlet apparatus. 
The extracted oils were dried over anhydrous Na2S04. The solvent was removed in 
vacuum. The analytical values of the oils and seeds were determined according to the 
AOCS methods^^ 
Purification of Triacylglycerols (TAGs) by Column Chromatography 
The TAGs were purified from the total lipid by column chromatography using silica gel 
(mesh 60-120). Activated silica gel (30g per Ig of the sample) was packed in dry 
petroleum ether (40-60 °C) and total lipid was added to it. The column was washed with 
200 ml of petroleum-ether/ Et20 (95:5, v/v) to afford TAGs fractions. These fractions 
were further concentrated in vacuum and the purity was checked by TLC. The purified 
TAGs showed only one spot indicating that these preparations contained no detectable 
lipid contaminants. 
Thin Layer Chromatograplty (TLC) 
Analytical TLC was performed on glass plates coated with 0.25 mm or I mm thick layer 
of silica gel G with 20% diethyl ether in n-hexane as developing solvent. The plates were 
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rendered visual by spraying with 20% aqueous solution of perchloric acid and heating in 
an oven (110 °C) for lOmin. DNPH (2,4-nitrophenyl hydrazinef'', picric acid^^  and 
Halphen's tests^^ were then performed to check for any unusual moiety viz. keto, epoxy 
or cyclopropene moiety respectively. 
Deacylation ofTAGs by pancreatic Lipase 
Lipase hydrolysis of the neutral TAGs was almost same as that described by Luddy et 
To the lipid sample (100 mg in a screw-capped tube) were added tris-
hydroxymethylaminomethane buffer (3 ml, 1 mol/ L) at pH 8, pig pancreatin lipase (20 
mg) was added and shaken vigorously on a magnetic stirrer. Bile salt solution (0.5 ml, 
Igm/L) and CaCb solution (0.2 ml, 2.2%, w/v) were added. The reaction mixture was 
kept at 40±0.5 °C for 3 minute while shaking. The content was cooled under running tap 
water and hydrochloric acid (1ml, 6moI/L) was then added to terminate the reaction. 
Reaction mixture was immediately extracted with diethyl-ether (3x10 ml). Combined 
ethereal solution was washed with water and dried over anhydrous Na2S04. The dried 
samples were immediately fractionated by boric acid TLC. 
Isolation of2-MAGs by boric acid TLC 
The boric acid TLC plates were prepared by mixing silica gel in saturated solution of 
boric acid and then spreading the slurry of silica gel on glass plates. 
The lipolytic products (dissolved in 1ml of chloroform) were applied on 
preparative boric acid plates in streaks. The chromatoplates were developed with a 
mixture of petroleum ether-diethyl ether- acetic acid (70: 30: 2, v/v). bands were detected 
under UV light after spraying the chromatoplates with 2', 7'- dichlorofluorescein. The 
compounds were separated out into four defined zones in the following order of 
increasing height travelled: monoacylglycerols, diacylglycerols, free fatty acids and 
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unreacted triacylglycerols. The band corresponding to 2-monoacylglycerols (identified 
using standard sample run in the side of the plates) was scrapped off and extracted with 
CH2CI2. The CH2CI2 extract was washed with water and dried over anhydrous Na2S04. 
Esterification of TAGs and2-MAGs 
TAGs and MAGs were refluxed for 1 hour in a large excess of absolute MeOH 
containing 1% H2SO4 (v/v). Resulting mixtures were diluted to the cloud point with 
water, chilled in an ice bath and then extracted repeatedly with Et20. Combined extracts 
were dried over anhydrous Na2S04 and evaporated in vacuum. 
Qualitative analysis of methyl esters 
The quantitative examination of methyl esters was done by comparing the gas 
chromatographs (GLCs) with those of the standard samples. GLC was carried out by 
using Varian Vista 600 instrument equipped with FID (290°C) detector using stainless 
steel column (2M x 2mm i.d.) packed with 15% of OV 275 on chromosorb-W (80-100 
mesh). Separations were carried out at a programmed temperature of 140 ''C-200°C (10 °C 
min"'). The peak areas were determined by Hewlett Packard HP 3396 series-II integrator, 
which was used to determine the composition of esters. The fatty acid esters were 
identified by comparing with those of standard mixed fatty acid methyl esters. TAGs 
structures were also determined using pancreatic hydrolysis data applying Gunstone's'°' 
method of calculation. 
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2.1 Theoretical 
Nitrogen heterocycles of different ring sizes, with different substitution 
patterns and embedded in various molecular frameworks constitute extremely 
important structure classes in the search for bioactivity. Despite the large availability 
of methods to construct nitrogen heterocycles, there is still a strong need to further 
explore synthetic methods to efficiently synthesize novel heterocyclic structures. This 
proposal aims at the development of novel methodology for the synthesis of nitrogen 
heterocyclic structural motifs, containing varied groups. 
Many compounds bearing five-membered heterocyclic rings in their structure 
have an extensive spectrimi of pharmacological activities. Among them, 1,2,4-triazole 
derivatives have attracted considerable interest and can be used as antifungal', 
antibacterial^, anti-inflammatory^, antiasthmatic'*, antidepressantV 
f\ 7 8 
tuberculotherapeutic , hypoglycemic and diuretic activities. 
The l//-l,2,4-triazole compounds are considered interesting heterocycles 
since they possess important pharmacological activities such as antifungal and 
antiviral activities. Examples of antifungal drugs^' '° are fluconazole (i)"' '^ , ICI 
153066 (ii)'^, itraconazole (iii)''*, ravuconazole (iv)'^, voriconazole (v)'^''*, and 
posaconazole (vi) 19 
(i) (ii) 
^^O~O"0 
(iii) 
ry 
lA 
3,5-Disubstituted-IH-I,2,4-triazoles 
(iv) 
CH, F 
(V) 
'-^^O^^O 
(vi) 
OH 
CH, 
Some 3-amino-l//-l,2,4-triazoles have been used as herbicides and defoliants; 
meanwhile they were described as catalase inhibitors and blockers for certain 
ethanol-induced behavior effects . It has been reported that only certain enantiomers 
of triazoles containing oxazolidine rings (e.g., (vii), 4(^), S{R)) are active against 
Candida albicans infections in mice 22 
0 
H Y' 
vr\ \ 
-N 
(vii) 
x23-27 Ribose N-glycoside (viii) ' is a broad spectrum antiviral agent containing 
the 3-aminocarbonyltriazole moiety. It is active against both RNA and DNA virus and 
is used in an aerosol for lower respiratory tract viral disease as well as in the treatment 
of influenza, Lassa fever and Hantaan virus ' . Amidine and guanidine derivatives 
T A 
(ix) (R = H'HCl, Me, CN) exhibiting a broad spectrum of antiviral activity have 
been prepared. 
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HO—I 
OH OH 
"°~L/°\|' 
HN 
T 
M 
OH OH 
(viii) (ix) 
Some triazole derivatives are considered as angiotensin II receptor 
antagonists^'"^^ These compounds, such as (x) and (xi) are used to increase the blood 
pressure. 
N, ,N 
W // 
N—N 
( X ) (xi) 
In addition, it was reported that compounds having triazole moieties, such as 
vorozole (xii), letrozole (xiii), and anastrozole (xiv), appeared to be very effective 
aromatase inhibitors, which in turn prevented breast cancer ,36-38 
(xii) (xiii) (xiv) 
It is known that 1,2,4-triazole moieties interact strongly with heme iron, and 
aromatic substituents on the triazoles are very effective for interacting with the active 
site of aromatase 39 
26 
3.5-Disubstituted-1H-1,2,4-triazoles 
Morpholine (xv) and N-methyl piperazine (xvi) derivative of 1 -aminomethyl-
3-substituted-4-[5-(4-methoxy-2-nitrophenyl)-2-furfurylidene]-amino-l,2,4-triazole-
5-thiones show potent anticancer activity' 
-o 
.40 
OMe OMe 
(XV) (xvi) 
The 3-[(4-methylphenoxy)-methyl]-4-(N-pyrazin-2'-yl-carboxamido)-5-
mercapto-l,2,4-triazoles (xvii) and 3-[(4-methylphenoxy)-methyI]-4-(N-pyrazin-2'-yl-
carboxamido)-5-hydrazino-l,2,4-triazoles (xviii) are shown to possess anti-
41 inflammatory and analgesic activity . 
Ar- . 0 
N—N 
'I V 
N 
SH Ar' 
N—N // w 
-NH 
o^^rl.M NH, 
N 
I 
NH 
^ N 
(xvii) (xviii) 
The various methods for the synthesis of 1,2,4-triazole derivatives are reported 
by numerous workers. Some of them are discussed here briefly. The reaction of 
hydrazine or substituted hydrazines with suitable electrophiles is the most common 
method for the preparation of the triazoles. Examples where hydrazines provide the 
triazole ring'*^ "'*'* are described in Scheme 2.1-2.3. 
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0 
H S 
H 
/ 
NH2NH2H2O N—N 
YH4C6 ^ N ^ ^ " ^ ^ 
NH, 
(xix) 
Scheme 2.1 
(XX) 
H3C 
I 
H 
\ 
NH,NH, ^ / 
NHNH2 A 
H X 
(xxi) 
Scheme 2.2 
(xxii) 
/ 
N 
\ \ l.KOH/CS, 
^N ^ 
EtOjC 
) H,NHN-
O 
/ 2.NH2NH2 
(xxiii) (xiv) 
N 
W 
^'^m 
N 
H2N 
(xxv) 
Scheme 2.3 
The conversion of a non-triazole ring system into a triazole usually included 
the substitution of nitrogen for another heteroatom in a five-membered ring, only a 
few typical examples''^ "^^ are illustrated in Scheme 2.4-2.5. 
COOH H 
H 2 N - \ / N 
"OH 0 - ^ " \ ^ C O O H 
*• \ If 
N—N 
/ 
H 
(xxvi) (xxvii) 
Scheme 2.4 
28 
3,5-Disubstituted-1H-1,2,4-triazoles 
^Ar 
At f^^3 
^ N 160°C N—N 
H 
(xxviii) (xxix) 
Scheme 2.5 
Microwave irradiation has become a widely used method to synthesize many 
useful organic chemicals rapidly, with good yields and high selectivity'**"'^ . By 
applying the microwave irradiation method, several 1,2,4-triazole derivatives were 
recently reported. 3,5-Disubstituted 4-amino-l,2,4-triazoles (xxxi) from the reaction 
of aromatic nitriles (xxx) with NH2NH2-2HC1 in the presence of NH2NH2-2H20 
excess in ethylene glycol under microwave irradiation'^ (Scheme 2.6). 
NH, 
I ^ 
Ethylene Glycol w 
Ar-CN - ^ A r ^ \ ^ A r 
NH,NH,2HC1 W // 
NHjNHjHp 
(xxx) (xxxi) 
Scheme 2.6 
An efficient microwave-assisted one-pot and three-component synthesis of 
substituted 1,2,4-triazoles (xxxv) has been achieved utilizing substituted primary 
amines (Scheme 2.7). 
MW N - N 
ACNHNH2 + Me2NCH(OMe)2 + RNH2 *- (I V ^ 
I 
R 
(xxxii) (xxxiii) (xxxiv) (xxxv) 
Scheme 2.7 
The l-[(l,5-dialkyl-l//-l,2,4-triazol-3-yl) methylthymines (xxxviii)'' have 
been prepared from cycloaddition of the 1 -cyanothymine (xxxvi)'^ with the reactive 
cumulenes (xxxvii), as potential anti-HIV agents since some acyclic 1,2,4-triazole C-
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O 
nucleosides" showed remarkable antiviral properties against HSV-1 and -2 along 
with other virus (Scheme 2.8). 
o 
ru. 
R, SbCi; 
) = N * R, 
R2 N-^Rj 
HN 
NC J 
CH3 HN 
SbCl;, CHjClj, -60 °C J ^ 
30 °C, then 23 °C 
CH, 
(xxxvi) (xxxvii) 
Scheme 2.8 
(xxxviii) 
A series of new 1,2,4-triazoloalkylphthalimides (xl) has been synthesized from 
cycloaddition of the cyanoalkylphthalimides (alkylmethyl, ethyl, propyl) (xxxix) 
respectively, with the reactive cumulenes (xxxvii), as promising inhibitors of TNF-a 
.58 production (Scheme 2.9). 
(xxxix) 
XXXVII 
SbClj, CHjCIj, -60 °C 
30°C,then23°C 
n=l-3 
Scheme 2.9 
" <.X 
N 
N' ^ R 
R, 
(Xl) 
1,2,4-triazole derivatives carrying piperazine residue, (xlii) and (xliv)^ ,^ have 
been synthesized from cycloaddition of (xxxvii) with the l,4-bis(cyanomethyl) 
piperazine (xli)^ ° and l-cyanomethyl-4-methylpiperazine (xliii)^', respectively 
(Scheme 2.10-2.11). 
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R 
NC 
\ N N-
XXXVIl 
\ SbCI,, CHjClj, -60 "C 
CN 30 °C, then 23 °C / ' ^ 
(xii) (xlii) 
Scheme 2.10 
^^ / \ xxxvii, SbClj, CHjClj,-60 °C .—N N—CH3 
-N N—CH 
'3 
\ / 30 °C, then 23 °C N: 
R 
(xliii) (xiiv) 
Scheme 2.11 
The short chain, alicyclic and variously substituted aromatic carboxylic acids 
have been utilized for the synthesis of 1,2,4-triazole derivatives. But 1,2,4-triazoles 
from long-chain carboxylic acid hydrazides have not been reported earlier. These 
considerations led to the series of present investigations to synthesize 3,5-
disubstituted-l//-l,2,4-triazoles from fatty acid hydrazides. 
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2.2 Synthesis, Antibacterial and Antifungal Activity of Some Novel 
3,5-Disubstituted-1H-1,2,4-triazoles* 
The development of new approaches for the synthesis of heterocycles 
decorated with unique functional groups forms the basis of extensive research activity 
in synthetic organic chemistry. Justification of much of the chemistry directed to the 
synthesis of the compounds, possessing nitrogen at the ring fusion is due to the 
application of compounds having interesting biological properties in the field of 
medicinal chemistry. The 1,2,4-triazole moiety is a structural element in certain 
antiasthmatic^^, antiviral (ribavirin)^'', antifungal (flucanoazole) '*, antibacterial^^ 
hypotonic (triazolam)^^ drugs. Certain compounds containing 1,2,4-triazole nucleus 
have been reported to possess bactericidal^^, antiviral^^, insecticidal^^, anticancer^", 
antinflammatory^', anticonvulsant^ '^ ^^  properties. Also some triazole derivatives have 
been synthesized as plant growth regulators'"^. 
Owing to its broad spectrum of biological activity'^"*' the 1,2,4-triazole ring 
system represents an attractive target to invent new substrates for their synthesis and 
production of combinatorial libraries. 3,5-Disubstituted-l,2,4-triazoles are found in 
several pharmacologically active compounds. Recent examples include selective 
adenosine A2A receptor antagonist and the phosphodiesterase V inhibitor . 
Previously, 1,2,4-triazoles were synthesized by hydrazides and nitriles either by 
Pinner reaction and Pellizzari condensation which involve the cyclodehydrative 
condensation between nitrile and hydrazide. These procedures (Scheme 2.12) path 
b-d are usually conducted at elevated temperature and involve the activation of nitrile 
to acylamidrazone intermediate 2 prior to cyclization. 
*Research paper entitled '•^Synthesis, antibacterial and antifungal activity of some novel 3,5-
disubstituted-lH-l,2,4-triazoles" is published (S. Sharma, S. Gangal, A. Rauf, M. Zahin, 
Archiv de Pharmazie, 2008, 341, 11, 714-720). 
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These conventional procedures not only involve high reaction temperature and long 
reaction time but also results in low yields of product*''"* .^Here in we are reporting 
simple and scalable methodology for the one-pot synthesis of 3,5-disubstituted-l//-
1,2,4-triazoles. 
u 
1 
N; 
NH-NHo 
b 
NH 
R. 
NH-NH, 
^ N 
'1 k 
NH 0 
Ri 
NH-NH 
Scheme 2.12 Pathways for synthesis of3,5-disubstUuted-lH-l,2,4-triazoles 
To the best of our knowledge 3,5-disubstituted-l//-l,2,4-triazoles have not yet 
been reported from long-chain saturated and olefinic carboxylic acids. The present 
v/ork is in continuation of study on the synthesis of heterocycles from such acids. 
Tetrazoles, pyrazolines, tetrazine, spiro [oxathiolane-2, 2'-dihydrotetrazoles], 
aziridines and benzothiazoles have been previously prepared from fatty acids^'^"''. 
Cyanoethoxy and morpholine derivatives of hydroxy long-chain acids and fatty 
esters*^^  showed significant antiftmgal and antibacterial activity. In view of the above 
mentioned pharmacological applications of 1,2,4-triazoles, the synthesis of this 
biologically active moiety was successfully carried out bearing long alkyl and alkenyl 
chain. 
2.3 Results and discussion 
3,5-Disubstituted-l//-l,2,4-triazoles 5a-o were synthesized by the 
condensation of long-chain saturated and olefinic carboxylic acid hyrazides 3a-e with 
nitriles 4 in presence of catalytic amount of K2CO3 in n-BuOH (Scheme 2.13). The 
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use of catalytic amount of K2CO3 provided the product in reduced reaction time in 
appreciable yield. 
R3 
NH-NH2 R 
3a-e 4a-c 5a-o 
a) R4=R5=H 
b) R4=H, Rs=OH 
c) R4=R5=OH 
Scheme 2.13 Synthesis of 3,5-disubstituted-lH-l,2,4-triazoles 
As can been seen from Table 2.1 the scope of the reaction using saturated, 
olefmic (internal and terminal) and hydroxy acid hydrazides was found to be good. 
The yield of 3,5-disubstituted-l//-l,2,4-triazoles did not depend on the length of 
chain of acid hydrazide and was found to be appreciable. The synthesized 
compounds were identified on the basis of elemental analysis, IR, ' H N M R '"'C N M R 
and mass spectra. 
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Entry 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
Table 2.1 3,5-Disubstituted-lH-l,2,4-triazoles 
Starting from 
3a, 4a 
3b, 4a 
3c, 4a 
3d, 4a 
3e, 4a 
3a, 4b 
3b, 4b 
3c, 4b 
3d, 4b 
3e,4b 
3 a, 4c 
3b, 4c 
3c, 4c 
3d, 4c 
3e, 4c 
R3 
" - ^ C H . 
H 
Hp 
0 5 
\r'^-=^T' 
OH 
i D 
/ H ^ C H , 
H 
D 5 
^O^yx.^^-. 
OH 
- - ( ^ C H . 
H 
Hg 
6 5 
OH 
OH 
3 6 
R4 
H 
H 
H 
H 
H 
H 
H 
H 
H 
H 
OH 
OH 
OH 
OH 
OH 
Rs Product 
H 5a 
H 5b 
H 5c 
H 5d 
H 5e 
OH 5f 
OH 5g 
OH 5h 
OH 5i 
OH 5j 
OH 5k 
OH 51 
OH 5m 
OH 5n 
OH 5o 
Yield (%) 
89 
85 
82 
82 
80 
81 
88 
85 
83 
80 
81 
80 
79 
79 
78 
'H N M R spectrum of 3-(4'-hydroxyphenyl)-5-(dec-9-enyl)-l//-l,2,4-triazole 
(5g) showed characteristic signals of 5 10.97 of-NH proton, multiplets at 8 7.57-7.53 
for four aromatic protons. Methine proton of C-9 showed signals at 5 5.82. C-10 
methylene designated as HE and Hz displayed two distinct 6 values when coupled 
with adjacent C-9 methine protons. Thus, the ' H NMR spectrum showed two doublet 
of doublet at 6 5.02 and 4.90 for Hz and HE protons respectively. A triplet for two 
hydrogens was observed at 5 2.91 for methylene protons alpha to triazole ring. The 
structure of 5g was further supported by its mass spectral studies, which showed 
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molecular ion peak at m/z 299 consistent with its molecular formula C18H25N3O. Base 
peak appears at m/z 160. Detailed spectra of titled compounds are given in the 
experimental section. 
All the newly synthesized compounds were evaluated in vitro against an 
assortment of two Gram-positive bacteria Staphylococcus aureus MSSA 22 and 
Bacillus subtilis ATCC 6051 and two Gram-negative bacteria Escherichia coli K 12 
iind Salmonella typhimurium MTCC 98 at a concentration of 100|ig/ml. 
Chloramphenicol was used as standard drug for the comparison of antibacterial 
results. Screening results are summarized in Table 2.2. 
Table 2.2 In vitro antibacterial activity of compounds 5a-o 
Compound 
5a 
5b 
5c 
5d 
5e 
5f 
5g 
5h 
5i 
5j 
5k 
51 
5m 
5n 
5o 
Chloramphenicol 
Control DMSO 
E.COli 
14.6±0.61 
14.2±0.64 
13.6±0.53 
13.2±0.53 
13.2±0.50 
16.1±0.98 
15.9±0.36 
15.4±0.6I 
13.3±0.75 
13.1±0.65 
16.6±0.59 
16.6±0.60 
15.9±0.65 
14.0±0.91 
14.2±0.53 
25 
— 
Diameter of zone of inhibition (mm) at 
Gram negative 
S.typhimurium 
14.6±0.42 
15.3±0.42 
15.6±0.53 
16.5±0.42 
16.3±0.46 
17.1 ±0.23 
16.7±0.61 
16.2±0.29 
17.1±0.42 
17.4±0.41 
18.2±0.53 
18.5±0.31 
17.1±0.12 
16.7±0.61 
17.2±0.35 
20 
— 
lOO^g/ml 
Gram positive 
B.subtilis 
19.1±0.66 
18.2±0.51 
17.1±0.23 
16.6±0.53 
16.5±0.50 
19.1 ±0.25 
18.5±0.46 
18.1 ±0.31 
17.1 ±0.63 
16.3±0.50 
20.3±0.42 
20.2±0.53 
19.7±0.31 
19.4±0.40 
19.2±0.35 
24 
— 
S. aureus 
15.4±0.51 
15.5±0.50 
16.7±0.31 
15.8±0.60 
16.6±0.53 
16.9±0.83 
16.9±0.34 
17.8±0.72 
18.5±0.42 
18.4±0.53 
20.3±0.46 
20.9±0.90 
21.3±0.64 
22.5±0.50 
22.2±0.81 
26 
— 
The newly generated compounds 5a-o have exerted significant inhibitory activity 
against the growth of the test bacterial strains. The data pertaining to Table 2.2 reveal 
that 5a-ohave significant influence on antibacterial profile of 5. typhimurium and 
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S. aureus. The synthesized compounds showed good inhibitory results against B. 
subtilis and E. coli 
In another set of experiments, the above mentioned compounds 5a-o were also 
examined for antifungal activity. Nystatin was used as standard drug for the 
comparison of antifungal results. The synthesized compounds showed excellent 
inhibitory results for Candida albicans IOA-109 and good results against Penicillium 
sp. (lab isolate) and Helminthosporum oryzae (2537 lab isolate) (Table 2.3). 
Table 2.3 In vitro antifungal activity of compounds 5a-o 
Compound 
Sa 
5b 
5c 
5d 
5e 
5f 
5g 
5h 
5i 
5j 
5k 
51 
5m 
5n 
5o 
Nystatin 
Control DMSO 
C. albicans 
18.4±0.31 
18.1±0.32 
18.3±0.55 
17.2±0.49 
17.2±0.35 
19.03±0.44 
18.9±0.55 
18.03±0.68 
17.6±0.38 
I8.03±0.85 
18.9±0.40 
18.2±0.43 
17.7±0.44 
18.4±0.40 
17.9±0.57 
20 
— 
Diameter of zone of inhibition (mm) at 100|ig/ml 
H.oryzae 
12.3±0.36 
12.5±0.50 
11.2±0.49 
10.7±0.61 
10.8±0.71 
13.1±0.57 
13.2±0.46 
14.0±0.47 
14.2±0.47 
14.2±0.60 
13.6±0.40 
13.9±0.75 
13.9±0.46 
14.1±0.60 
14.7±0.55 
18 
— 
A.niger 
15.0±0.25 
14.7±0.86 
15.1±0.42 
14.4±0.40 
14.8±0.80 
15.1±0.42 
14.8±0.91 
15.1±0.55 
15.7±0.42 
15.5±0.50 
16.1 ±0.40 
16.0±0.50 
15.7±0.80 
16.1 ±0.48 
16.0±0.30 
18 
— 
T.viridae 
5.1±0.42 
5.4±0.46 
5.6±0.60 
5.5±0.5 
5.4±0.58 
6.5±0.50 
6.7±0.42 
6.7±0.61 
6.8±0.50 
6.9±0.59 
8.1±0.50 
8.2±0.43 
8.8±0.25 
8.7±0.50 
9.2±0.62 
15 
— 
Penicillium sp. 
12.5±0.5 
12.7±0.61 
12.9±0.80 
13.2±0.53 
13.2±0.5 
14.6±0.55 
14.7±0.56 
15.2±0.43 
15.2±0.58 
15.6±0.40 
16.0±0.30 
16.5±0.55 
17.2±0.50 
17.0±0.36 
17.4±0.43 
20 
— 
All compound showed moderate activity results against Trichoderma viridae 
(lab isolate) and Aspergillus niger (lab isolate). The data also revealed that 5a-o has 
produced the marked enhancement in the potency of these analogues as antibacterial 
and antifungal agents. 
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2.4 Experimental 
Anhydrous conditions were achieved by oven drying flasks and other 
equipments. Reactions were monitored by TLC on silica gel G. 60-80 mesh silica gel 
was used for column chromatography. All reagents and solvents were generally used 
as received from commercial suppliers and when required solvents were dried and 
distilled before use. Undec-10-enoic, (Z)-octadec-9-enoic and octadecanoic acids and 
BF3.0Et2 were obtained commercially from Fluka Chemicals (Switzerland). The 
eluent was a mixture of petroleum ether/EtOAc in different proportions for different 
compounds and visualized under iodine chamber. {9Z, 72i?)-12-Hydroxyoctadec-9-
enoic (ricinoleic) and (9R, 72Z)-9-hydroxyoctadec-12-enoic (isoricinoleic) acids were 
isolated from the natural sources i.e. from Ricinus communis and Wrightia tinctoria 
seed oils respectively. The concentrate of pure hydroxy acids were obtained by 
Gunstone's partitioning of freshly prepared fatty acids and fiirther purified by 
column chromatography. ' H N M R spectra was recorded in CDCI3 on a Bruker DRX-
400 instrument. The chemical shifts (6) were measured relative to TMS as an internal 
standard. Coupling constants {J) are expressed in Hz. Mass spectra were obtained on a 
Jeol SX-102 (FAB) spectrometer. The molecular ion peak is designated as (M^). IR 
spectra were obtained on Shimadzu 8201 PC FT-IR using KBr pellet with absorption 
given in cm' . 
General procedure for the preparation of fatty acid hyrazides (3a-e) 
The hydrazides of corresponding fatty acids 3a-e were prepared by refluxing 
the (O.OlmmoI) methyl esters with hydrazine hydrate (0.02nimol) in MeOH at about 
130°C for 2 hours^^. The mixture was then cooled to room temperature. The 
hydrazide was solidified in solvent. Filtered, washed with water and recrystallized in 
EtOH. The fatty acid hydrazides 3a-e were characterized by melting points. The 
spectral details of 3d, 3e is given below. 
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(9Z, 12R)-12-Hydroxyoctadec-9-enoic acid hydrazide (3d) 
Yield85%;Mp=108-110°C. 
IR (KBr): 3390, 3280, 2960,2890 cm"'. 
'HNMR (400 MHz, CDCb): 8 8.20 (s, IH, -N//-), 5.46 (m, 2H, -CH=CH-), 4.16 (d, 
y=6.9 Hz, 2H, -N//2), 3.88 (m, IH, -C//OH), 2.88 (t, 2H,J= 7.9 Hz, -CH2 a to ring), 
2.31 (m, IH, -CHO//), 2.04 (m, 4H, -C//2-CH=CH-C//2-), 1.93 (m, 2H, -CH2 p to 
ring), 1.33 (br.s, 18H, chain C//2), 0.86 (3H, dist.t, CH3). 
MS: 309 (IvT), 175,87,73,59. 
Anal: Calcd. for C18H36N2O2: C, 69.90; H, 11.65; N, 9.06. Found: C, 69.88; H, 11.62; 
N, 9.08%. 
(9R, 12Z)-9-Hydroxyoctadec-12-enoic acid hydrazide (3e) 
Yield 80%; Mp=l 10-112 °C. 
IR (KBr): 3390, 3280,2960,2890 cm"'. 
'HNMR (400 MHz, CDCI3): 8 8.11 (s, IH, -N//-), 5.39 (m, 2H, -CH=CH-), 4.11 (d, 
,7-6.9 Hz, 2H, -N//2), 3.76 (m, IH, -C//OH), 2.90 (t, 2H,J= 7.9 Hz, -C//2 a to ring), 
2.28 (m, IH, -CnOH), 2.09 (m, 4H, -C//2-CH=CH-C//2-), 1.98 (m, 2H, -CH2 p to 
ring), 1.31 (br.s, 18H, chain CH2), 0.86 (3H, dist.t, CH3). 
.MS: 309 (M+), 199,87,73,59. 
Anal: Calcd. for C18H36N2O2: C, 69.90; H, 11.65; N, 9.06. Found: C, 69.88; H, 
11.62; N, 9.08% 
General procedure for the preparation of 3,5-disubstituted-lH-l,2,4-triazoles from 
fatty acid hydrazides (5a-o) 
A mixture of nitrile 4 (3mmol), acid hydrazide (3a-e) (Immol) and K2CO3 
(O.Smmol) in n-BuOH (2ml) was stirred and refluxed at 150°C for 4 hours. The 
progress of reaction was monitored on TLC. After completion of reaction the solvent 
v/as removed under reduced pressure and the compounds were adsorbed on silica gel 
and purified by column chromatography. All the compounds 5a-o were obtained as 
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oily liquid. The purity of compounds was ascertained by TLC resolution studies using 
petroleum ether/EtOAc (4:1, v/v) and few drops of MeOH as mobile phase. For 
column chromatography (Hexane:EtOAc, v:v) 5a, (99:1); 5b, (99:1)- 5c, (98:2), 5d, 
(95:5); 5e, (95:5); 5f, (98:2), 5g, (98:2); 5h, (96:4); 5i, (95:5); 5j, (95:5); 5k, (98:2); 
51, (97:3); 5m, (95:5); 5n, (94:6); 5o, (94:6). 
Antibacterial activity 
The newly synthesized compounds were screened in vitro against an 
assortment of two Gram-positive bacteria Staphylococcus aureus MSSA 22 and 
Bacillus subtilis ATCC 6051 and two Gram-negative bacteria Escherichia coli K12 
and Salmonella typhimurium MTCC 98. Screening results are summarized in Table 
2.2. All the synthesized compounds were dissolved in DMSO. The antibacterial 
activity of test compounds and standard chloramphenicol was done by filter paper 
disc method^''. Media with DMSO was set up as control. All cultures were routinely 
maintained on NA (nutrient agar) and incubated at 37°C. The inoculums of bacteria 
were performed by growing the culture in NA broth at 37°C for overnight. The culture 
was centriftiged at lOOOrpm and pellets was resuspended and diluted in sterile NSS to 
obtain viable count lO^CFU/ml. 0.1 ml of approximately diluted bacterial culture 
suspension was spread with the help of spreader on NA plates uniformly. Sterile 8mm 
discs (Hi-media Pvt. Ltd.) were impregnated with lOO^g/ ml concentration of the test 
compounds. Antibiotic disc, chloramphenicol (30ng/disc Hi-Media) was used as 
control. The disc was placed onto the plate. Each plate had one control disc 
impregnated with solvent. The plates were then incubated for 24 hours at 37°C. 
Diameters of the zone of inhibition (mm) were measured and the average diameters 
for the test samples were calculated in triplicate sets. 
Antifungal activity 
The standard agar disc diffusion method^'' was performed to evaluate the 
antifungal property of the test compounds and standard nystatin. The newly 
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synthesized compounds were screened for Aspergillus niger (lab isolate), Candida 
albicans IOA-109, Penicillium sp. (lab isolate), Trichoderma viridae (lab isolate), 
Helminthosporwn oryzae (2537 ICAR, Jaipur). The synthesized compounds were 
dissolved in DMSO. Media with DMSO was set up as control. All cultures were 
routinely maintained on SDA and incubated at 28°C. Spore formation of filamentous 
fungi was prepared from 7 day old culture in sterile normal solution (8% NaCl) and 
approximately diluted to obtain lO^CFU/ml. The inoculums of non sporing fungi, C. 
albicans were performed by growing the cuhure in SD broth at 37°C for overnight. 
The culture was centrifiiged at lOOOrpm and pellets was resuspended and diluted in 
sterile NSS to obtain viable count lO^CFU/ml. 0.1 ml of approximately diluted fungal 
culture suspension was spread with the help of spreader on SDA plates uniformly. 
Sterile 8mm discs (Hi-media Pvt. Ltd.) were impregnated with test compoimds. 
Antibiotic disc, nystatin (30ng/disc Hi-Media) was used as control. The disc was 
placed onto the plate. Each plate had one control disc impregnated with solvent. The 
plates were incubated at 28°C for filamentous fiingi for 72 hours or more while for C. 
albicans plates were incubated at 37*'C for 18-48 hours. Antifiangal activity was 
determined by measuring the diameters of the inhibition zone (mm) in triplicate sets. 
Spectroscopic data 
3-Phenyl-5-heptadecyl-lH-l,2,4-triazole(5a) 
IR (KBr): 3382,1607,1123 cm"V 
'HNMR (400 MHz, CDCI3): 6 10.96 (s, IH, -NH-), 7.69-7.67 (m, 2H, Ai-H), 7.65-
7.60 (m, IH, Ai-H), 7.49-7.42 (m, 2H, Ai-H), 2.96 (t, 2H, J = 7.6 Hz -CH2 a to ring), 
2.05 (m, 2H, -CH2 P to ring), 1.72 (br.s, 28H, chain CH2), 0.86 (3H, dist.t, CH3). 
"CNMR (100 MHz, CDCI3): 159.15, 147.91, 133.81, 129.15, 127.35, 32.17, 30.39, 
29.91,28.66,23.17,14.84. 
MS {m/z, %): (M+1)^ 384 (10.5), M'' 383 (36.1), 354 (25.3), 270 (27.7), 214 (63.8), 
186(16.6), 158(100). 
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Anal. Calcd. forC25H4iN3 : C, 78.29; H, 10.76; N, 10.95. Found: C, 78.85; H, 10.70; 
N, 10.90%. 
3-Phenyl-5-(dec-9-enyl)-lH-l,2,4-triazole (Sh) 
IR (KBr): 3392, 1594,1122 cm''. 
'HNMR (400 MHz, CDCI3): 6 10.98 (s, IH, -N//-), 7.66-7.64 (m, 2H, Ax-H), 7.62-
7.58 (m, IH, Ax-H), 7.49-7.45 (m, 2H, Ar-//), 5.82 (IH, tdd, y„ . = 6.6 Hz, 
J„_„^= 10.2 Hz, Jn-nr 17.1 Hz, CH2=C//-), 5.02 (IH, dd, ^^_^= 10.2 Hz, 
,/^ _^^ ^ = 1.2 Hz, i/zC^CH-), 4.90 (IH, dd, J„^_, = 17.1 Hz, J,^^_„^= 1.2 Hz, 
J=/£C=CH-), 3.10 (t, 2H J = 7.6 Hz, -CH2 a to ring), 2.05 (m, 2H, -C//2-CH=CH2), 
1.99 (m, 2H, -CH2 p to ring), 1.38 (br.s, lOH, chain CH2). 
'^C NMR (100 MHz, CDCI3): 158.94, 147.24, 139.82, 133.91, 129.6,6 127.63, 
114.67, 32.81, 30.85,29.26,28.32,22.97,14.21. 
MS (m/z, %): (M+1)* 284 (14.7), M^ 283 (10.8), 270 (28.3), 242 (29.9), 228 (11.8), 
214(18.3), 186(26.2), 144(100). 
Anal. Calcd. for C18H25N3: C, 76.29; H, 8.88; N, 14.83. Found: C, 76.75; H, 8.82; N, 
14.77%. 
3-Phenyl-5-(heptadec-8-enyl)-lH-l,2,4-triazole (5c) 
IR (KBr): 3382,1597,1133 cm"'. 
'HNMR (400 MHz, CDCI3): 6 10.96 (s, IH, -NH-), 7.67-7.63 (m, 2H, Ar-H), 7.60-
7.56 (m,lH,Ar-//), 7.49-7.44 (m, 2H, Ar-77), 5.34 (m, 2H,-C//=C//-), 2.97 (t,2H, 
J= 7.6 Hz, -CH2 a to ring), 2.05 (m, 4H, -CHi-CU^CU-CHj-), 1.96 (m, 2H, -CH2 p 
to ring), 1.73 (br.s, 20H, chain C//2), 0.86 (3H, dist.t, CH3). 
'^CNMR (100 MHz, CDCI3): 158.22, 146.91, 134.14, 131.15, 129.01, 128.14, 33.81, 
30.86,29.91,28.63,22.62,14.68. 
MS (tn/z, % ) : (M+1)^ 382 (40.5), M^ 381 (30.1), 338 (38.3), 310 (27.7), 268 (63.8), 
242(16.6), 158(100), 144(10.9). 
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Anal. Calcd. for C25H39N3: C, 78.70; H, 10.29; N, 11.01. Found: C, 78.28; H, 10.35; 
N, 11.07%. 
3-Phenyl-5-f(8Z,llR)-ll-hydroxyheptadec-8-enylJ-lH-l,2,4-triazole (Sd) 
jW(KBr):3386, 1590,1119 cm-'. 
'HNMR (400 MHz, CDCI3): 5 10.99 (s, IH, -N//-), 7.66-7.64 (m, 2H, Ar-H), 7.60-
7.57 (m, IH, AT-//), 7.49-7.46 (m, 2H, Ai-H), 3.88 (m, IH, -C//OH), 3.11 (t, 2H, 
J= 7.6 Hz, -CH2 a to ring), 2.43 (m, IH, -CHO/f), 2.05 (m, 4H, C//2-CH=CH-C//2), 
1.89 (m, 2H, -CH2 p to ring), 1.73 (br.s, 18H, chain CH2), 0.89 (3H, dist.t, CH3). 
"CNMR (100 MHz, CDCI3): 157.93, 146.82, 134.05, 131.61, 129.24, 127.95, 67.85, 
39.22, 34.62, 31.22,29.43,28.72,27.14,22.75,14.91. 
MS {m/z, %): (M+1)^  398 (9.8), M^ 397 (21.2), 340 (13.2), 312 (13.1), 282 (26.8), 
200(39.9), 186(100), 172(30.0). 
Anal. Calcd. for C25H39N3O: C, 75.53; H, 9.88; N, 10.56. Found: C, 75.01; H, 9.93; 
N, 10.61%. 
3-Pheny-S-f(8R,llZ)-8-hydroxyheptadec-ll-enylJ-lH-I,2,4-triazole(5e) 
IR (KBr): 3387,1594, 1124 cm-'. 
'HNMR (400 MHz, CDCI3): 5 10.98 (s, IH, -N//-), 7.69-7.65 (m, 2H, Ai-H), 7.62-
7.55 (m, IH, AT-H), 7.49-7.45 (m, 2H, Ai-H), 3.88 (m, IH, -CHOH), 3.11 (t, 2H, J = 
7.6 Hz, -CH2 a to ring), 2.42 (m, IH, -CHOH), 2.03 (m, 4H, -C7/2-CH=CH-C//2-), 
1.98 (m, 2H, -CH2 P to ring), 1.29 (br.s, 18H, chain CH2), 0.88 (3H, dist.t, CH3). 
'^CNMR (100 MHz, CDCI3): 157.27, 146.81, 134.73, 131.52, 129.57, 127.21, 67.36, 
39.17, 34.61, 31.81,29.14,28.71,27.15,22.51,14.71. 
MS {m/z, %): (M+1)^  398 (5.8), M^ 397 (31.2), 368 (33.2), 326 (13.1), 272 (26.1), 
228 (19.9), 214 (100), 172(30.0). 
Anal Calcd. for C25H39N3O: C, 75.53; H, 9.88; N, 10.56. Found: C, 75.99; H, 9.82; 
N, 10.51%. 
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8-(4'-Hydroxyphenyl)-5-heptadecyl-lH-l,2,4-triazole (5f) 
IR (KBr): 3387, 1590, 1132 cm"'. 
'HNMR (400 MHz, CDCI3) : 8 10.97 (s, IH, -N//-), 7.57-7.53 (m, 4H, Ax-H), 6.95 
(Ar-0//), 2.78 (t, 2H, J= 7.6 Hz, -C//2 a to ring), 1.92 (m, 2H, -CH2 p to ring), 1.23 
(br.s, 20H, chain CH2), 0.88 (3H, dist.t, CH3). 
'^CNMR (100 MHz, CDCI3): 159.14, 151.84, 148.76, 138.97, 129.75, 117.33, 32.52, 
30.72,22.82,21.72,14.56. 
MS {m/z, %): (M+1)M00 (13.8), M^ 399 (41.6), 286 (16.6), 272 (83.3), 258 (16.6) 
188(8.3), 174(44.4), 160(100). 
Anal. Calcd. for C25H41N3O: C, 75.15; H, 10.33; N, 10.51. Found: C, 75.66; H, 10.39; 
N, 10.45%. 
3-(4 '-Hydroxyphenyl)-5-(dec-9-enyl)-lH-l,2,4-triazole (5g) 
IR (KBr): 3390, 1590,1129 cm-'. 
^HNMR (400 MHz, CDCI3): 8 10.97 (s, IH, -N//-), 7.57-7.53 (m, 4H, kr-H), 6.93 
(Ar-0//), 5.82 (IH, tdd, J,,_.,.„= 6.6 Hz, J^^^^^ 10.2 Hz, J„_f,^= 17.1 Hz, 
CH2-C//-), 5.02 (IH, dd, J„^_„= 10.2 Hz, J„^_„^ = 1.2 Hz, //2C=CH-), 4.90 (IH, 
dd, JH,-H = 17.1 Hz, J„^_„^ = 1.2 Hz, //fC-CH-), 2.91 (t, 2H, 7= 7.9 Hz, -C//^ a 
to ring), 2.02 (m, 2H, -Ci/rCH-CHj), 1.93 (m, 2H, -CH2 p to ring), 1.38 (br.s, lOH, 
chain CH2). 
"C NMR (100 MHz, CDCI3): 158.76, 151.23, 148.15, 139.72, 129.16, 116.27, 
114.43, 34.25, 33.76, 29.22,24.72. 
MS {m/z, %): (M+1)^  300 (19.9), M^ 299 (12.3), 272 (12.5), 244 (17.3), 230 (3.9), 
216 (2.2), 188 (3.9), 174 (4.2), 160 (100). 
Anal. Calcd. for CigHjsNsO: C, 72.22; H, 8.41; N, 14.03. Found: C, 72.74; H, 8.46; 
N, 14.09%. 
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3-(4'-Hydroxyphenyl)-5-(heptadec-8-enyl)-lH-l,2,4-triazole{5h) 
/.»(KBr): 3387, 1594, 1130 cm''. 
'HNMR (400 MHz, CDCI3): 5 10.97 (s, IH, -N//-), 7.57-7.56 (m, 4H, kx-H), 6.93 
(Ar-0//), 5.39 (2H, m, -CH=CH-), 2.79 (t, 2H, J = 5.7 Hz, -CH2 a to ring), 2.02 (m, 
4H, -C//2-CH=CH-C//2-), 1.96 (m, 2H, -CH2 P to ring), 1.23 (br.s, 20H, chain CH2), 
0.88 (3H, dist.t, CH3). 
'^CNMR (100 MHz, CDCh): 157.73, 151.24, 148.72, 130.82, 129.17, 118.41,34.27, 
31.83,29.68,29.19,27.04, 24.74,22.56,14.61. 
MSim/z, %): (M+1)^  398 (13.8), M^ 397 (41.6), 284 (16.6), 258 (16.6) 188 (8.3), 174 
(100), 160(44.4). 
Anal. Calcd. for C25H39N3O: C, 75.53; H, 9.88; N, 10.56. Found: C, 75.99; H, 9.83; 
N, 10.50%. 
3-(4'-Hydroxyphenyl)-5-l(8Z,llR)-n-hydroxyheptadec-8-enyl]-lH-l,2,4-triazole 
(5i) 
IR (KBr): 3390,1590, 1123 cm''. 
'HNMR (400 MHz, CDCI3): 5 10.98 (s, IH, -N//-), 7.58-7.52 (m, 4H, Ax-H), 6.98 
(Ar-0//), 5.46 (m, 2H, -CH=CH-), 3.88 (m, IH, -C//-OH), 3.44 (t, 2H, J = 7.5 Hz, -
CH2 a to ring), 2.31 (m, IH, -CH-OH), 2.04 (m, 4H, -C//rCH=CH-C//r), 1.91 (m, 
2H, -CH2 p to ring), 1.33 (br.s, 18H, chain CH2), 0.86 (3H, dist.t, CH3). 
'^CNMR (100 MHz, CDCI3): 157.94, 151.62, 148.52, 130.86, 129.36, 118.74, 67.87, 
39.26, 34.17, 31.84, 29.63,28.96,27.27,24.72,22.54,14. 36. 
MS [m/z, %): (M+1)^  414 (12.2), M^ 413 (26.1), 370 (75.8), 356 (60.9), 328 (33.4), 
202 (69.8), 174 (14.2), 160 (100). 
Anal. Calcd. for C25H39N3O2: C, 72.61; H, 9.49; N, 10.16. Found: C, 72.05; H, 9.55; 
N, 10.20%. 
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3-(4'-Hydroxyphenyl)-5-[(8R,llZ)-8-hydroxyheptadec-ll-enyl]-lH-l,2,4-triazole 
(5j) 
//?(KBr): 3379, 1592, 1119 cm"'. 
^HNMR (400 MHz, CDCI3): 5 10.99 (s, IH, -N//-), 7.57-7.53 (m, 4H, Ar-H), 6.93 
{kx-OH), 5.39 (m, 2H,-C//=C//-), 3.88 (m, IH,-C//-OH),3.23 (t,2H, J=6.4 Hz, 
-CH2 a to ring), 2.28 (m, IK, J =1.2 Hz, -CH-0//), 2.04 (m, 4H, -CT/^ -CH-CH-
C//2), 1.89 (m, 2H, -CH2 p to ring), 1.27 (br.s, 18H, chain CH2), 0.86 (3H, dist.t, 
CHs). 
"CNMR (100 MHz, CDCI3): 158.94, 151.62, 148.74, 131.11, 129.46, 118.67, 67.36, 
39.64, 34.16, 317.8,29.55, 28.73,27.22,24.55,22.11,14.42. 
MS{m/z, %): (M+l)^414 (12.5), M^413 (29.1), 342 (51.2), 316 (33.3), 288 (9.8), 188 
(100), 174(18.8), 160(80.2). 
Anal. Calcd. for C25H39N3O2: C, 72.61; H, 9.49; N, 10.16. Found: C, 72.99; H, 9.43; 
N, 10.11%. 
3-(4 ',5'-Dihydroxyphenyl)-5-(heptadecyl)-lH-l,2,4-triazole (5k) 
IR (KBr): 3349,1604,1134 cm"'. 
'HNMR (400 MHz, CDCI3): 6 10.97 (s, IH, -N//-), 7.16 (d, IH, J - 1.6 Hz, Ax-H), 
1.^1 (d, IH, J = 2 Hz, Ax-H), 7.03 (d, IH, J = 2 Hz, Ax-H), 6.89 (Ar-O/f), 6.87 (Ar-
OH), l.n (t, 2H, J= 7.6 Hz, -CH2 a to ring), 1.92 (m, 2H, -CH2 p to ring), 1.23 (br.s, 
28H, chain CH2), 0.88 (3H, dist.t, CH3). 
'^CNMR (100 MHz, CDCI3): 164.57, 145.16, 144.24, 121.92, 115.91, 32.19, 30.38, 
28.91,22.37,14.50. 
MS (m/z, %): (M+1)^  416 (17.0), M^ 415 (66.0), 356 (10.4), 314 (2.1), 300 (31.2), 
208(19.2), 190(12.5), 176(100). 
Anal. Calcd. for C25H41N3O2: C, 72.26; H, 9.93; N, 10.11. Found: C, 72.79; H, 9.99; 
N, 10.15%. 
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3-(4 ',5'-Dihydroxyphenyl)-5-(dec-9-enyl)-lH-l,2,4-triazole (51) 
7^(KBr): 3387, 1596, 1130 cm"'. 
'HNMR (400 MHz, CDCI3): 6 10.98 (s, IH, -N//-), 7.11 (d, IH, J = 1.6 Hz, Ar-H), 
7.04 (d, IH, J = 2 Hz, Ai-H), 7.02 (d, IH, J = 2 Hz, Ax-H), 6.88 (AT-OH), 6.87 (Ar-
OH), 5.82 (IH, tdd, J^^^.^^ = 6.6 Hz, J„_„,^ = 10.2 Hz, J„_^,^= 17.1 Hz, CU2=CH-), 
5.02 (IH, dd, Jf,,^_„ = 10.2 Hz, ^^.„^, = 1.2 Hz, //zC=CH-), 4.90 (IH, dd, J//^ _^ = 
17.1 Hz, J„^_f,^ = 1.2 Hz, H^=CH), 3.13 (t, 2H, J= 8 Hz, -CH2 a to ring), 2.02 (m, 
2H, -C/6-CH=CH2), 1.93 (m, 2H, -CH2 p to ring), 1.38 (br.s, lOH, chain CH2). 
'^C NMR (100 MHz, CDCI3): 164.91, 145.82, 144.85, 139.94, 121.96, 116.72, 
114.67, 34.22, 33.79, 29.24,28.42,24.21. 
MS (m/z, %): (M+1)^  316 (25.7), M^ 315 (23.8), 288 (44.2), 274 (66.6), 243 (17.1), 
208(36.3), 198(14.6), 176(100). 
Anal. Calcd. for C18H25N3O2: C, 68.55; H, 7.98; N, 13.32. Found: C, 68.05; H, 7.93; 
N, 13.26%. 
3-(4\S'-Dihydroxyphenyl)-5-(heptadec-8-enyl)-lH-l,2,4-triazole{5m) 
/«(KBr): 3384,1594,1127 cm"'. 
^HNMR (400 MHz, CDCI3): 5 10.97 (s, IH, -N//-), 7.11 (d, IH, J - 1.6 Hz, Ax-H), 
7.04 (d, IH, J = 2 Hz, Ar-i^, 7.02 (d, IH, J = 2 Hz, Ax-H), 6.93 {Ai-OH), 6.89 (Ar-
0//), 5.34 (m, 2H,-C//=C//-), 2.78 (t,2H,J=7.6 Hz,-C/6 a to ring), 2.02 (m,4H, 
-C//2-CH-CH-C//2-), 1.92 (m, 2H, -CH2 P to ring), 1.23 (br.s 20H, chain CH2), 0.88 
(3H, dist.t, CHi). 
"CNMR (100 MHz, CDCI3): 163.42,146.83, 144.84, 131.91, 121.66, 119.83, 33.18, 
29.96, 25.69, 22.76,14.92. 
MS {m/z, %): (M+1)^  414 (17.0), M^ 413 (66.0), 356 (10.4), 314 (12.1), 300 (31.2), 
208(19.2), 190(100), 176(57.5). 
Anal. Calcd. for C25H39N3O2: C, 72.61; H, 9.49; N, 10.16. Found: C, 72.06; H, 9.44; 
N, 10.21%. 
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3-(r,5'-Dihydroxyphenyl)-5-[(8Z,llR)-n-hydroxyheptadec-8-enyl]-lH-l,2,4-
triazole (5n) 
m (KBr): 3386, 1597, 1123 cm-'. 
'HNMR (400 MHz, CDCI3): 6 10.98 (s, IH, -N//-), 7.13 (d, IH, J = 1.6 Hz, Ar-//), 
7.04 (d, IH, J = 2 Hz, Ar-//), 7.01 (d, IH, J = 2 Hz, Ax-H), 6.89 (Ar-O//), 6.86 (Ar-
OH), 5.46 (m, 2H, -CH=CH-), 3.88 (m, IH, -C//-OH), 3.44 (t, 2H, J= 7.5 Hz, -CH2 
a to ring), 2.31 (m, IH,-CH-O//),2.04 (m, 4H,-C//rCH=CH-C/6-), 1.91 (m,2H, 
-CH2 p to ring), 1.33 (br.s, 18H, chain CH2), 0.86 (3H, dist.t, CH3). 
'^CNMR (100 MHz, CDCI3): 163.92,147.84, 145.15,131.86,121.17, 119.23, 68.25, 
39.84, 37.25, 33.18, 29.94, 27.6,24.19,22.70,14.35. 
MS {m/z, %): (M+1)* 430 (6.6), M^ 429 (28.3), 344 (43.3), 260 (13.8), 253 (41.6), 
208(8.3), 190(47.2), 176(100). 
Anal. Calcd. for C25H39N3O3: C, 69.91; H, 9.14; N, 9.77. Found: C, 69.30; H, 9.21; N, 
9.72%. 
3-(4',5'-Dihydroxyphenyl)-5-[(8R,llZ)-8-hydroxyheptadec-ll-enylJ-lH-l,2,4-
triazole (5o) 
IR (KBr): 3392,1600,1123 cm"'. 
'HNMR (400 MHz, CDCI3): 6 10.98 (s, IH, -N//-), 7.11 (d, IH, J = 1.6 Hz, Ax-H), 
7.04 (d, IH, J = 2 Hz, Ax-H), 1.01 (d, IH, J = 2 Hz, Ax-H), 6.89 {Ar-OH), 6.87 (Ar-
0/f), 5.39 (m, 2H, -CH^CH), 3.88 (m, IH, -C//-OH), 3.23 (t, 2H, J= 6.4 Hz, -CH2 a 
to ring), 2.28 (m, IH, -CK-OH), 2.04 (m, 4H, -C/6-CH=CH-Ci/r), 1-89 (m, 2H, 
-CH2 p to ring), 1.27 (br.s, 18H, chain CH2), 0.86 (3H, dist.t, CH3). 
'^CNMR (100 MHz, CDCI3): 163.63, 147.55, 145.16, 131.72, 121.26, 119.68, 68.49, 
39.80, 37.41, 33.12,29.5,27.33,24.24,22.47,14.21. 
MS (m/z, %): (M+1)^  430 (55.5), M^ 429 (8.3), 372 (55.5), 332 (41.6), 301 (22.2), 
280 (13.6), 208 (8.3), 176(100). 
Anal. Calcd. for C25H39N3O3: C, 69.91; H, 9.14; N, 9.77. Found: C, 69.28; H, 9.20; N, 
9.71%. 
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3.1 Theoretical 
The widespread use of 1,3,4-oxadiazoles as a scaffold in medicinal chemistry 
establishes this moiety as an important bio-active class of heterocycles. These 
molecules are also utilized as pharmacophores due to their favorable metabolic profile 
and ability to engage in hydrogen bonding. 1,3,4-Oxadiazoles have a wide range of 
pharmaceutical and biological activities including antimicrobial, antifungal, anti-
inflammatory, and antihypertensive'"^ In particular, marketed antihypertensive agents 
such as tiodazosin^ and nesapidiP as well as antibiotics such as furamizole^ contain 
the oxadiazole nucleus. Biologically relevant entities containing the 1,3,4-oxadiazole 
motif include the HIV integrase inhibitor (i)^ angiogenesis inhibitor (ii)i§i'; «,•***** r-^ ^/A.*^ 
F,C 
(i) (ii) 
The substituted oxadiazoles serve both as biomimetic and reactive 
pharamacophores and many are key elements with potential biological activities"''^ 
such as pesticidal''', antiperipheral vasomotility'^, CNS stimulant, antiinflammatory, 
hypotensive'^, insecticidal'^, bactericidal'^, hypoglycemic'^'^", analgesic, 
anticonvulsive, antiemetic, diuretic^', muscle relaxant^ '^^ ,^ herbicidaP'*'^ ^ and 
fungicidal activity ' . 
N-Substituted 2-amino- and 2-alkylthio-I,3.4-oxadiazoles containing 
benzothiazole fragments in position 5 possess a wide spectrum of biological activity, 
including anti-inflammatory (iii)^ '^^ ,^ antimicrobial" and hypotensive^' activity. 
55 
2,5-Disubstituted-1,3,4-oxadiazoles 
NHR 
(iii) 
The 1,3,4-oxadiazole derivatives show leprostatic and tuberculostatic 
properties and exhibit antibacterial, antiproteolytic and anticonvulsant activities. Also 
they have analgesic, antipyretic, antiphologistic, bactericides, insecticides, 
fungicidical and several other biological activities . 
Moreover, 1,3,4-oxadiazoles are becoming an important member in the 
heterocyclic family not only because of their wide usage as dyes, photosensitive and 
electrical materials^^. 
3-Methyl-2-({[5-aryM,3,4-oxadiazol-2-yl)methyl]aniline}methyl)-4(3H) 
quinazolinone (iv) was synthesized by Komaraiah et aO^. The amino alkyl bridge 
was conceived to provide conformational flexibility and improve binding 
characteristics to (iv). 
o 
Ar 
(iv) 
1,3,4-oxadiazoles have attracted considerable interest in medicinal chemistry 
as surrogates of carboxylic acids, esters and carboxamides^\ In particular the 2-
amino-1,3,4-oxadiazoles have recently been reported to exhibit promising anti-tumour 
activity^^ 
Bis-mercapto-l,3,4-oxadiazoles were used as active substances to control 
Meloidogyne incognita in tomato^^. 
The common synthetic route to these compounds involves cyclization of 
diacylhydrazines with a variety of anhydrous reagents such as thionyl chloride''^, 
phosphorus pentoxide^^, phosphorus oxychloride''°, triflic anhydride'" (Scheme 3.1). 
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R/^NH-'Y"'^ Tfp^ '^ -^^  ;^  
N—N 
(V) (vi) 
Scheme 3.1 
triphenylphosphine'*^, polyphosphoric acid''"' and sulfuric acid'. The acylation of 
tetrazoles is another synthetic route to these compounds'* .^ They have also been 
prepared by oxidation of acylhydrazones with different oxidizing agents''^^^. One-pot 
synthesis of 1,3,4-oxadiazoles from acid hydrazides and hydrazine with an acid 
chloride'*^ as well as from hydrazines with carboxylic acids'*^ have also been reported. 
When terephthalic acid hydrazide (vii) was refluxed with phenyl isocyanate 
(viii) using the procedure described for the synthesis of bis-semicarbazide (ix) was 
formed (Scheme 3.2). The compound (ix) on treatment with POCI3 imderwent 
cyclization to the corresponding 5,5'-(l,4-phenylene)-bis-(2-phenyIamino-l,3,4-
oxadiazole) (x)^°. The compound (x) showed potential antibacterial activity. 
1 n 
HN' "^ O 
(vii) (viii) (ix) (x) 
Scheme 3.2 
The reaction of 1-adamantanecarbonyl chloride (xi) with certain carboxylic 
acid hydrazides (xii) in pyridine yielded the corresponding N-acyl adamantane-1-
carbohydrazide derivatives (xiii), which were cyclized to the corresponding 2-(l-
adamantyl)-5-substituted-l,3,4-oxadiazoles (xiv) via heating with phosphorus 
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J l oxychloride (Scheme 3.3). The synthesized compounds showed antiinflammatory 
activity. 
+ R 
Pyridine 
NH-NH2 
NH 
NH R 
N—N 
(xi) (xii) (xiii) (xiv) 
R= C6H5,4-FC6H5,4-CIC6H5, 4-BrC6H5,4-NO2C6H5, 3,5-(N02)2C6H3, 3,4-(OCH3)2C6H3,2-Cl,4-
NO2C6H3, 1-Adamantyl 
Scheme 3.3 
52 Polshettiwar et al. reported the green protocol for the synthesis of 1,3,4-
oxadizoles (xvii) catalyzed efficiently by solid supported Nafion®NR50 (NF) and 
phosphorus pentasulfide in alumina (P4S10/AI2O3) with excellent yields (Scheme 3.4). 
. Y Y / * ^o\V. NF \ / \ / / NH-NH2 H3C MW 
(XV) 
CH3 
(xvi) (xvii) 
R, = H, F, OMe, 2-fiiryl, 2-thienyl, 4-pyridyl R2 = H, C2H5, CsHj 
Scheme 3.4 
5-Aryl-2-(2-hydroxy-phenyl)-l,3,4-oxadiazoles (xx) by reaction of salicylic 
hydrazide (xviii) with carboxylic acids (xix) in the presence of thionyl chloride under 
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COOH 
SOCL 
MW (1.3-2.2) 
R 
(xviii) (xix) (xx) 
R = H, 4-lVIe, 4-MeO, 3,4-(MeO)2, 3,4,5-(MeO)3, 3-CI, 2-Br, RC6H4 = 3-MeOC6H4CH2 
Scheme 3.5 
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2,5-Disubstituted-l,3,4-oxadiazoles (xxiv) were prepared by oxidation of 1-
aroyl-2-arylidene hydrazines (xxiii) with potassium permanganate on the surface of 
silica gel and also in mixtures of acetone and water under microwave irradiation '^* 
(Scheme 3.6). 
0 o O O 
R l ^ + J ] SiO,.HM^W V _ N H R2 KMO.,SiO,.MW^ f ^ l - / \ ^ 
NH-NH2 R2 H EtOH,H* R N = / or Acetone .Water N—N 
R2 
(xxi) (xxli) (xxiii) (xxiv) 
Scheme 3.6 
2-(4-Methoxylphenyloxyacetylamido)-5-aryloxymethyl-l,3,4-oxadiazoles 
(xxvii) were synthesized by cyclization of l-aryloxyacetyl-4-(4-
methoxylphenyloxyacetyI)-thiosemicarbazides (xxvi) in the presence of mercuric 
acetate under microwave irradiation^^ (Scheme 3.7). 
0CH3 
OCH3 I O 
r - ^ - ^ NH,SCN.PEG-400/CH,CI, [| ^ HE(OACVACOH. MW \ \ / / V ' ^ Q 
AiOCHjCONHNHj 
6CH2COCI OCH^COHNCOHNHNCOCHjOAr 
H3CO 
(xxv) (xxvi) (xxvii) 
Scheme 3.7 
5,5'-Dimercapto-bis-[l,3,4-oxadiazol-2-yl]octane (xxix) and 5,5'-dibenzylthio-
bis-[l,3,4-oxadiazol-2-yl]-butane were synthesized by reaction of alkanedioic acids 
hydrazides (xxviii) with CS2 in alcoholic KOH solution to give (xxix) which yielded 
(xxx) with addition of benzyl bromide^^ (Scheme 3.8). 
KOH/EtOH HS x ' ° \ L~l / ° \ ^SH n , -. o 
" ^ ^ ^ " Y ^ ' " N H . _ ^ L _ I ~ ^ K t i y KOH PHH.CS^°yH.ysCH.P. 
0 0 2PhCHjBr 
(xxviii) (xxix) (xxx) 
Scheme 3.8 
59 
2,5-Disubstituted-1,3,4-oxadiazoles 
Shu Wang, Zhitao and Wenting Hua have synthesized the macrocycles 
containing 1,3,4-oxadizole moiety (xxxi). 
R=H, (CH2)3CH3 
(xxxi) 
2,5-Substituted-1,3,4-oxadiazoles containing 2-benzothiazolythiomethyl 
moiety (xxxiv) were synthesized by condensation of (2-benzothiazoIyhhio)acetic acid 
imino ester dihydrochloride (xxxii) with hydrazides of various carboxylic acids^^ 
(Scheme 3.9). 
\V / ^ /NH.HCI / / 
(xxxii) (xxxiv) (xxxiii) 
Scheme 3.9 
Brain et al.^^ reported the synthesis of simple 1,3,4-oxadiazoles via 
cyclodehydration of 1,2-diacylhydrazines using a polymer-supported Burgess reagent 
or the polymer-bound phosphazine base PS-BEMP in the presence of toluenesulfonyl 
chloride as a dehydrating agent^°. Brown^' and Kilbum^^ have also shown that 2-
amino-1,3,4-oxadiazoles can be prepared in excellent yields on solid phase from the 
. corresponding immobilised 1,4-disubstituted semicarbazides using either 1,3-
diisopropylcarbodiimide (DIPC), 1,3-dicyclohexylcarbodiimide (DCC) or l-(3-
dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCHCl) as the 
cyclisation mediator. 
60 
2,5-Disubstituted-1,3,4-oxadiazoles 
Wang et al. have reported the one step synthesis of 1,3,4-oxadizoles from 
diacyl hydrazide in the presence of DMC (2-chloro-l,3-diniethylimidazolinium 
chloride), 1,3,4-oxadiazoles can be obtained in good yields from carboxylic acids and 
acid hydrazides in CH2CI2 by heating under microwave condition (Scheme 3.10). 
^NH2 2eqiv. DMC 
NH 3eqiv. PSBEMP 
CHjCN, MW 
150°C,20min 
(xxxv) (xxxvi) (xxxvii) 
Scheme 3.10 
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3.2 Synthesis, Antibacterial and Antifungal Activity of Some New 
2,5-Disubstituted-1,3,4-oxadiazoles* 
1,3,4-oxadiazoles are a class of heterocycles which have attracted significant 
interest in medicine, pesticide chemistry and material science. They are of significant 
interest in medicinal chemistry as ester bioesters in a number of biological targets 
including 5-HT receptor agonists^, muscarinic agonists^'', 5-HT antagonists^^, human 
NKi antagonists^^, antirhinoviral compounds^^ and anti-inflammatory agents^*. 
Numerous compounds containing 1,3,4-oxadiazoles have been evaluated for their 
antimicrobial , psychotropic , antiaflatoxigenic , anticonvulsant , tuberculostatic , 
antimitotic^'', analgesic^^ and CNS activity^ .^ They have been used as peptide 
mimetics due to their particular geometric and electrostatic properties . A variety of 
2,5-dialkyl, 2,5-diaryl, 2-alkyI,5-aryl-1,3,4-oxadiazoles show herbicidal activity'^. 
Therefore the development of novel synthetic routes to achieve access to these 
molecules is of prime interest. Further, the increasing number of multidrug resistant 
pathogens has led us to screen the newly synthesized derivatives against the 
representative panel of bacterial and fungal strains. 
Keeping in mind the practical applications of 1,3,4-oxadiazoles, the design 
and synthesis of hitherto unknown oxadiazoles bearing long alkyl and alkenyl chain 
and their in vitro biological screening against Gram positive and Gram negative 
bacteria and fungi was performed. The symmetrically disubstituted-1,3,4-oxadiazoles 
have not yet been reported from saturated and olefinic long-chain carboxylic acids. 
Tetrazoles^ '^*", pyrazolines*', tetrazine* '^^ ^ spiro [oxathiolane-2, 2'-
dihydrotetrazoles] , aziridines and benzothiazoles have been previously prepared 
in author's laboratory. Cyanoethoxy and morpholine derivatives of hydroxy fatty 
87 RR 
acids and long-chain alkenoates showed significant antifungal and antibacterial 
activity. 
*Research paper entitled "One-pot synthesis, antibacterial and antifungal activities of novel 
2,5-disubstituted-l,3,4-oxadiazoles" is published. (A. Rauf, S. Sharma, S. Gangal, Chin. 
Chem. Lett., 2008, 19,5-8). 
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3.3 Results and discussion 
A typical reaction procedure in a single step involves the addition of a solution 
of hydrazine hydrate to acid chloride 2a-f at O^ C in dry dioxane and stirring at room 
temperature to furnish corresponding 1,2- diacylhydrazine 3a-f (Scheme 3.11). To the 
prior acid chloride was synthesized from saturated and olefinic fatty acids by in situ 
preparation. Since fatty acid chlorides 2a-f are not commercially available the present 
method has greatly solved the problem by facile and efficient in situ preparation. We 
have used BF3 0Et2 for cyclodehydration of 1,2-diacylhydrazines 3a-f. BF3 0Et2 in 
dry dioxane was added to the 1,2-diacylhydrazine 3a-f without isolating the product 
and reaction mixture refluxed for 1-2 hours. 
\ 80°C,2h \ dry dioxane, 0°C \ / N—N 
OH CI NH-NH 
la-f 2a-f 3a-f 4a-f 
Scheme 3.11 Synthesis of2,5-disubstituted-l,3,4-oxadiazoles. 
Table 3.1 2,5-Disubstituted-l,3,4-oxadiazoles 
Compound 
1,2,3,4 
a 
b 
c 
d 
e 
f 
R 
/ ^ C H , 
/ ^ C H , 
H 
HE 
•9^^^CH, 
4 OH 5 
OH 
J 6 
Yield % 
4 
98 
98 
97 
98 
95 
90 
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As can been seen from Table 3.1 the scope of the reaction using saturated, 
olefinic (internal and terminal) and hydroxy fatty acid is found to be good. The yields 
of 1,3,4-oxadiazoles 4a-f are excellent and independent of the substituents present in 
the precursor. In ' H N M R spectra of 2,5-di-(dec-9-enyl)-l,3,4-oxadiazole (4c), 
multiplet for four hydrogens was observed at 5 2.54 for methylene protons alpha to 
oxadiazole moiety. Methine proton of C-9 showed signals at 5 5.82. C-10 methylene 
designated as HE and Hz displayed two distinct 8 values when coupled with adjacent 
C-9 methine protons. Thus, the H NMR spectrum showed two doublet of doublet at 8 
5.02 and 4.90 for Hz and HE protons respectively. The structure of 4c was further 
supported by its mass spectral studies, which showed molecular ion peak at m/z 346 
consistent with its molecular formula C22H3gN20. Base peak appears at m/z 111. 
Detailed spectra of titled compounds are given in the experimental section. 
All the newly synthesized compounds were evaluated in vitro against an 
assortment of two Gram-positive bacteria Staphylococcus aureus MSSA 22 (SA) and 
Bacillus subtilis ATCC 6051 (BS) and two Gram-negative bacteria Escherichia coli K 
12 (EC) and Salmonella typhimurium MTCC 98 (ST) . Screening results are 
summarized in Table 3.2. 
Table 3.2 In vitro antibacterial activity of compounds 4a-f 
Diameter of zone of inhibition (mm) at lOO^g/ml 
Gram-positive bacteria Gram-negative bacteria 
Compound 
4a 
4b 
4c 
4d 
4e 
4f 
Chloramphenicol 
Control (DMSO) 
B.subtilis 
27 
29 
24 
24 
20 
20 
40 
— 
S.aureus 
26 
24 
25 
25 
26 
26 
36 
— 
E.coli 
20 
18 
18 
17 
18 
18 
20 
~ 
S.typhimurium 
17 
17 
15 
13 
14 
14 
28 
~ 
The minimum inhibitory concentrations (MIC) of all the tested compounds 
were lOO i^g/ml. The newly generated compounds 4a-f have exerted significant 
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inhibitory activity against the growth of the tested bacterial strains. The data 
pertaining to Table 3.2 reveal that 4a-f have significant influence on antibacterial 
profile of Gram-positive bacteria. The higher susceptibility of Gram-positive bacteria 
is due to absence of a unique outer membrane of peptidoglycon, hence the wall of 
these bacteria is permeable to these derivatives. The compounds 4a-f showed good 
inhibitory results against S. typhimurium and E. coll Fig. 3.1 and 3.2 shows that in 
vitro screening of synthesized compounds gives promising results compared to the 
reference drug chloramphenicol and nystatin. 
c 0 
** 
n 
c 
3? 
70 
60 
50 
40 
30 
20 
10 
0 
4a 4b 4c 4d 
Compound 
Fig. 3.1 Percent inhibition of antibacterial activity for compounds 4a-fover 
control drug 
All the synthesized compounds were screened for antifimgal activity against 
Candida albicans (IOA-109) (CA), Penicillium sp. (lab isolate) (PN), Fusarium 
oxysporum (lab isolate from ICAR, Jaipur) (FO), Trichoderma viridae ATCC 5170 
(TV) and Aspergillus niger (lab isolate from ICAR, Jaipur) (AN) at a concentration of 
lOO^g/ml. Nystatin was used as standard drug for the comparison of antifimgal 
results. 
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Table 3.3 In vitro antifungal activity of compounds 4a-f 
Compound 
Diameter of zone of inhibition (mm) at lOOfig/ml 
Calbicans T.viridae PenicilUum sp. F.oxysporum A.niger 
4a 
4b 
4c 
4d 
4e 
4f 
Nystatin 
ControI(DMSO) 
27 
22 
21 
22 
27 
23 
30 
~ 
18 
15 
14 
15 
15 
13 
20 
~ 
22 
20 
21 
23 
18 
17 
25 
— 
18 
16 
16 
17 
18 
17 
20 
— 
14 
14 
13 
15 
16 
11 
20 
~ 
Among the tested organisms, compounds 4a, 4e showed excellent inhibitory 
results for C. albicans IOA-109. Compounds 4b, 4c, 4d revealed good results against 
Penicillium sp. and F. oxysporum. All compound showed moderate activity results 
against T. viridae ATCC 5170 and^. niger (Table 3.3). The data also revealed that 
4a, 4c, 4d has produced the marked enhancement in the potency of these analogues as 
antifungal agents. 
•£ 
'£ 
c 
ss 
70 
60 
50 
40 
30 
20 
10 
0 
OCA 
HTV 
nPN 
DFO 
• AN 
Fig. 3.2 Percent inhibition of antibacterial activity for compounds 4a-fover 
control drug 
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3.4 Experimental 
The sources of all the fatty acids and instrumentation details are the same as 
given in Chapter 1 (page 38). 
General procedure for the synthesis of 2,5-disubstituted-l,3,4-oxadiazoles (4a-f) 
Thionyl chloride (3 mmol) was added to fatty acid la-f (2.5 mmol) at 80°C 
for about 2 hours to form the corresponding acid chloride 2a-f. The progress of 
reaction was monitored by TLC. The excess of thionyl chloride was distilled off. To a 
stirred solution of acid chloride (2.5 mmol) in dry dioxane (25ml) was added 
hydrazine hydrate (1.25 mmole) at 0°C and stirred further for 30 minutes at room 
temperature. BF3 0Et2 (6.25 mmole) in dry dioxane (5ml) was added dropwise to the 
above stirred reaction mixture in 15 minutes and reaction mixture further refluxed for 
I to 2 hours at I30°C. The resulting solution was concentrated in vacuum, saturated 
NH4CI solution added at till the pH becomes 6, extracted with EtOAc, dried over 
anhydrous Na2S04 and concentrated in vacuum to give the crude product 4a-f as oily 
liquids, which is further purified by column chromatography (Hexane:EtOAc, v:v) 4a, 
(99:1); 4b, (99:1); 4c, (98:2), 4d, (97:3); 4e, (95:5); 4f, (95:5). 
Antibacterial Activity 
The antibacterial activity of test compounds and standard chloramphenicol was done 
by filter paper disc method against Staphyloccous aureus MSSA 22, Escherichia 
coli K12, Bacillus subtilis ATCC 6051, Salmonella typhimurium MTCC 98 at a 
concentration of 1 OOfig/ml. Media with DMSO was set up as control. 
Antifungal activity 
The standard agar disc diffusion method''' was performed to evaluate the antifungal 
property of the test compounds and standard nystatin. Aspergillus niger (lab isolate 
from ICAR, Jaipur), Candida albicans IOA-109, Penicillium sp (lab isolate), 
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Fusarium oxysporum (lab isolate from ICAR, Jaipur), Trichoderma viridae ATCC 
5170 were used in this study. Solvent control DMSO was also run. 
Percent inhibition (% inhibition) of antibacterial and antifungal activity for different 
derivatives over control drug, was calculated by using the following formula: 
a - 6 
% inhibition = ^ x 100 
a 
where, a and P stand for zone of inhibition of control drug and synthesized 
compounds, respectively. 
Spectroscopic data 
2,5-Dipentadecyl-l,3,4-oxadiazole (4a) 
IR fKBr): 1024, 1247,1639 cm"'. 
'HNMR (400 MHz, CDCI3): 5 2.54 (m, 4H, a to oxadiazole ring), 1.63 (m, 4H, p to 
oxadiazole ring), 1.30 (br.s, 48H, chain CHi), 0.88 (6H, dist. t, CZ/s)-
'^CNMR (100 MHz, CDCI3): 172.63, 34.15,31.98,29.45,24.73, 22.75,14.17. 
MS {m/z, % ) : (M+1)^ 491 (8), (M^) 490 (15), 475 (60), 433 (100), 405 (50), 377 
(100), 349 (25), 335 (10), 321 (85), 279 (22). 
Anal. Calcd. for C32H62N2O: C, 78.36; H, 12.65; N, 5.71. Found: C, 78.39; H, 12.99; 
N, 5.66%. 
2,5-Diheptadecyl-l,3,4-oxadiazole (4b) 
IR (KBr): 1030, 1250,1645 cm''. 
'HNMR (400 MHz, CDCI3): 5 2.56 (m, 4H, a to oxadiazole ring), 1.64 (m, 4H, p to 
oxadiazole ring), 1.33 (br.s, 56H, chain C//2), 0.88 (6H, dist. t, C//3). 
'^CNMR (WO MHz, CDCI3): 173.26*, 34.09, 31.95, 29.42, 24.71, 22.72, 14.15. 
MS {m/z, %): (M+1)^  547 (5), (M )^ 546 (32), 517 (68), 489 (100), 447 (40), 419 (12), 
363 (22), 321 (60), 298 (10), 235 (31), 214 (21). 
Anal. Calcd. for C36H70N2O: C, 79.12; H, 12.82; N, 5.12. Found: C, 79.28; H, 12.80; 
N, 5.32%. 
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2,S-Di-(dec-9-enyl)-l,3,4-oxadiazole (4c) 
IR (KBr): 1040, 1240, 1640 cm"' . 
'HNMR (400 MHz, CDCI3): 5 5.82 (tdd, IH, J^ .^ ^ = 6.6 Hz, J„_„^ = 10.2 Hz, 
J„_f^^/= 17.1 Hz, CH2=C//-), 5.02 (dd, IH, J„^.n= 10.2 Hz, JH,-H,= 1-2 Hz, 
//2C=CH), 4.90 (dd, IH, J^^_„ = 17.1 Hz, JH,-H,= 1-2 Hz, //£C=CH-), 2.55 (m, 
4H, a to oxadiazole ring), 2.03 (m, 4H, -C//2-CH=CH2), 1.62 (m, 4H, p to oxadiazole 
ring), 1.29 (br.s, 20H, chain C//2). 
"CiVM/?(100MHz,CDCl3): 172.73, 139.19, 114.22,34.20,33.84,29.15,24.72. 
MS {m/z, % ) : (M+1)^ 347 (10), (M^) 346 (18), 305 (39), 291 (16), 277 (100), 263 
(46), 249 (48), 235 (82), 207 (8). 
Anal. Calcd. for C22H38N2O: C, 76.30; H, 10.98; N, 8.09. Found: C, 76.33; H, 10.86; 
N, 8.17%. 
2,5-Di-(heptadec-8-enyl)-J,3,4-oxadiazole (4d) 
IR (KBr): 1024,1300,1639 cm"'. 
'HNMR (400 MHz, CDCI3): 5 5.38 (m, 4H, -CH=CH-), 2.60 (m, 4H, a to oxadiazole 
ring), 2.01 (m, 8H, -C//2-CH=CH-C//2-), 1.51 (m, 4H, p to oxadiazole ring), 1.13 
(br.s, 40H, chain CH2), 0.92 (6H, dist. t, CH3). 
'^C NMR (100 MHz, CDCI3): 172.63, 129.82, 40.53, 34.00, 29.39, 31.64, 26.33, 
24.74,14.14. 
MS {m/z, %): (M+1)^  545 (15), (M )^ 544 (44), 529 (100), 515 (8), 501 (71), 487 (39), 
473 (26), 391 (67), 391 (37), 307 (5), 139 (62). 
Anal Calcd. for C36H66N2O: C, 79.41; H, 12.13; N, 5.14. Found: C, 79.62; H, 12.18; 
N, 5.33%. 
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2,5-Di-[(8Z,llR)-ll-hydroxy-heptadec-8-enylJ-l,3,4-oxadiazole{4e) 
IR (KBr): 1025, 1280, 1650 cm"'. 
'HNMR (400 MHz, CDCb): 6 5.37 (m, 4H, -C//-C//-), 3.63 (m, 2H, -C//-OH), 2.54 
(m, 4H, a to oxadiazole ring), 2.29 (m, 2H, -CH-O/f), 2.02 (m, 8H, -C//2-CH=CH-
C//2-), 1.54 (m, 4H, p to oxadiazole ring), 1.37 (br.s, 36H, chain CHj), 0.88 (6H, 
dist. t, C//3). 
'^C NMR (100 MHz, CDCI3): 174.67, 130.51, 71.67, 37.06, 34.30, 31.64, 28.88, 
25.47,23.42,14.53. 
MS- (m/z, %): (M+1)^ 559 (12), (M^) 558 (40), 543 (100), 501 (17), 487 (16), 443 
(37), 403 (58), 361 (41), 347 (10), 333 (61), 155 (82). 
Anal Calcd. for C36H66N2O2: C, 77.41; H, 11.82; N, 5.01. Found: C, 77.49; H, 11.72; 
N, 5.09%. 
2,5-Di-f(8R,llZ)-8-hydroxy-heptadec-ll-enylJ-l,3,4-oxadiazole {4f) 
IR (KBr): 1024,1240,1640 cm"'. 
'HNMR (400 MHz, CDCI3): 6 5.39 (m, 4H, -CH=CH-), 3.68 (m, 2H, -C//-OH), 2.47 
(m, 4H, a to oxadiazole ring), 2.27 (m, 2H, -CE-OH), 2.04 (m, 8H, -C//2-CH=CH-
CH2-), 1.57 (m, 4H, p to oxadiazole ring), 1.37 (br.s, 36H, chain C//2), 0.88 (6H, 
dist. t, C//3). 
'^C NMR (100 MHz, CDCI3); 174.65, 130.56, 71.67, 37.06 34.36, 31.63, 28.82, 
25.48, 23.44, 14.58. 
MS {m/z, % ) : (M+1)^ 559 (13), (M^) 558 (40), 529 (28), 487 (100), 461 (56), 449 
(37), 389 (13), 375 (10), 333 (61), 97 (82). 
Anal. Calcd. for C36H66N2O2: C, 77.41; H, 11.82; N, 5.01. Found: C, 77.44; H, 11.76; 
N, 5.12%. 
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4.1 Theoretical 
Nitrogen-oxygen heterocycles are of synthetic interest because they constitute 
an important class of natural and non-natural products, many of which exhibit useful 
biological activities'. 3,5-Functionalized-l,2,4-oxadiazoles have received 
considerable attention in the pharmaceutical industry as heterocyclic amide and ester 
biosteres . The oxadiazole nucleus is well studied pharmacophoric scaffold that has 
emerged as a core structural unit of various muscarinic agonists , benzodiazepine 
receptor partial agonists'*, dopamine transporters^, tyrosine kinase inhibitor^, a growth 
hormone secretatogue and antiinflammatory agents . 
The wide spread interest in 1,2,4-oxadiazoles containing structures has 
prompted extensive studies for their synthesis. Irrespective of the steric and electronic 
nature of acylating agents (chloroanhydrides and anhydrides of carboxylic acids), the 
primary products of the acylation of amidoximes in equimolar mixtures of reactants 
aretheO-acylatedamidoximes^"' . 
The acylation of amidoximes of (2-oxopyrrolidino)- alkane acids (i) in 
dioxane leads to 0-alkoylamidoximes (ii) which on subsequent thermolysis leads to 
1,2,4-oxadiazole (iii)' (Scheme 4.1). 
tXo 0 N 0 N *- N 
NH2 NH2 \ 
CH3 
(i) (ii) (iii) 
Scheme 4.1 
Hikmet and Dogan'^ reported that the reaction of acetamidoxime (iv) with 
monochloroacetic acid chloroanhydride on boiling in chloroform led to the formation 
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of 1,2,4-oxadiazole (v) and 3-methyl-4H-l,2,4-oxadiazin-5(6H)-one (vi) (Scheme 
4.2). 
N—O 
H,C / / 
NOH HoC J ^ \ 
C1CH,C0CI " 3 ^ - ^ ^ ^ o 
H , C - ^ - ^ \ _ / + 
CH20N=CCH3NH2 H ^^^ 
(iv) (V) (vi) 
Scheme 4.2 
It was also reported that the interaction of a mixture of ElZ isomers of 
NCC(=NOH)NHAr with BrCOCHzBr in CH2CI2 at 20°C in the presence of EtsN led 
to the formation of 3-cyano-4-Ar-l,2,4-oxadiazin-5(4H)-ones with 10-84% yields'*, 
while the reactions between N-/7ara-tolylamidoximes of substituted benzoic acids 
(vii) with chloroacetyl chloride led to 3-aryl-4-(/?ara-tolyl)-l,2,4-oxadiazin-5(4H)-
kl9 
ones (viii)'" (Scheme 4.3). 
XQ •^,-i 
NOH 
ClCH C^OCl X C « H . - / 6^4 
NHC6H4P-CH3 
(Vii) 
P-CH3H6C4 
(viii) 
Scheme 4.3 
j20 According to Goddard , regioisomeric 5-thienyl-l ,2,4-oxadiazoles (xi) were 
synthesized using the following Scheme 4.4. 
TV-
(ix) 
HjCOOC-^ \ g 
H2N 
% 
0 , 
H,C 
Scheme 4.4 
(xi) 
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Potential muscarinic receptor agonists — quinuclidines (xiii) containing 1,2,4-
oxadiazole rings — were synthesized in single-stage reactions between 
methylquinuclidine-3-carboxylate (xii) and the corresponding amidoxime or 
hydroxyguanidine. The reactions were carried out on boiling in THF in the presence 
of sodium hydride or on boiling in ethanol in the presence of dispersed molecular 
sieves^' (Scheme 4.5). 
c;^' 
H-^  
COOCH 
(xii) 
Scheme 4.5 
Methyloxadiazole (xv) was obtained with a 65% yield by treating the 
muscarine agonist arecoline (xiv) with acetamidoxime sodium salt (Scheme 4.6). 
CH3 
.COOCHj 
N 
I 
CH3 
(xiv) 
Scheme 4.6 
The same method was used for obtaining methyl (xvii) and amino (xviii) derivatives 
in the quinuclidine series (Scheme 4.7). 
(xvii) 
CH, 
\^ \ / 
COOCH3 
(xviii) 
NH, 
h I / 
Scheme 4.7 
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The ability of the 1,2,4-oxadiazole ring to play the role of a bioisosteric ester 
moiety in the development of stable muscarinic receptor agonists (possessing activity 
with respect to the central nervous system) stimulated the synthesis of a series of 5-
[(3-alkyl)-l,2,4-oxadiazol-5-yl]-l,4,5,6-tetrahydropyrimidines (xx). The removal of 
the trityl protection in the initial esters (xix) in trifluoroacetic acid led to the formation 
of the corresponding trifluoroacetates (xx) (Scheme 4.8). 
(xix) 
H N ^ ^ N .TFA 
(XX) 
Scheme 4.8 
The notion that 1,2,4-oxadiazoles are perfect bioisosteric moieties for the ester 
groups of well-known cocaine analogs involved in dopamine transport also inspired 
the synthesis of 3-p-(substituted phenyl)-2-p-(3-substituted-l,2,4-oxadiazole-5-yl) 
\24 tropanes (xxii) (Scheme 4.9). 
H,C 
COOH H,C 
l.(COCl)j,CHjClj 
2. RC(=N0H)NHj 
Py, CHClj 
(xxi) (xxii) 
Scheme 4.9 
A single-stage condensation of R1C6H4I (xxiii) with NH2CR2=NOH in CO 
atmosphere in the presence of a catalyst [Cl2Pd(PPh3)2, (Ph3P)4P, or Cl2Pd(dppf)] and 
a base (EtsN) in an appropriate solvent (DMF, N-methylpyrrolidone, or toluene) was 
used for the synthesis of substituted-1,2,4-oxadiazoles (xxiv)^^ (Scheme 4.10). 
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(xxiii) (xxiv) 
Scheme 4.10 
Substituted 1,2,4-oxadiazoles (xxvii) were also obtained with good yields 
using a single-stage condensation of the corresponding amidoximes (xxv) with 
carboxylic acids (xxvi) in the presence of a peptide condensation agent. The process 
was conducted by heating the reaction mixture in diglyme for several hours at 
100°C^^ (Scheme 4.11). 
NOH 
~NH2 + 
HOOC 
EDC 
110°C HjC 
H,C 
(xxv) (xxvi) (xxvii) 
Scheme 4.11 
The several groups of 1,2,4-oxadiazoles (xxix) were obtained via the 
interaction of amidoximes (xxviii) with nitriles in the presence of ZnCb and HCl in 
97 
butyl- and wo-butylacetate (Scheme 4.12). 
I \ /NOH 
O2N RCN 
-*' ^ 2 0,N' 
NH, 
(xxviii) 
Scheme 4.12 
r\ 
o 
N^ 
N—O 
(xxix) 
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The reaction of thiocarbamoylformamidoxime (xxx) with orthoformic ester at 
room temperature in the presence of a catalyst (boron trifluoride etherate) leads to the 
formation of I,2,4-oxadiazole-3-carboxylic acid thioamide (xxxi)^ ^ (Scheme 4.13). 
NH2 
HoN NH, 
// \ CH{OEt,) 
S NOH 
(xxx) (xxxi) 
Scheme 4.13 
A convenient method for the synthesis of five-membered heterocycles is 
offered by 1,3-dipolar cycloaddition. The formation of 1,2,4-oxadiazole systems in 
the course of cycloaddition of N-oxides to nitriles was studied. In particular, 1,2,4-
oxadiazoles (xxxv) were obtained as cycloadducts formed as a resuh of the reaction of 
liberated N-oxide (xxxiii) with dipolarophilic nitrile (xxxiv)^ ^ (Scheme 4.14). 
CH3OCO' 
(CH30CO)2CHN02 ' - ^ [CH,OCO—C=N—0]+ RCN ^ y ^ \ \ 
J N ^ 
0 ' 
(xxxii) (xxxiii) (xxxiv) (xxxv) 
Scheme 4.14 
-R 
Oxadiazoles (xxxviii) were obtained via the reaction of benzonitrile N-oxide 
(xxxvi) with aromatic nitriles (xxxvii) (Scheme 4.15) 
0 + <\ / ) — = N 
, _ ^ . , 
(xxxvi) (xxxvii) (xxxviii) 
(X = 2-,3-, 4-OH, 2-OCH3; Y = H, S-OCHj, S-NOj) 
Scheme 4.15 
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The interaction of ethinylnitrochlorocyanoacetate (xxxix) with N-oxides of 4-, 
3-, and 2-methoxybenzonitriles (xl) leads to the formation of 3-aryl-5-
nitrochloroethoxycarbonyl- methyl- 1,2,4-oxadiazoles (xli) (Scheme 4.16). 
H5C202C(02N)C(CI>—C=N + CHjOCgH—C=N-—0 *- Hf,p^C{O^H)C(C\\^_^yO 
C6H4OCH3 
(xxxix) (xl) (xli) 
Scheme 4.16 
Itoh et al?^ have synthesized the 3-benzoyl and 3-acetyl-l,2,4-oxadiazole 
derivatives (xliv) by the reaction of nitriles (xlii) with iron (III) nitrate at 80°C in 
benzophenone and acetophenone respectively (Scheme 4.17). 
0 . . R i ^ / ° \ . 
Fe(N03)2 ' ^ ,N 
CH3 \=0 
R 2 
(xlii) (xliii) (xliv) 
Scheme 4.17 
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4.2 Efficient, One-pot Synthesis of Novel 3,5-Disubstituted-1,2,4-
oxadiazoles from Long-Chain Carboxylic Acid Derivatives Under 
Conventional and Microwave Conditions 
Among oxadiazoles, 1,2,4-oxadiazoles derivatives have gained importance in 
medicinal chemistry. In the literature, 1,2,4-oxadiazoIes have shown affinities for 
serotonin and norepinephrine transporters^ 1,2,4-Oxadiazole ring system has also 
been used as a urea bioisostere in p3 adrenergic receptor agonists , as biosteres of 
ester and amide^^ and as antitumor agents '^*. Furthermore, derivatives containing 
1,2,4-oxadiazoles ring systems have been employed as serotoninergic (5-HT3) anti-
inflammatory agents, antittimor agents, monoamine oxidase inhibitors, coronary 
artery dilaters, anesthetic agents, muscle relaxants, antischistosomal agents, aldose 
reductase inhibitors and histamine H3 antagonists . 
Knowing the pharmacological importance of the oxadiazole ring systems and 
in continuation of study on the derivatization of fatty acids in author's laboratorty, 
this chapter focused on the synthesis of this nucleus bearing long-alkyl and alkenyl 
chains at C-5. It describes the facile synthesis of 1,2,4-oxadiazoles by conventional 
heating and by application of microwave energy in solvent-free conditions. The 
interest in one pot conversion of carboxylic acid derivatives and amidoximes to 3,5-
disubstituted-1,2,4-oxadiazoles prompted to utilize derivatives of carboxylic acids-
esters and acid chlorides for the synthesis. To the best of my awareness this 
contribution reports for the first time a simple and straightforward synthesis of 1,2,4-
oxadiazoles under microwave condition having long hydrocarbon chain attached at 
C-5. 
The methods reported in chapter tolerates variety of fimctional groups on both 
the reaction partners and presents a straightforward procedures for the efficient and 
facile synthesis of 3,5-disubstituted-1,2,4-oxadiazoles in moderate to excellent yields. 
The reactions described in this chapter have a remarkable synthetic utility and are 
valuable addition to the synthesis and manipulation of fatty acid derivatives because 
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they make compounds available in one step from acid derivatives with or without 
microwave irradiation. 
4.3 Results and discussion 
The following methods of 1,2,4-oxadiazole synthesis shows that there are 
broad possibilities for the synthesis of new compoimds offering highly effective 
agents bioisosteric with ester and amide groups. Modem trends in the synthesis of 
new 1,2,4-oxadiazoles are the search for highly effective pathways of room-
temperature synthesis (excluding undesired high-temperature rearrangements) and the 
use of effective catalysts and microwave-stimulated processes. 
At first the investigation of one-pot synthesis of 3,5-disubstituted-1,2,4-
oxadiazoles from easily synthesized fatty esters la-d and amidoximes 2a-e was 
carried out. To the solution of fatty ester in toluene was added amidoxime followed 
by addition of K2CO3 and allowed to reflux for 9-13 hours (Scheme 4.18). The one-
pot procedure provided 3a-t in 50-58% yield (Table 4,1). The need for higher yield of 
products prompted to employ more reactive acid chloride I'a-d (Scheme 4.19). The 
I'a-d was added dropwise to a stirred solution of the amidoxime 2a-e in pyridine and 
reaction was refluxed for 1-2.5 hours. In most of the cases the yield of product was 
60-62% (Table 4.1). 
0 NOH ^pp, ^, /° 
R,-{ + R-/ _ : ^ f ^ \,/ 
OMe NH2 toluene, reflux / " ' ^ 
(9-13h) ^ 
la-d 2a-e 3a-t 
Scheme 4.18 Synthesis of 3,5-disubstituted-l,2,4-oxadizoles from long-chain esters 
and amidoximes 
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Table 4.1 3,5-Disubstituted-l,2,4-oxadiazoles under conventional heating 
conditions 
Entry Ri (R) Product Time (h) Yield(%) 
Method 1 Method Method 1 Method 
2 2 
^^H. 
CH. 3a 10 1.2 51 60 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
OH 
OH 
H A 
0^;-=-0';"= 
v;r"=^ '^ 
OH 
S ( ^ _ ^ C H , 
Hx 
H A 
OH 
S 9 ^ _ ^ C H , 
Hx 
BHYk».^H^ 
H A 
OH " 
OH 
Hx 
BHY^k»^^H, 
H A 
OH 
OH 
3 " 6 
CH3 
CH3 
CH3 
A'H 
A'H 
A'H 
A'H 
CI-CH2 
CI-CH2 
CI-CH2 
CI-CH2 
-QHs 
-CeHs 
-CeHs 
4-OH-C6H4 
4-OH-C6H4 
4-OH-C6H4 
4-OH-C6H4 
3b 
3c 
3d 
3e 
3f 
3g 
3h 
3i 
3j 
3k 
31 
3in 
3n 
3o 
3p 
3q 
3r 
3s 
3t 
10.5 
10.5 
11 
11 
10 
11 
11 
10 
11 
12 
12 
9 
9.5 
10 
10 
12 
13 
13 
13 
1.2 
1.4 
1.4 
1.3 
1.5 
2 
2.3 
2.4 
2.5 
2.5 
2 
1.4 
1.5 
1.2 
2 
2 
2.5 
2.5 
2.5 
52 
53 
53 
50 
51 
52 
52 
53 
54 
55 
55 
57 
58 
58 
51 
52 
53 
55 
56 
61 
60 
62 
62 
62 
69 
60 
60 
61 
63 
64 
65 
62 
62 
60 
61 
62 
60 
61 
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O NOH '^ 
// . / / PvriHinp r' 
CI NH 
+ R-^ py"^ ^^  . y_/y 
R 
I'a-d 2a-e 3a-t 
Scheme 4.19 Synthesis of 3,5-disubstituted-l,2,4-oxadizoles from long-chain acid 
chlorides and amidoximes 
To explore the probability of getting the pharmacophoric important moiety in 
higher yields and in shorter reaction time, our attention has turned to employ 
microwave irradiation. The application of microwave energy to organic compounds 
for conducting synthetic reactions at highly accelerated rates is an emerging 
technique. Infact in later years, microwave have become popular among synthetic 
organic chemists both to improve classical organic reactions, shortening reaction time 
iind/or improving yields, as well as to promote new reactions. The esters la-d, acid 
chlorides I'a-d and amidoximes 2a-e were supported on neutral alumina in same 
molar ratio as in conventional reaction method and subjected to microwave irradiation 
in open pyrex glassware for appropriate time (Scheme 4.20). 
R 
3a-t 
Scheme 4.20 Synthesis of3,5-disubstituted-l,2,4-oxadiazoles under microwave 
irradiation 
At first the condensation reaction of amidoxime (2a) with undec-10-enoic acid 
derivatives was chosen as a model to optimize the conditions for the preparation of 
compounds 3a-t (Table 4.2). In order to determine the optimum conditions for the 
synthesis of oxadiazoles, variations in molar ratios of reagents and the irradiation time 
and power level of microwave set-up were investigated. 
0 
R , ^ + 
X 
la-d (X=OMe) 
l'a-d(X=Cl) 
NOH 
NH2 
2a-e 
microwave 
3 * 
neutral alumina 
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Table 4.2 Optimization of the microwave -assisted condensation of la (a') and 2a 
on neutral alumina 
la (X=OMe) 
l'a(X=Cl) 
Entry 
1 
2 
3 
4 
5 
Support 
Neutral 
alumina 
Neutral 
alumina 
Neutral 
alumina 
Neutral 
alumina 
Neutral 
alumina 
molar 
ratios 
0.5/1 
0.8/1 
1/1 
1/1.1 
1/1.2 
Time 
(min) 
5 
7 
9 
11 
13 
Esters 
Power 
(%) 
20 
30 
40 
50 
60 
Yield 
(%) 
30 
40 
48 
55 
78 
molar 
ratios 
0.5/0.8 
0.8/1 
1/1.1 
1/1.2 
1/1.4 
Acid Chlorides 
Time 
(min) 
5 
6 
7 
8 
9 
Power Yield 
(%) (%) 
10 30 
20 36 
30 45 
40 88 
40 92 
After some experimentation, we found a set of conditions that generally 
provide products in good yield. The optimum conditions for molar ratio of fatty 
esters, fatty acid chlorides and amidoxime, irradiation time and power level of 
microwave set up are given in Table 4.3. 
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Table 4.3 Reaction of long chain carboxylic acid derivatives with amidoximes to 
synthesize 3,5-disubstituted-l,2,4-oxadiazole under microwave-assisted, 
solvent-free conditions. 
Product 
3a 
3b 
3c 
3d 
3e 
3f 
3g 
3h 
3i 
3j 
3k 
31 
3m 
3n 
3o 
3p 
3q 
3r 
3s 
3t 
1/2" 
1/1.2 
1/1.2 
1/1.2 
1/1.2 
1/1.2 
1/1.2 
1/1.2 
1/1.2 
1/1.2 
1/1.2 
1/1.2 
1/1.2 
1/1.2 
1/1.2 
1/1.2 
1/1.2 
1/1.2 
1/1.2 
1/1.2 
1/1.2 
Esters 
Power'' 
(%) 
60 
60 
60 
60 
60 
60 
60 
60 
60 
60 
60 
60 
60 
60 
60 
60 
60 
60 
60 
60 
Time*^  
(min) 
13 
13 
14 
14 
15 
15 
15 
16 
16 
16 
17 
18 
18 
18 
17 
17 
19 
19 
19 
19 
Yield" 
(%)' 
78 
78 
77 
75 
78 
78 
75 
71 
77 
72 
70 
78 
75 
70 
71 
70 
72 
70 
71 
71 
172*' 
1/1.1 
l/l.l 
I/l.l 
1/1.1 
1/1.1 
1/1.1 
1/1.1 
1/1.1 
1/1.1 
1/1.1 
1/1.1 
1/1.1 
1/1.1 
1/1.1 
I/l.l 
1/1.1 
1/1.1 
1/1.1 
l/I.I 
1/1.1 
Acid chlorides 
Power" 
(%) 
40 
40 
40 
40 
40 
40 
40 
40 
40 
40 
40 
40 
40 
40 
40 
40 
40 
40 
40 
40 
Time' 
(min) 
8 
8 
8 
7 
8 
9 
9 
8 
9 
9 
9 
8 
9 
8 
8 
7 
7 
7 
8 
8 
Yield" 
(%) 
92 
91 
90 
89 
89 
91 
90 
88 
85 
84 
83 
85 
86 
80 
82 
83 
81 
81 
80 
80 
" All reactions were carried out using esters (la-d) (leq), amidoxime (2a-e) (1.2eq) and K2CO3 under 
microwave irradiations 
" All reactions were carried out using acid chlorides (I'a-d) (leq) and amidoxime (2a-e) (l.leq) under 
microwave irradiations. 
''•'' Microwave equipment multimode was used. Full power means 100% and is 1.35 KW. 
'•'• Monitored by TLC. 
''• ^' All yields refer to isolated products and the products were characterized by IR, 'H NMR, MS and 
elemental analysis. 
Multimode microwave irradiation at variable power was used. As per our 
requirement, the strategy was successfully worked out for both esters and acid 
chlorides. In both the cases the reaction proceeded in shorter reaction time and 
appreciable increment in product yield was obtained as compared to conventional 
reaction conditions. The maximum yield was obtained in case of acid chlorides in 7-9 
minutes whereas esters were obtained in 70-78% in 13-19 minutes. The generality and 
scope of the synthetic procedures was demonstrated by subjecting aliphatic, vinyl and 
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aromatic amidoximes with olefinic (terminal and internal) and hydroxy olefmic 
cairboxylic acid derivatives. 
It was observed that when reaction was allowed to proceed for time longer 
than mentioned in Table 4.3 no further increase in yield of product was observed. The 
compounds were characterized by IR, ' H N M R , '^C N M R , Mass and elemental 
analysis. IR absorptions characteristic of C=N and C-0 was observed in all the newly 
synthesized compounds. The characteristic signals for NCO and NCN in '^ C NMR at 
180.7-178.7 and 169.8-168.1 further strengthen the synthesis of oxadiazole moiety in 
3a-t. Detailed spectral values of 3a-t are given in experimental section. 
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4.4 Experimental 
The sources of all the fatty acids and instrumentation details are the same 
as given in Chapter 1 (page 38). 
General procedure for the synthesis ofamidoximes (2a-e) 
Amidoximes 2a-e were prepared by heating under reflux 2-4 days a solution of the 
appropriate nitrile with, in 10-20% excess, equimolar amounts of hydroxylamine 
hydrochloride and sodium hydroxide in aqueous EtOH. The mixture was then 
concentrated under vacuum, diluted with cold water and left overnight. The solid that 
formed was recovered, washed with cold water, dried under vacuum and 
recrystallized with EtOtf I (2a mp 127-128 "C, 2b mp 90-92 °C , 2c mp 110-112 °C , 
2d mp 76-78 °C, 2e mp 130-132 °C). 
General procedure for the synthesis of 3,5-disubstituted-l,2,4-oxadiazoles (3a-t) 
from long-chain esters la-d with amidoximes (2a-e) (Method 1) 
To the solution of ester la-d (3 mmol) in toluene (5 ml) was added amidoxime 2a-e 
(3.6 mmol) followed by K2CO3 (3.3 mmol). The reaction mixture was stirred for 
suitable time (9-13 hours) under refluxed conditions and product formation is detected 
by TLC. The reaction mixture was cooled to room temperature, diluted with EtOAc 
(25 ml) and washed successively with brine (10 ml) and water. The organic phase was 
dried over anhydrous Na2S04, filtered and concentrated. The crude product was 
further purified by column chromatography. (Hexane:EtOAc, v:v) 3a, (99:1); 3b, 
(98:2); 3c, (97:3), 3d, (97:3); 3e, (99:1); 3f, (98:2), 3g, (97:3); 3h, (97:3); 3i, (99:1); 
3j, (98:2); 3k, (97:3); 31, (97:3); 3in, (98:2); 3n, (97:3); 3o, (95:5), 3p, (95:5); 3q, 
(99:1); 3r, (98:2); 3s (94:6); 3t, (94:6). 
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General procedure for the synthesis of 3,5-disubstituted-l,2,4-oxadiazoles (3a-t) 
from long-chain acid chloride (1 'a-d) with amidoximes (2a-e) (Method 2) 
The acid chlorides I'a-d were synthesized as reported earlier in Chapter 3 (page 67). 
An acid chloride I'a-d (3 mmol) was added dropwise to a stirred solution of the 
amidoxime 2a-e (3.3 mmol) in pyridine. An exothermic reaction occurred after which 
in most cases, the solution was heated under reflux for 1-2.5 hour, after which the 
synthesis of product could be detected by TLC. The reaction mixture was cooled to 
room temperature, diluted with EtOAc (25 ml) and washed successively with brine 
(10 ml) and water. The organic phase was dried over anhydrous Na2S04, filtered and 
concentrated. The crude product was further purified by column chromatography. 
General procedure for the synthesis of 3,5-disubstituted-l,2,4-oxadiazoles (3a-t) 
under solvent-free microwave condition 
The acid chloride I'a-d (2mmol) and amidoxime 2a-e (2.2mmol) were mixed with 
neutral alumina in a 4:1 ratio. The mixture was shacked for 4-5 minutes. To have a 
complete mixture CH2CI2 was added in a small quantity to solubilize the reagent and 
then solvent was evaporated. The reaction mixture was irradiated in microwave for 
required time (Table 4.3). After irradiation crude product was extracted in CH2CI2 
diluted (25 ml) and washed successively with brine (10 ml) and water. The organic 
phase was dried over anhydrous Na2S04, filtered and concentrated and purified by 
silica gel chromatography. The same procedure was employed in case of ester 
derivative la-d (2 mmol) and amidoxime 2a-e (2.4 mmol) and K2CO3 (2.4 mmol). 
Spectroscopic data 
3-Methyl-5-(dec-9-enyl)-l,2,4-oxadiazole(3a) 
Coloriess oily liquid 
rR (KBr): 2926, 2854,1660,1440 cm"'. 
'HNMR (400 MHz, CDCI3): 5 5.82 (tdd, IH, J^ ._,^ .^  = 6.6 Hz, JXB= 10.2 Hz, 
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JxA =17.1 Hz, CH2=Ci/x-), 5.02 (IH, dd, Jnx^ 10.2 Hz, JBA = 1.2 Hz, / /BC=CH), 
4.90 (IH, dd, JAX = 17.1 Hz, JAB = 1.2 Hz, HAC=CK-), 2.35 (t, 2H, J = 7.56 Hz, 
CHj a to ring), 2.20 (s, 3H, C//3 at ring), 2.05 (m, 2H, -C//2-CH=CH2), 1.65 (m, 2H, 
C//2 p to ring), 1.29 (br.s, lOH, chain CH2). 
'^CNMR (100 MHz, CDCI3): 179.71, 168.72, 139.22, 114.26, 34.17, 33.82, 29.42, 
28.64,28.12,24.53,22.12,15.02. 
MS (m/z, %): (M+1)^ 223 (7), (M^) 222 (25), 139 (43), 126 (32), 112 (61), 27 (15). 
Anal. Calcd. for C13H22N2O: C, 70.24; H, 9.97; N, 12.59. Found: C, 70.85; H, 9.91; 
N, 12.62. 
3-Methyl-5-(heptadec-8-enyl)-l,2,4-oxadiazole{^h) 
Colorless oily liquid 
IR (KBr): 2928,2859,1661,1440 cm"'. 
^H NMR (400 MHz, CDCI3): 5 5.80 (m, 2H, -CH=CH-), 2.34 (t, 2H, J = 7.48 Hz 
C//2, a to ring), 2.21 (s, 3H, CHj at ring), 2.04 (m, 4H, -CH2- CH=CH-C//2), 1.64 (m, 
2H, CHj p to ring), 1.27 (br.s, 20H, chain C//2), 0.88 (3H, dist.t, CH3). 
'^C NMR (100 MHz, CDCI3): 180.62, 168.12, 130.13, 40.55, 34.91, 33.64, 29.75, 
29.55, 29.32, 29.16, 27.12, 25.54,24.82,14.95. 
MS (m/z, %): (M+1)^ 321 (18), (M^) 320 (28), 237 (55), 139 (71), 113 (14), 86 (35). 
Anal. Calcd. for C20H36N2O: C, 74.96; H, 11.31; N, 7.34. Found: C, 74.90; H, 11.37; 
N, 7.39. 
3-Methyl-5-[(8Z, 11R)-1 l-hydroxyheptadec-8-enylJ-l,2,4-oxadiazole {3c) 
Colorless oily liquid 
IR (KBr): 2930, 2853, 1664,1443 cm*'. 
'HNMR (400 MHz, CDCI3): 6 5.82 (m, 2H, -CH^CH-), 3.81 (m,lH, -C//-OH), 2.33 
(t, 2H, y = 7.51 Hz, CH2 a to ring), 2.19 (s, 3H, C//3 at ring), 2.35 (m, IH, CH-OH), 
2.04 (m, 4H, -CHi-CU^CH-CHj), 1.65 (m, 2H, CH2 p to ring), 1.27 (br.s, 18H, chain 
C//2), 0.88 (3H, dist. t, CH3). 
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'^CNMR (100 MHz, CDCI3): 180.25, 169.16, 130.52, 71.61, 37.16, 34.61, 33.82, 
31.86, 31.47, 29.68, 29.22, 28.97, 27.16, 25.97, 15.06. 
MS (m/z, %): (M+1)^ 337 (10), (M^) 336 (15), 251 (30), 251 (54), 207 (25), 183 (19). 
Anal. Calcd. for C20H36N2O2: C, 71.39; H, 10.77; N, 8.33. Found: C, 71.90; H, 10.71; 
N, 8.38. 
3-Methyl-5-f(8R,llZ)-8-hydroxyheptadec-ll-enylJ-l,2,4-oxadiazole (3d) 
Colorless oily liquid 
IR (KBr): 2926, 2850,1665,1445 cm"'. 
'HNMR (400 MHz, CDCI3): 6 5.81 (m, 2H, -CH=CH-), 3.80 (m,lH, -C//-OH), 2.36 
(t, 2H, J = 7.55 Hz, CH2 a to ring), 2.21 (s, 3H, C//3 at ring), 2.35 (m, IH, C H - 0 ^ , 
2.03 (m, 4H, -C//2-CH=CH-C//2), 1.64 (m, 2H, CH2 p to ring), 1.29 (br.s, 18H, chain 
CH2), 0.88 (3H, dist.t, CH3). 
'^C NMR (100 MHz, CDCI3): 180.51, 168.92, 131.53, 71.84, 37.85, 34.86, 33.51, 
31.71, 30.63, 29.54,28.92,27.74,25.41,15.05. 
MS {m/z, %): (M+1)^ 337 (5), (M*) 336 (30), 225 (54), 182 (43), 128 (37), 177 (45). 
Anal. Calcd. for C20H36N2O2: C, 71.39; H, 10.77; N, 8.33. Found: C, 71.93; H, 10.82; 
N, 8.37. 
3- Viny-5-(dec-9-enyl)-l,2,4-oxadiazole (3e) 
Yellow oily liquid 
IR (KBr): 2930,2859,1669,1442 cm''. 
'HNMR (400 MHz, CDCI3): 5 6.24 (IH, dd, JX'A-'= 17.8 Hz, JB'A'^OM HZ, H/^Cr 
= CrHx-), 6.08 (IH, dd, JX'B =11-7 Hz, JB-A' = 0.88 Hz, H^'Cr = Ci-Hr), 5.67 (IH, 
dd, Jrr=17.8Hz,Jrf i '= 11.7Hz„C2"H2=C,"//x'-),5.82(tdd,lH, J^ .^ .^  = 6.6Hz, 
JxB = 10.2 Hz, JxA = 17.1 Hz, CH2 = C//x-), 5.02 (1H, dd, JBX = 10.2 Hz, JBA = 1 -2 Hz, 
/ /BC = CH), 4.90 (IH, dd, JAX= 17.1 Hz, JAB = 1-2 Hz, //AC = CH-), 2.35 (t, 2H, J 
= 7.44 Hz, C//2 a to ring), 2.06 (m, 2H, -C//2-CH = CH2), 1.64 (m, 2H, C//2 p to 
ring), 1.29 (br.s, lOH, chain C//2). 
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'^CNMR (100 MHz, CDCI3): 179.81, 168.34, 135.20, 117.92, 139.62, 114.63, 34.76, 
33.17, 29.29, 28.77, 28.15, 24.66, 22.51. 
MS (m/z, %): (M+1)^ 235 (15), (M^) 234 (70), 139 (10), 111 (40), 97 (23), 95 (32). 
Anal. Calcd. for C14H22N2O: C, 71.44; H, 9.45; N, 11.95. Found: C, 71.93; H, 9.40; 
N, 11.99. 
3- Vinyl -5-(heptadec-8-enyl)-l,2,4-oxadiazole (3f) 
Colorless oily liquid 
IR (KBr): 2931, 2857,1666,1444 cm"'. 
'HNMR (400 MHz, CDCI3): 5 6.24 (IH, dd, JrA'= 17.8 Hz, JB'A' = 0.88 Hz, H/^CY = 
Ci-Hx-), 6.09 (IH, dd, Jrs ' = 11-7 Hz, JBT = 0.88 Hz, //B- Cr = CrHx'), 5.68 (IH, 
dd, Jx'A'^ 17.8 Hz, JrB- = 11.7 Hz„ C2"H2= Cj-i/x-), 5.81 (m, 2H, -CH=CH-), 2.33 
(t, 2H, J = 7.56 Hz, C//2 a to ring), 2.04 (m, 4H, -C//2-CH=CH-C//2), 1.65 (m, 2H, 
CH2 p to ring), 1.30 (br.s, 20H, chain CH2), 0.88 (3H, dist.t, CH3). 
'^CNMR (100 MHz, CDCI3): 180.13, 169.35, 132.73, 118.56, 131.17, 33.83, 31.68, 
29.93, 29.64, 29.21, 27.63, 25.74, 24.16,14.91. 
MS (m/z, %): (M+1)^ 333 (12), (M^^ ) 332 (66), 237 (10), 211 (60), 169 (56), 113 (19). 
Anal Calcd. for C21H36N2O: C, 75.86; H, 10.91; N, 8.42. Found: C, 75.30; H, 10.96; 
N, 8.38. 
3- Vinyl-5-f(8Z, llR)-ll-hydroxyheptadec-8-enyl]-l,2,4-oxadiazole (3g) 
Colorless oily liquid 
IR (KBr): 2933, 2850, 1663, 1449 cm''. 
'HNMR (400 MHz, CDCI3): 5 6.24 (IH, dd, JX'A'= 17.8 Hz, JB-A' = 0.88 Hz, HACT = 
CrHx-), 6.08 (IH, dd, JX-B' ^ 11.7 Hz, JB'A' == 0.88 Hz, HB'CT- Ci-Hx'), 5.67 (IH, 
dd, J r r = 17.8 Hz, JA-B- = 11.7 Hz„ CT}\I= CyHx-), 5.82 (m, 2H, -CH=CH-), 3.82 
(m,lH, -C//-OH), 2.57 (t, 2H, J = 7.51 Hz, CH2 a to ring), 2.32 (m, IH, CH-0//), 
2.04 (m, 4H, -C//2-CH=CH-C//2), 1.67 (m, 2H, p to ring), 1.29 (br.s, 18H, chain 
C//2), 0.88 (3H, dist.t, CH3). 
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'^CNMR (100 MHz, CDCI3): 179.93, 168.14, 136.22, 118.15, 130.52, 71.51, 37.66, 
34.17, 33.53, 31.82, 31.44, 29.66, 29.57, 28.38, 27.81, 25.23, 14.61. 
MS (m/z, %): (M+1)^ 349 (20), (M^) 348 (32), 263 (62), 227 (30), 219 (77), 170 (15). 
Anal. Calcd. for C21H36N2O2: C, 72.38; H, 10.40; N, 8.04. Found: C, 72.90; H, 10.44; 
N, 8.09. 
3- Vinyl -5-[(8R, llZ)-8-hydroxyheptadec-ll-enyl]-l,2,4-oxadiazole (3h) 
Colorless oily liquid 
IR (KBr): 2928, 2860,1665,1446 cm''. 
'HNMR (400 MHz, CDCI3): 5 6.24 (IH, dd, JX'A'= 17.8 Hz, JB'A' = 0.88 Hz, H/^Cr = 
C,..HxO, 6.08 (IH, dd, JX'A-= 17.8 Hz, J^B' =11-7 Hz„ C2"H2= Ci..//x-), 5.67 (IH, dd, 
Jx'A'= 17.8 Hz, Jx'B' = 11.7 Hz„ C2-H2 = Ci-Z/x-), 5.82 (m, 2H, -C//-C//-), 3.81 
(m,lH, -C//-OH), 2.36 (t, 2H, J = 7.56 Hz, CHi a to ring), 2.36 (m, IH, CH-07^, 
2.04 (m, 4H, -CH2- CU^CE-CHz), 1.66 (m, 2H, C//2 P to ring), 1.30 (br.s, 18H, chain 
C//2), 0.89 (3H, dist.t, CH3). 
'^CNMR (100 MHz, CDCI3): 179.91, 168.16, 136.27, 118.18, 130.54, 71.52, 37.66, 
34.15, 33.82, 31.85, 31.43, 29.68,29.59,28.33, 27.8,4 25.22, 14.64. 
MS (m/z, %): (M+1)^ 349 (14), (M*) 348 (54), 277 (30), 253 (44), 223 (25), 127 (17). 
Anal Calcd. for C21H36N2O2: C, 72.38; H, 10.40; N, 8.04. Found: C, 72.89; H, 10.35; 
N, 8.08. 
3-Chloromethyl -5-(dec-9-enyl)-l,2,4-oxadiazole (31) 
Colorless oily liquid 
TR (KBr): 2932, 2854, 1660,1449 cm''. 
'HNMR (400 MHz, CDCI3): 5 5.82 (tdd, IH, J^_,^.^^ = 6.6 Hz, JXB= 10.2 Hz, 
JxA= 17.1 Hz, CH2=C//x-), 5.02 (IH, dd, JBX= 10.2 Hz, J^^ = 1.2 Hz, / /BC=CH), 4.90 
(IH, dd, JAX - 17.1 Hz, JAB = 1.2 Hz, / /AC=CH), 4.13 (s, 2H, CI-C//2), 2.34 (t, 2H, 
J = 7.23 Hz, C//2 a to ring), 2.05 (m, 2H, -C//2- CH=CH2), 1.66 (m, 2H, CH2 P to 
ring), 1.29 (br.s, lOH, chain CH2). 
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'^CNMR (100 MHz, CDCI3): 180.52, 168.15, 139.64, 114.42, 47.81, 35.73, 32.71, 
29.53,28.12,25.13,24.15,22.41. 
MS {m/z, % ) : (M+2)^ 258 (24), (M+1)^ 257 (30), (M^) 256 (72), 147 (15), 145 (45), 
133(17), 131(56), 83(37). 
Anal. Calcd. for CoHsiClNsO: C, 60.82; H, 8.24; N, 10.90. Found: C, 60.31; H, 
8.53; N, 10.94. 
3-Chloromethyl -5-(heptadec-8-enyl)-l,2,4-oxadiazole (3j) 
Colorless oily liquid 
IR (KBr): 2927,2855, 1667,1441 cm"'. 
'HNMR (400 MHz, CDCI3): 5 5.82 (m, 2H, -CH=CH-), 4.15 (s, 2H, CI-C//2), 2.34 (t, 
2H, J = 7.64 Hz, CH2 a to ring), 2.04 (m, 4H, -CH2- CH=CH2-C//2), 1.65 (m, 2H, 
CH2 P to ring), 1.30 (br.s, 20H, chain CH2), 0.88 (3H, dist.t, CH3). 
"C NMR (100 MHz, CDCI3): 180.51, 168.12, 131.91, 48.86, 34.73, 33.91, 31.55, 
29.92,29.74,29.15, 27.67,25.14,24.12, 15.19. 
MS {m/z, %): (M+2)^ 356 (10), (M+l)"" 355 (15), (M^) 354 (30), 243 (7), 241 (21), 
217 (4), 215 (12), 153 (60), 139 (62). 
Anal. Calcd. for C20H35CIN2O: C, 67.68; H, 9.93; N, 7.89. Found: C, 67.16; H, 9.97; 
N, 7.93. 
3-Chloromethyl -5-[(8Z, llR)-ll-hydroxyheptadec-8-enyl]-l,2,4-oxadiazole (3k) 
Colorless oily liquid 
IR (KBr): 2926,2858,1669, 1450 cm"'. 
'HNMR (400 MHz, CDCI3): 5 5.82 (m, 2H, -CH=CH-), 4.17 (s, 2H, CI-C//2), 3.82 
(m,lH, -C//-OH), 2.35 (t, 2H, J = 7.53 Hz, CHj a to ring), 2.17 (m, IH, CU-OH), 
2.04 (m, 4H, -CH2-CU=CH-CH2), 1.67 (m, 2H, CH2 P to ring), 1.29 (br.s, 18H, chain 
C//2), 0.88 (3H, distt, CH3). 
'^C NMR (100 MHz, CDCI3): 180.43, 169.64, 31.74, 71.66, 47.82, 37.84, 34.56, 
33.17, 31.65, 31.43, 29.62, 29.56, 28.24, 26.87,24.29, 14.56. 
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MS {m/z, % ) : (M+2)^ 372 (12), (M+1)^ 371 (22), 370 (36), 287 (10) , 285 (30), 241 
(10), 215 (20), 207 (28). 
Anal. Calcd. for C20H35CIN2O2: C, 64.76; H, 9.50; N, 7.55. Found: C, 64.26; H, 9.54; 
N, 7.60. 
3-Chloromethyl-5-[(8R, llZ)-8-hydroxyheptadec-ll-enylJ-l,2,4-oxadiazole{il) 
Colorless oily liquid 
IR (KBr): 2930,2857,1661, 1450 cm''. 
'HNMR (400 MHz, CDCI3): 5 5.82 (m, 2H, -CH=CH-), 4.14 (s, 2H, CI-C//2), 3.82 
(m,lH, -C//-OH), 2.32 (t, 2H, J = 7.52 Hz, C//2 a to ring), 2.15 (m, IH, CH-OH), 
2.04 (m, 4H, -C//2-CH=CH-C//2), 1.66 (m, 2H, CH2 P to ring), 1.30 (br.s, 18H, chain 
CH2), 0.89 (3H, dist.t, CH3). 
'^CNMR (100 MHz, CDCI3): 180.76, 169.85, 130.71, 71.24, 47.86, 37.87, 34.86, 
33.43, 31.74, 31.62, 29.51,28.92,28.23,25.84,24.20,14.05. 
MS (m/z, %): (M+2)^ 372 (15), (M+1)^ 371 (25), (M^) 370 (45), 273 (50), 247 (6), 
245 (18), 301 (11), 299 (33). 
Anal. Calcd. for C20H35CIN2O2: C, 64.76; H, 9.50; N, 7.55. Found: C, 64.30.; H, 
9.47; N, 7.59. 
3-Plienyl-5-(dec-9-enyl)-l,2,4-oxadiazole{3m) 
Colorless oily liquid 
IR (KBr): 2926, 2855,1660,1443 cm''. 
'HNMR (400 MHz, CDCI3): 6 7.68 (m, 2H, Ai-H), 7.59 (m, IH, Ar-H), 6.90 (m, 
2H, Ai-H), 5.82 (tdd, IH, J^ ,^ ,^ ^ - 6.6 Hz, JXB= 10.2 Hz, JXA = 17.2 Hz, CH2=C//x-), 
5.02 (IH, dd, JBX^ 10.2 Hz, JBA = 1.2 Hz, / /BC=CH-) , 4.90 (IH, dd, JAX =17.1 Hz, 
JAB = 1.2 Hz, HAC=CH-), 2.33 (t, 2H, J - 7.23 Hz, CHj a to ring), 2.05 (m, 2H, -
C//2- CH=CH2), 1.61 (m, 2H, CH2 P to ring), 1.29 (br.s, 1 OH, chain CH2). 
" C NMR (100 MHz, CDCI3): 179.51, 168.32, 139.25, 129.96, 129.17, 128.68, 
127.92, 114.27, 34.22, 33.86, 29.87, 29.18, 28.74, 28.23, 24.52, 22.41. 
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MS {m/z, %): (M+l)^ 285 (16), (M )^ 284 (54), 257 (25), 229 (70), 145 (58), 97 (45). 
Anal. Calcd. for C,8H24N20: C, 76.03; H, 8.49; N, 9.85. Found: C, 76.55; H, 8.44; N, 
9.83. 
3-Pfienyl-5-(heptadec-8-enyl)-l,2,4-oxadiazole (3n) 
Colorless oily liquid 
IR (KBr): 2929, 2859,1666,1451 cm''. 
'HNMR (400 MHz, CDCI3): 5 7.67 (m, 2H, Ax-H), 7.59 (m, IH, hx-H), 6.92 (m, 
2H, Ax-H), 5.82 (m, 2H, -CH=CH-), 2.34 (t, 2H, J = 7.61 Hz, CH2 a to ring), 2.04 (m, 
4H, -C//2-CH=CH-C//2), 1.65 (m, 2H, C//2 P to ring), 1.30 (br.s, 20H, chain C//2), 
0.88 (3H, dist.t, CH3). 
'^C NMR (100 MHz, CDCI3): 179.91, 169.52, 131.93, 129.34, 128.95, 128.76, 
128.17, 34.58, 31.91, 29.92,25.83,25.24,24.75,23.76,14.77. 
MS {m/z, %): (M+1)^ 383 (9), (M^) 382 (56), 311 (42), 269 (65), 243 (70), 223 (52). 
Anal. Calcd. for C25H38N2O: C, 78.49; H, 10.01; N, 7.32. Found: C, 78.01; H, 10.06; 
N, 7.36. 
3-Phenyl-5-[(8Z,llR)-ll-hydroxyheptadec-8-enyl]-l,2,4-oxadiazole{2o) 
Colorless oily liquid 
IR (KBr): 2933,2854, 1665, 1446 cm"'. 
'HNMR (400 MHz, CDCI3): 6 7.66 (m, 2H, Ar-H), 7.57 (m, IH, Ar-H), 6.93 (m, 
2H, Ai-H), 5.82 (m, 2H, -CH=CH-), 3.82 (m,lH, -C//-OH), 2.35 (t, 2H, J = 7.54 Hz, 
CH2 a to ring), 2.19 (m, IH, CH-0//), 2.04 (m, 4H, -C//2-CH=CH-C//2), 1.67 (m, 2H, 
CH2 P to ring), 1.29 (br.s, 18H, chain CH2), 0.88 (3H, dist.t, CH3). 
'^C NMR (100 MHz, CDCI3): 180.61, 169.72, 132.63, 129.74, 129.55, 129.26, 
128.97, 65.61, 37.09, 34.38, 33.67,31.66,28.95,25.54, 23.43,22.52, 14.51. 
MS {m/z, %): (M+1)^ 399 (8), (M^) 398 (80), 313 (75), 269 (60), 155 (56), 130 (13). 
Anal Calcd. for C25H38N2O2: C, 75.34; H, 9.60; N, 7.03. Found: C, 75.80; H, 9.64; N, 
7.06. 
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3-Pheny-5-f(8R, 1 lZ)-8-hydroxyheptadec-ll-enylJ-l,2,4-oxadiazole {3p) 
Colorless oily liquid 
IR (KBr): 2931, 2854, 1660, 1440 cm"'. 
'HNMR (400 MHz, CDCI3): 5 7.67 (m, 2H, Ar-i^, 7.57 (m, IH, Ax-H), 6.95 (m, 
2H, Ax-H), 5.82 (m, 2H, -CH=CH-), 3.82 (m, IH, -CH-OH), 2.36 (t, 2H, J = 7.51 Hz, 
CH2 a to ring), 2.17 (m, IH, CU-OH), 2.04 (m, 4H, -C//2-CH=CH-C//2), 1.66 (m, 2H, 
CH2 P to ring), 1.30 (br.s, 18H, chain C//2), 0.89 (3H, dist.t, CH3). 
'^C NMR (100 MHz, CDCI3): 180.41, 168.32, 132.93, 129.84, 129.64, 128.76, 
128.37, 71.21,36.82, 34.63,33.23, 31.62, 28.91,25.51,23.42,22.52, 14.52. 
MS {m/z, %): (M+l)"" 399 (13), (M )^ 398 (34), 327 (29), 273 (45), 256 (77), 130 (35). 
Anal. Calcd. for C25H38N2O2: C, 75.34; H, 9.60; N, 7.03. Found: C, 75.82; H, 9.66; N, 
7.00. 
3-(4 '-Hydroxyphenyl)-5-(dec-9-enyl)-l,2,4-oxadiazole (3q) 
Colorless oily liquid 
IR (KBr): 2926,2854,1660,1440 cm"'. 
'HNMR (400 MHz, CDCI3): 6 7.72 (m, 2H, Ar-H), 7.43 (m, 2H, Ar-H), 5.82 (tdd, 
IH, J^ ,^ .^ ^ = 6.6 Hz, JxB = 10.2 Hz, JXA - 17.1 Hz, CH2=CHx-), 5.02 (IH, dd, JBX = 
10.2 Hz, JBA = 1.2 Hz, / /BC=CH ), 4.90 (IH, dd, JAX = 17.1 Hz, JAB = 1-2 Hz, 
/ /AC=CH-) , 3.49 (m, IH, Ai-OH), 2.33 (t, 2H, J = 7.34 Hz, C//2 a to ring), 2.05 (m, 
2H, -C//2- CH=CH2), 1.66 (m, 2H, CH2 P to ring), 1.29 (br.s, lOH, chain CH2). 
'^C NMR (100 MHz, CDCI3): 178.73, 169.83, 160.21, 139.72, 116.42, 128.83, 
114.55, 33.74, 32.12, 29.92,28.71,27.36,23.53,21.42. 
MS (m/z, %): (M+1)^ 301 (10), (M^) 300 (78), 272 (35), 259 (60), 217 (72), 175 (28). 
Anal. Calcd. for C,8H24N202: C, 71.98; H, 8.05; N, 9.32. Found: C, 71.50; H, 8.09; 
N, 9.37. 
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3-(4'-Hydroxyphenyl)-5-(heptadec-8-enyl)-l,2,4-oxadiazole{ir) 
Colorless oily liquid 
IR (KBr): 2930, 2854, 1668, 1447 cm-'. 
^HNMR (400 MHz, CDCI3): 6 7.73 (m, 2H, ki-H), 7.52 (m, 2H, Ai-H), 5.82 (m, 2H, 
-CH=CH-), 2.36 (t, 2H, J = 7.63 Hz, C//2 a to ring), 3.55 (m, IH, Ar-OH), 2.04 (m, 
4H, -C//2-CH=CH2-C7/2), 1.65 (m, 2H, C//2 p to ring), 1.30 (br.s, 20H, chain CH2), 
0.88 (3H, dist.t, CH3). 
'^CNMR(\OOMnz,CDCh): 180.15, 169.21, 159.11, 131.56, 117.16, 129.17,35.91, 
33.25,29.12,28.63,28.42, 27.82,24.74,23.13,14.52. 
MS (m/z, %): (M+1)^ 399 (8), (M^) 398 (36), 369 (70), 285 (30), 217 (10), 161 (12). 
Anal. Calcd. for C25H38N2O2: C, 75.34; H, 9.60; N, 7.03. Found: C, 75.85; H, 9.55; N, 
7.08. 
3-(4'-Hydroxyphenyl)-5-[(8Z, llR)-ll-hydroxyheptadec-8-enyl]-l,2,4-oxadiazole 
(3s) 
Colorless oily liquid 
IR (KBr): 2932,2860,1666,1450 cm"'. 
'HNMR (400 MHz, CDCI3): 6 7.75 (m, 2H, Ar-//), 7.55 (m, 2H, Ar-//), 5.82 (m, 2H, 
-CH=CH-), 3.82 (m, IH, -CH-OH), 3.50 (m, IH, Ar-OH), 2.36 (t, 2H, J = 7.53 Hz, 
CH2 a to ring), 2.15 (m, IH, CH-0//), 2.04 (m, 4H, -C//2-CH=CH2-C//2), 1.67 (m, 
2H, CH2 P to ring), 1.29 (br.s, 18H, chain CHj), 0.88 (3H, dist.t, CH3). 
'^CNMR (100 MHz, CDCI3): 179.72, 168.82, 159.83, 131.84, 116.97, 128.17, 71.28, 
37.71, 34.56, 33.71, 31.62,28.91,25.51,23.42,22.55,14.51. 
MS (m/z, %): (M+1)^ 415 (15), (M^) 414 (18), 399 (67), 329 (80), 285 (33), 213 (43). 
Anal. Calcd. for C25H38N2O3: C, 72.44; H, 9.23; N,6.75. Found: C, 72.95; H, 9.28; N, 
6.79. 
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3-(4'-Hydroxyphenyl)~S-[(8R, llZ)-8-hydroxyheptadec-ll-enyl]-l,2,4-oxadiazole 
(3t) 
Colorless oily liquid 
IR (KBr): 2933, 2858, 1670, 1448 cm"'. 
'HNMR (400MHZ, CDCI3): 7.76 (m, 2H, Ax-H), 7.54 (m, 2H, hx-H), 5.82 (m, 2H, -
CH^CH-l 3.82 (m,lH, -C//-OH),, 3.48 (m, IH, Ai-OH), 2.36 (t, 2H, J = 7.52 Hz, a 
to ring), 2.16 (m, IH, CU-OH), 2.04 (m, 4H, -C//2-CH=CH2-C/f2), 1.65 (m, 2H, CH2 
p to ring), 1.30 (br.s, 18H, chain CH2), 0.89 (3H, dist.t, CH3). 
'^CNMR (100 MHz, CDCI3): 178.7, 168.9, 159.8, 131.6, 116.7, 129.9, 65.9, 37.5, 
33.9,32.7, 31.6,29.9,27.5,24.6,23.4,22.5,14.7. 
MS (m/z, %): (M+1)^ 415 (14), (M*) 414 (22), 371(65), 357 (40), 303 (57), 217 (20). 
Anal. Calcd. for C25H38N2O3: C, 72.44; H, 9.23; N, 6.75. Found: C, 72.01; H, 9.29; N, 
6.70. 
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2-Substituted-benzimidazoles, tetrahydrobenzimidazoles and imidazoles 
5.1 Theoretical 
The incorporation of the imidazole and benzimidazole nuclei is an important 
synthetic strategy in drug discovery'. The high therapeutic properties of the related 
drugs have encouraged the medicinal chemists to synthesize the large number of 
novel chemotherapeutic agents. Imidazole and benzimidazole drugs have broaden 
scope in remedying various dispositions in clinical medicine . Optimization of 
benzimidazole based structures has resulted in marketed medicines such as 
Omeprazole^ and Pimobendan'* and lead compounds in a wide range of therapeutic 
areas (e.g. casein kinase 2 , factor Xa , hepatitis C virus ). Pharmaceutical properties 
including; antifungal and antimycotic^, antiprotozoal and trichomonas infection^, 
antineoplastic'°, antiulcer ", antihistaminic, antiallergic'^, anesthetic, hypnotic'^, 
antihypertensive'"*, anthelmintic'^, neuroleptic, antipsychotic'^ and thromboxane 
synthetase inhibitor'^, all are unique characteristics known from imidazole and 
benzimidazole derivatives. 
Benzimidazole is a versatile core contained in several substances possessing a 
broad spectrum of pharmacological activity such as anticancer, antimicrobial, 
pesticide, and antithelmintic properties'^. This class of molecules has also found 
commercial applications in several therapeutic areas such as antiulcerative, antiviral, 
and antihistaminic agents''. Benzimidazoles exhibit significant activity against 
several viruses including HIV^", herpes (HSV-1)"', RNA^% influenza"' and human 
cytomegalovirus (HCMV)^" .^ In recent years benzimidazoles have been reported to 
act as topoisomerase I inhibitors^'', selective neuropeptide YYl receptor antagonists^^, 
angiotensin II (All) inhibitors'^, inhibition of HCMV replication'^*, HT3 antagonists 
in isolated guinea pig ileum'^. Hence, the development of new synthetic methods for 
benzimidazoles, which are currently not easily attainable by existing methods, is 
considered important by organic chemists. 
Several biologically active synthetic compounds possess five-membered 
nitrogen-containing heterocycles in their structures'^. The imidazole core is a 
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common moiety in a large number of natural products and pharmacologically active 
compounds . Recently, there has been considerable amount of progress in imidazole 
chemistry due to the recognition of the importance of the imidazole structure in 
biological processes and the increasing application of imidazole-containing 
compoimds, such as etomidate, cimetidine, omeprazole and lansoprazole, in drug 
therapy . The imidazole ring system is a key structural fragment found in many 
natural products^'. It also serves as a good ligand for various metal ions. Metal 
binding properties of imidazole-based ligands have been explored in detail because of 
their presence at the active site of metallo-proteins or enzymes involved in several 
important metabolic processes . 
N,N-Dimethylchlorosulfitemethaniminium chloride has been found to be an 
efficient reagent for the one-pot synthesis of benzimidazoles (iii) in excellent yield by 
condensation of carboxylic acids (i) with o-phenylenediamine (ii)^^ (Scheme 5.1). 
MejNr=CH -O -SOCl CI" 
NH2 -HCl - DMF - SOj - HjO 
(i) (ii) 
R— CgHs, 3-CH3-C5H4, 2-CI-C6H4 
Scheme 5.1 
(iii) 
Vlaskina and Perevalov'''' have synthesized substituted benzimidazoles (vi) by 
reduction of esters of 4-alkylamino-3,5-dinitrobenzoic acids (v) by tin chloride 
(Scheme 5.2). 
Kin. . . ^ 
NH2 
i-Pr02C 
NHR 
SnCl, 
CI 
2 i-PrOjC" 
(-PrOH, HCl 
NO2 
i-Pr02C 
H 
N 
// 
(iv) 
R = CfiHs, /-Pr 
(V) 
Scheme 5.2 
(vi) 
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In an effort to find an orally bioavailable antiviral for the treatment of 
rhino/enteroviral infections, a series of vinylacetylene benzimidazoles (viii) were 
made by Tebbe et al.^^ (Scheme 5.3). 
Y 
+ 
CN CI 
NO, 
NH, 
(Vii) (viii) 
Scheme 5.3 
Several 2'-aryl-5-substituted-2,5'-bi-l//-benzimidazole derivatives were 
synthesized^^ and evaluated as topoisomerase I poisons and for their cytotoxicity 
toward the human lymphoblast cell line RPMI 8402 (Scheme 5.4). 
(ix) 
V-
NC. 
^ / - N " • " ' , l l 5 N NaOH HoN 
(X) 
Scheme 5.4 
The preparation and anthelmintic properties of methyl 5(6)-phenylsulfinyl-2-
benzimidazolecarbamate (xii) were described by Averkin et al. . 
H 
-NHCOOMe 
(xii) 
R= PhS-0, PhS-, PhS-02 
,38 Walker et ar^ have synthesized the l-[4-(4-chlorophenyl)-2-(2,6-
dichlorophenylthio) -n -butyl]-1-//-imidazole nitrate (xiii), as potent antifungal agent. 
'Cl-
io? 
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CH2CH2CHCH2-—N I . HNO3 
(xiij) 
2-(N-Substituted)-aminobenzimidazoles are widely used structural motifs in 
medicinal chemistry as well as in drug discovery and can be found in a number of 
biologically active molecules^^. Several compounds from this class have been used as 
anticancer, antihistamine and antiviral agents'*". Some examples of pharmaceutical 
interest are given below. 
(xiv) 
Norastemizole : R = H 
(XV) 
Mebendazole (anticancer) 
Astemizole : R -
antiallergic, antihistamine 
Das et al!^^ have reported the highly efficient synthesis of 2-
aminobenzimidazoles (xviii) using various diamines (xvi) and substituted 
dithiocarbamates (xvii). The reaction is promoted by dithiocarbamate and catalytic 
amount of CuO (Scheme 5.5). 
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S M 
(xvi) (xvii) (xviii) 
Scheme 5.5 
Antibacterial''^ " '^', anti-inflammatory''^ antiulcer''^'''' and antiviral*'''' effects 
have been shown with various thiazolo-[3,2-a]-benzimidazole derivatives. 
Furthermore, certain thiazolo-[3,2-a]-benzimidazole derivatives, such as tilomisole 
(WY-18,251) (xix) was largely studied^"'^ ' demonstrating their anti-
inflammatory ^ a^nd immunomodulatory^^ activities. 
CI 
(xix) 
Also, some thiazolo-[3,2-a]-benzimidazole derivatives were used for treatment 
of cancer^'', cerebral infarction^^ neurogenic pain^ ,^ and bone diseases^^. 
A series of 2-(substituted phenyl)-l//-benzimidazole (xxii) derivatives with 
various substituents were synthesized via microwave irradiation using a short 
synthetic route and Na2S205 as oxidant^* (Scheme 5.6). 
lNli2 
NH2 O H C - " V 
R2 
•^Rj MW, 30-60 sec 
(xx) (xxi) (xxil) 
Ri=H, CH,; CFi. R2=H, OCH3, NO2, OCH2CH3 R3=H, OCH3. R4=H, OH, OCH3, N(CH3)2 R,=H, 
OCH3 
Scheme 5.6 
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The interaction of 2-acetyl-(aroyl)-methyl-l//-benzimidazoles (xxiv) with 
phenylhydrazine on heating in trifluoroacetic acid proceeds by a type of Fischer 
reaction with the formation of 2-[2-methyl(aryl)-3-indolyl]-l//-benzimidazoles 
(xxv)^^ (Scheme 5.7). 
CH2COR NH^NHPh 
CFjCOOH 
NH40H 
(xxiii) (xxiv) 
Scheme 5.7 
Dzvinchuk et al.^'^ developed a convenient preparative method for synthesis 
of 2-(l,2,3-thiadiazol-5-yl)-l//-benzimidazoles (xxvi) based on reaction of 
benzoylhydrazones of 2-acylmethyl-l//-benzimidazoles (xxv) with thionyl chloride 
(Scheme 5.8). 
SOClj 
^=N dioxane, 15°C, 0. 5h 
R NHCOPh 
(xxv) 
R = CfiHs, 4-MeC6H4, 4-MeOC6H4, 3,4,5-(MeO)3C6H4, 2-thienyl, Me 
(xxvi) 
Scheme 5.8 
Some chloroaryloxyalkyl imidazole and benzimidazole derivatives were 
synthesized^'. The relevant step in the synthetic sequence was the initial condensation 
of 4-chIoro or 2,4-dichlorophenol with 1, n-dibromoalkanes (n = 2, 4, 5) (xxvii) to 
provide (xxviii) in sufficient yields. The subsequent condensation of (xxviii) with 
some imidazole derivatives and benzimidazole afforded products (xxix) and (xxx) in 
good yields (Scheme 5.9). 
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B. > ^ 3 ^ ' - ^ 
OK ' ( 
^-\_/ ° TBAl/MeCN . • v - ^ ^ TBAB.E.,N/MeCN 
reflux, I day J\ „ ,„u 
, . . , -^  Rr reflux, lOhrs 
(x*vii) (xxviii) n*^ ' 
n=l-3,X=H,Cl, Y=C1, R,=CH3, C2H5, H Ri^H.NOj 
Scheme 5.9 
A simple, high-yielding synthesis of 2,4,5-trisubstituted imidazoles (xxxiii) 
from 1,2-diketones (xxxi) and aldehydes (xxxii) in the presence of NH4OAC under 
microwave irradiation in described*^ (Scheme 5.10). 
Ri 0 Q ^1 M 
\ // // NH.OAc(IOeqiv) V ^ \ 
/ ^ + R3-f — E ^ i — ^ I y-R^ 
O R \ , 180 °C, microwave y ^ . Y 
^ "^  5 minutes p " 
(xxxi) (xxxii) (xxxiii) 
Scheme 5.10 
Frantz et al.^^ has described synthesis of substituted imidazoles (xxxvii) via 
organocatalysis (Scheme 5.11). 
CH: 
HjC 
H °^t II (^-^O-""'"/") "> NH R,^H^ y^ ^ p j ^ 
D ^ ^ u " * " o - ^ M U - R Et,N. solvent* R 5 - / y-R2 * " ^\ f^ 
R5 H R4 NH R2 35 6o°c \ \ / / AcOH ) = / 
R4 R5 
(xxxiv) (xxxv) (xxxvi) (xxxvii) 
Scheme 5.11 
Synthesis of 1,5-disubstituted and 1,4,5-trisubstituted imidazoles (xxxix) from 
aldimines and imidoyl chlorides was given by van Leusen et al.^'^ (Scheme 5.12). 
I l l 
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H 
K2CO3 (or RNHj) \ N 
ToSCH2N=C — ' 
in MeOH i (DME), ToSH R - - - ^ / ~ ^ H 
I 
R2 
(xxxviii) (xxxix) 
Scheme 5.12 
lizuka et al.^^ have reported the synthesis of imidazole derivatives (xlv) as 
highly selective inhibitors of thromboxane synthetase (Scheme 5.13). 
HOOC(CH2)6COOMe ^"^'^ > CICO(CH2)6COOMe LiAlHCO-t-Bu),^ OHCCCHzlgCOOMe 
'' H00C''''^0N20 
(CH2)eC00Me.HCI (CH2)6COOMe (CH2)eC00Me 
N ^ NH NaOH f f 7) 180700 °C . . - i ^ . . ^ , \=J ^- lEi jj^ O 
HOOC COOH HOOC^~^COOH 
(xlv) (xliv) (*'"') 
Scheme 5.13 
Synthesis of N-alkylated derivatives of imidazoles (xlvii) as antibacterial 
agents was reported by Khabnadideh et al^^ (Scheme 5.14). 
l.TEAI,NaOh,CjH5CH, I 
X 2 r ^ ^"3(CH,)nBr ^^BAB. K^ co,, CH,CN ^ N^^(CH2)nCH3 
) S.EtjN.C.H^CHj ) = / 
R2 R, 
(xlvi) (xlvii) 
Scheme 5.14 
Van Vliet et al!'^ have reported the synthesis of 2-substituted-benzimidazoles 
(xlix) from nitroanilines using microwave conditions (Scheme 5.15). 
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,N0, 
SnClj.2HjO 
V-^^^^NHz R,COOH y ^ ^ ^ N orv 
/ H 
(xlviii) 
Scheme 5.15 
(xHx) 
Lin et al.^^ reported the high-throughput synthesis of benzimidazoles (li) 
derivatives under microwave conditions (Scheme 5.16). 
,NH, 
R'COOH ^^ ^^ v-*^  
^NHj P(0Ph)3, MW, 220 °C 
lOmin 
y-^3 
H 
(0 
Scheme 5.16 
(10 
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5.2 Convenient One-pot synthesis of Novel 2-Substituted-
benzimidazoles, Tetrahydrobenzimidazoles and Imidazoles and 
Evaluation of their in vitro Antibacterial and Antifungal Activities* 
The benzimidazole has been an important pharmacophore and privileged 
structure in medicinal chemistry, encompassing a diverse range of biological activities 
including antiarrhythmic, antiulcer, anthelmintical, inotropic, antihistamine, 
antifungal, antiviral, and cytotoxicity displaying diverse range of biological 
activities'^. Benzimidazoles exhibit significant activity as potential antitumor agents^ , 
smooth muscle cell proliferation inhibitors^', a treatment for intestinal cystitis^^, and 
in diverse area of chemistry . The imidazole core is a conmion moiety in a large 
number of natural products and pharmacologically active compounds '^*. Recently, 
there has been considerable amoimt of progress in imidazole chemistry due to the 
recognition of importance of the imidazole structure in biological processes and the 
increasing application of imidazole containing compounds, such asetomidate, 
cimetidine, omeprazole and lansoprazole, in drug therapy . Therefore the 
development of facile synthetic routes to achieve access to these molecules is of 
prime interest. In view of the above mentioned pharmacological applications of 
benzimidazoles and imidazoles and in continuation of the synthesis of biologically 
active molecules'"', the design and synthesis of hitherto unknown benzimidazoles arid 
imidazoles bearing long alkenyl chain was carried out. 
Further, the increasing number of multidrug resistant pathogens led to screen 
the newly synthesized derivatives against the representative panel of Gram positive 
and Gram negative bacteria and fungi. 
•Research paper entitled "Convenient one-pot synthesis of novel 2-substituied 
benzimidazoles, tetrahydrobenzimidazoles and imidazoles and evaluation of their in vitro 
antibacterial and antifungal activities" is in press. (S. Sharma, S. Gangal, A. Rauf, Eur. J. 
Med. Chem., (2008)doi:10.1016/j.ejmech.2008.03.026. 
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5.3 Results and discussion 
A typical one-pot procedure for the synthesis of 4a-l involves the addition of 
1,2-phenylenediamine derivatives 2 to the acid chloride la-d (Scheme 5.17) at 0 °C in 
dry dioxane and stirring for 30 minutes at room temperature to furnish the 
corresponding N-acyl-l,2-phenylenediamine derivatives 3. To the prior, acid chloride 
la-d was synthesized from olefmic and hydroxy olefinic long-chain acids by in situ 
preparation. 
NH, 
2a-c 
CI 
la-d 
BFj OEtj 
2a, R,=H 
2b, R,=N02 
2c, Ri=CI 
3a-d 
3'a-d 
3"a-d 
Scheme 5.17 Synthesis ofl-substituted-benzimidazoles 
Since acid chlorides la-d are not commercially available the present method 
has greatly solved the problem by facile and efficient in situ preparation. We have 
used BF3 0Et2 for cyclization of 3. BF3 0Et2 in dry dioxane was added to the 3 
without isolating the product and reaction mixture refluxed for 1-2 hours at 130 °C. 
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Entry 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
Table 5.12-substUuted-benzitnidazoles 
R 
H 
3 6 
H 
'3 ^'6 
H 
OH 
3 '6 
R. 
H 
H 
H 
H 
NO2 
NO2 
NO2 
NO2 
CI 
CI 
CI 
CI 
Starting 
la 
lb 
Ic 
Id 
la 
lb 
Ic 
Id 
la 
lb 
Ic 
Id 
from 
2a 
2a 
2a 
2a 
2b 
2b 
2b 
2b 
2c 
2c 
2c 
2c 
Product 
4a 
4b 
4c 
4d 
4e 
4f 
4g 
4h 
4i 
4j 
4k 
41 
The yields of products 4a-l are excellent and independent of the substituents 
present in the precursor. The scope of the reaction using olefinic (internal and terminal) 
and hydroxy acids is found to be good. This strategy was also be used to increase the 
structural diversity of the member library through the synthesis of benzimidazole 4in-p 
(Scheme 5.18). 
BF3 OEtj 0 
CI 
5 
NH, 
la-d 6a-d 4ni-p 
Scheme 5.18 Synthesis of 2-substiiuted-imidazoles 
Similarly 4q-t (Scheme 5.19) have been prepared by the reaction of 
ethylenediamine 7 to the acid chloride la-d at 0 °C in dry dioxane and stirring for 30 
16 
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minutes at room temperature to furnish the corresponding 8a-d which undergo 
cyclization in presence of BF3 OEta to form the 4q-t. 
CI 
la-d 
NH, 
,NH, 
8a-d 
BF3 0Et2 
4q-t 
Scheme 5.19 Synthesis ofl-suhstituted-tetrahydohenzitnidawles 
The yield of products was found to be appreciable. The preliminary study of 4a, 
77 
4b, 4r has been reported earlier . The newly synthesized compounds were analyzed for 
C, H and N content and structures were confirmed by IR, ' H N M R , '^C N M R and mass 
spectral data. IR absorptions at 1630 cm'' (C=N) was obtained for 2-(dec-9-enyl)-l//-
benzimidazole 4a. The 'H NMR showed signal of methine proton of C-9 at 6 5.82. C-
10 methylene designated as HE and Hz displayed two distinct 5 values when coupled 
with adjacent C-9 methine protons. The spectrum showed two doublets of doublet at 6 
5.02 and 4.90 for Hz and HE protons respectively. The structure of 4a was further 
supported by its mass spectral studies, which showed molecular ion peak at m/z 256 
consistent with its molecular formula C17H24N2. 
The antibacterial and antifungal screening revealed that all the tested 
compounds 4a-l, 4m-p, 4q-t showed moderate to good inhibition. 
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Table 5.1 In vitro antibacterial activity of compounds 4a-t 
Compound 
4a 
4b 
4c 
4d 
4e 
4f 
4g 
4h 
4i 
4j 
4k 
41 
4in 
4n 
4o 
4p 
4q 
4r 
4s 
4t 
Chloramphenicol 
Control DMSO 
E.coli 
18(150) 
16(150) 
17(150) 
17(150) 
20(75) 
20(75) 
16(37.5) 
18(37.5) 
20(75) 
18(75) 
18(75) 
19(37.5) 
17(37.5) 
17(150) 
15(150) 
16(150) 
15(150) 
11(150) 
12(150) 
12(150) 
25(12.5) 
— 
Diameter of: 
S.typhimurium 
16(75) 
14(75) 
12(75) 
12(75) 
12(37.5) 
11(37.5) 
12(37.5) 
13(37.5) 
14(37.5) 
15(37.5) 
17(37.5) 
17(37.5) 
11(75) 
10(75) 
12(75) 
13(75) 
14(74) 
11(75) 
12(75) 
12(75) 
20(6) 
— 
zone of inhibition (mm) 
B.subtiiis S.aureus 
22(75) 20(150) 
21(75) 18(150) 
21(75) 19(150) 
19(75) 19(150) 
19(37.5) 22(150) 
20(37.5) 21(37.5) 
21(37.5) 19(37.5) 
22(37.5) 19(37.5) 
19(75) 22(37.5) 
18(75) 20(37.5) 
19(75) 21(37.5) 
20(75) 21(37.5) 
18(75) 18(75) 
19(75) 16(75) 
19(75) 17(75) 
23(75) 16(75) 
22(37.5) 16(150) 
19(37.5) 15(150) 
18(37.5) 15(150) 
19(37.5) 15(150) 
24(6) 26(12.5) 
— 
Values in brackets are MIC values (ng/ml) 
The antibacterial screening indicated that among the tested bacterial strains, 
good inhibitory results were obtained against Salmonella typhimurium and 
Escherichia coll. The structural activity study showed that benzimidazoles and their 
substituted derivatives 4a-l have varying degrees of microbial inhibition. The 
antibacterial and antiftingal activity seemed to be dependent on the heterocyclic 
moiety as well as on the nature of substituents. Although the benzimidazoles 4a-l 
itself are observed active but the activity was further enhanced by the presence of 
nitro and chloro substituent on the benzimidazoles moiety (Table 5.1). 
The nitro substituted derivatives 4e, 4f have shown good activity against E. 
coli and S. aureus. The maximum inhibition was observed in 4h against B. subtilis. 
The chloro substituted derivatives 4i-l have shown maximum inhibition against S. 
aureus. The tetrahydrobenzimidazoles 4m-p are moderately active against S. 
typhimurium and 4m, 4p are best active against E. coli and B. subtilis whereas the 
imidazoles 4q-t showed moderate activity results against test bacterial strains. 
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In another set of experiments, the above mentioned compounds were also examined 
for antifungal activity (Table 5.2). Nystatin was used as standard drug for the 
comparison of antifungal results. The nitro and chloro substituted compounds 4e- 1 
showed same trend in case of fungal strains. 
Table 5.2 In vitro antifungal activity of compounds 4a-t 
Compound 
4a 
4b 
4c 
4d 
4e 
4f 
4g 
4h 
4i 
4j 
4k 
41 
Am 
4n 
4o 
4p 
4q 
4r 
4s 
4t 
Nystatin 
Control DMSO 
Calbicans 
19(75) 
19(75) 
19(75) 
18(75) 
18(37.5) 
19(37.5) 
19(37.5) 
19(37.5) 
18(37.5) 
18(37.5) 
18(37.5) 
18(37.5) 
18(75) 
18(75) 
17(75) 
19(75) 
19(75) 
18(75) 
18(75) 
18(75) 
20(6) 
.. . 
Diameter of z»ne of inhibition (mm) 
H.oryzae A.niger 
13(150) 14(150) 
12(150) 16(150) 
13(150) 16(150) 
11(150) 14(150) 
10(75) 15(37.5) 
12(75) 15(37.5) 
15(75) 16(37.5) 
14(75) 14(37.5) 
15(75) 15(37.5) 
16(75) 15(37.5) 
14(75) 14(37.5) 
14(75) 14(37.5) 
11(150) 12(37.5) 
12(150) 13(37.5) 
11(150) 12(37.5) 
11(150) 12(37.5) 
12(150) 11(150) 
12(150) 12(150) 
13(150) 13(150) 
12(150) 14(150) 
18(12.5) 18(12.5) 
. . . 
T.viridae 
7(75) 
6(75) 
8(75) 
8(75) 
8(37.5) 
8(37.5) 
9(37.5) 
9(37.5) 
10(37.5) 
9(37.5) 
9(37.5) 
8(37.5) 
7(37.5) 
6(37.5) 
7(37.5) 
8(37.5) 
6(75) 
4(75) 
6(75) 
6(75) 
15(6) 
.. . 
PenicMum sp. 
18(75) 
18(75) 
19(75) 
17(75) 
18(37.5) 
18(37.5) 
19(37.5) 
19(37.5) 
19(37.5) 
19(37.5) 
19(37.5) 
19(37.5) 
18(75) 
17(75) 
16(75) 
17(75) 
16(150) 
17(150) 
18(150) 
19(150) 
20(6) 
.. . 
Values in brackets are MIC values (ng/ml) 
The excellent inhibition results were obtained against C. albicans and 
Penicillium sp. by 4e-h. The moderate activity was obtained in H. oryzae and A. 
niger. The inhibitory activity against the T. viridae was significantly lower than the 
other tested microorganisms. Hence we conclude that higher activity of compounds 
4e-h and 4i-l may be attributed to the presence of nitro and chloro groups. The 
inhibition by 4a-d, 4m-p and 4q-t is due to the presence of benzimidazole, 
tetrahydrobenzimidazole and imidazole respectively. Thus the nature of substituents 
and basic skeleton of molecule have strong influence on the extent of antibacterial and 
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antifungal activities. Thus data revealed that all comounds have produced the marked 
enhancement in the potency of these analogues as antifungal and antifungal agents. 
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5.4 Experimental 
The sources of all the fatty acids and instrumentation details are the same as 
given in Chapter 1 (page 38). 
General procedure for the synthesis of 2-substituted benzimidazoles, 
tetrahydobenzimidazoles and imidazoles (4a-t) 
The acid chlorides la-d were prepared as reported earlier in Chapter 3 (page 67). 
Then, 1,2-phenylenediamine derivatives (0.01 mmol) 2a-c and 5 was added to the 
stirred solution of acid chloride at 0°C in dry dioxane and keep stirring for 30 minutes 
at room temperature to furnish the corresponding 3 and 6a-d respectively. Similarly 
2-substituted imidazoles 4q-t was synthesized by utilizing cis cyclohexanediamine to 
furnish 8a-d. BF3 OEta (0.015 mol) in dry dioxane (10 ml) was added dropwise to the 
above stirred reaction mixture in 10 minutes and reaction mixture further refluxed for 
1 to 2 hours at 130 °C. The resulting solution was concentrated in vacuum, saturated 
NH4CI solution added at till the pH becomes 6, extracted with EtOAc, dried over 
anhydrous Na2S04 and concentrated in vacuum to give the crude product 4a-t, which 
was further purified by column chromatography (Hexane:EtOAc, v:v) 4a, (99:1); 4b, 
(98:2); 4c, (97:3), 4d, (97:3); 4e, (99:1); 4f, (98:2), 4g, (97:3); 4h, (97:3); 4i, (99:1); 
4j, (98:2); 4k, (97:3); 41, (97:3); 4m, (99:1); 4n, (98:2); 4o, (97:3), 4p, (97:3); 4q, 
(99:1); 4r, (98:2); 4s (94:6); 4t, (94:6). 
Antibacterial Activity 
The antibacterial activity of test compounds and standard chloramphenicol was done 
78 
by filter paper disc method against Staphyloccous aureus MSSA 22, Escherichia 
coll K12, Bacillus subtilis ATCC 6501, Salmonella typhimurium MTCC 98 at a 
concentration of lOO^g/ml. Media with DMSO was set up as control. 
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Antifungal activity 
no 
The standard agar disc diffusion method was performed to evaluate the antifungal 
property of the test compounds and standard nystatin. Aspergillus niger (lab isolate 
from ICAR, Jaipur), Candida albicans IOA-109, Penicillium sp (laboratory isolate), 
Helminthosporum oryzae (lab isolate from ICAR, Jaipur), Trichoderma viridae 
ATCC 5170 were used in this study. Solvent control DMSO was also run. 
SPECTROSCOPIC DATA 
2-(Dec-9-enyl)-lH-benzimidazole(4si) 
Colorless oily liquid: yield: 89% 
IR (KBr): 3350, 1630,1585 cm '^. 
'HNMR (400 MHz, CDCI3): 8 9.01(s, IH, ^-H), 6.73-6.71 (m, 4H, Ai-H), 5.82 (tdd, 
IH, J^ _H .^^ =^ 6.6 Hz, J„_„^ = 10.2 Hz, J„_„^= 17.1 Hz, CH2=C//-), 5.02 (dd, IH, 
J„^_„= 10.2 Hz, J„^_„^= 1.2 Hz, HzC=CH), 4.90 (dd, IH, J„^_„ = 17.1 Hz, 
J„ .^^ = 1.2 Hz, //£C=CH-), 2.34 (t, 2H, J = 7.12 Hz, a to benzimidazole ring), 2.03 
(m, 2H, -C//2-CH=CH2), 1.63 (m, 2H, p to benzimidazole ring), 1.30 (br.s, lOH, chain 
C//2). 
"CTVM/f (100 MHz, CDCI3): 143.44,139.01,133.56,121.45,118.17,114.14,34.25, 
33.77,29.20,28.88,24.73. 
MS(mJz, %): (M+1)^ 257 (56), M^256 (45), 229 (34), 145 (40), 117 (100). 
Anal. Calcd. for C,7H24N2: C, 79.65; H, 9.43; N, 10.92. Found: C, 79.06; H, 9.49; N, 
10.87%. 
2-(Heptadec-8-enyl)-lH-benzintidazole (4h) 
Pale yellow oily liquid; yield: 89%. 
TR (KBr): 3360, 1640, 1590 cm"'. 
'HNMR (400 MHz, CDCI3): 5 9.12 (s, IH, N-/f), 6.73-6.70 (m, 4H, Ar-H), 5.38 (m, 
2H, -CH=CH-), 2.35 (t, 2H, J = 7.22 Hz, a to benzimidazole ring), 2.02 (m, 4H, -
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C//2-CH=CH-C//2-), 1.61 (m, 2H, p to benzimidazole ring), 1.30 (br.s, 18H, chain 
C//2), 0.89 (3H, dist. t, C//3). 
'^CNMR (100 MHz, CDCI3): 143.22,133.66,122.77,118.41, 34.20, 31.81,29.65, 
29.49, 29.09, 27.05, 24.72, 22.56, 22.45, 14.92. 
MS(m/z, %): (M+l)^355 (40), M^354 (34), 237 (25), 181 (25), 117 (100). 
AnaL Calcd. for C24H3gN2: C, 81.31; H, 10.79; N, 7.90. Found: C, 81.88; H, 10.73; N, 
7.94%. 
2-f(8Z, J 1R)-11-Hydroxyheptadec-8-enylJ-lH-benzimidazole (4c) 
Yellow oily liquid; yield: 88%. 
IR (KBr): 3390,1650,1580 cm-'. 
'HNMR (400 MHz, CDCI3): 5 9.25 (s, IH, N-//), 6.12-6.IQ (m, 4H, Ax-H), 5.42 (m, 
2H, -CH=CH-), 3.66 (m, IH, -CH-OH), 2.32 (t, 2H, J = 7.19 Hz, a to benzimidazole 
ring), 2.27 (m, IH, -OH), 2.02 (m, 4H, -CHi-CU^CH-CHi-), 1.57 (m, 2H, p to 
benzimidazole ring), 1.39 (br.s, 18H, chain CH2), 0.88 (3H, dist. t, C//3). 
'^CNMR (100 MHz, CDCI3): 143.44,134.09,123.22,117.81, 34.02, 31.81,29.56, 
29.94,29.90, 27.51, 24.27, 22.65,22.54,14.17. 
MS (m/z, %): (M+l)^371 (38), M^370 (34), 255 (20), 241 (100), 173 (15). 
AnaL Calcd for C24H38N2O: C, 77.79; H, 10.33; N, 7.56. Found: C, 77.16; H, 10.39; 
N,7.51%. 
2-f(8R, llZ)-8-Hydroxyheptadec-ll-enyl]-lH-benzimidazole (4d) 
Yellow oily liquid; yield: 88%o. 
IR (KBr): 3355, 1626,1596 cm"'. 
'HNMR (400 MHz, CDCI3): 5 9.04 (s, IH, N-//), 6.78-6.76 (m, 4H, Ar-//), 5.44 (m, 
2H, -CH=CH-), 3.64 (m, IH, -C//-OH), 2.31 (t, 2H, J = 7.20 Hz, a to benzimidazole 
ring), 2.11 (m, IH, -OH), 2.04 (m, 4H, -CH2-CH=CH-CH2-), 1.61 (m, 2H, p to 
benzimidazole ring), 1.40 (br.s, I8H, chain C//2), 0.88 (3H, dist. t, CH3). 
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^^CNMR(\OQ MWzX^Ch): 143.66, 133.17, 123.22, 118.12,34.25,31.41,29.58, 
29.39, 29.23, 27.26, 24.72, 24.22, 14.91. 
M5(m/z, %): (M+l)^371 (20), M^370 (45), 299 (10), 245 (100), 131 (15). 
Anal. Calcd. for C24H38N2O: C, 77.79; H, 10.33; N, 7.56. Found: C, 77.21; H, 10.27 
N, 7.53%. 
2-(Dec-9-enyl)-5-nitro-lH-benzimidazole{4e) 
Light yellow oily liquid; yield: 85%. 
IR (KBr): 3375,1660,1575 cm-'. 
'HNMR (400 MHz, CDCI3): 5 9.22 (s, IH, N-//), 7.12 (d, IH, Ai-H), 7.04 (m, IH, 
Ar-H), 6.91 (m, IH, Ar-H), 5.82 (tdd, IH, J^_.^^^= 6.6 Hz, J„_„^= 10.2 Hz, 
J„_„^= 17.1 Hz, CH2=C//-), 5.02 (dd, IH, J„^_„^ 10.2 Hz, J„^.„^= 1-2 Hz, 
//zC-CH), 4.90 (dd, IH, J„^_^ = 17.1 Hz, J„^_„^ = 1.2 Hz, HE<2=CH-), 2.28 (t, 2H, 
J = 7.17 Hz, a to benzimidazole ring), 2.04 (m, 2H, -CHi-CR^CHi), 1-66 (m, 2H, p 
to benzimidazole ring), 1.31 (br.s, lOH, chain CH2). 
"CNMR (100 MHz, C^Ch): 143.12,139.01,136.22, 130.12,131.65, 122.26, 
117.31, 33.91, 31.61,28.22,27.19, 22.33. 
MS (m/z, %): (M+l)^302 (10), M^301 (82), 274 (10), 176 (100), 162 (60). 
Anal. Calcd. for C17H23N3O2: C, 67.76; H, 7.68; N, 13.94. Found: C, 67.30; H, 7.73; 
N, 13.99%. 
2-(Heptadec-8-enyl)-5-nitro-JH-benzimidazole(4f) 
Pale yellow oily liquid; yield: 84%. 
//f(KBr):3352,1636,1580 cm-'. 
'HNMR (400 MHz, CDCI3): 6 9.21 (s, IH, N-H), 7.13 (d, IH, Ar-H), 7.04 (m, IH, 
Ar-H), 6.90 (m, IH, Ar-H), 5.38 (m, 2H, -CH=CH-), 2.34 (t, 2H, J = 7.24 Hz, a to 
benzimidazole ring), 2.02 (m, 4H, -C//2-CH-CH-C//2-), 1.63 (m, 2H, p to 
benzimidazole ring), 1.30 (br.s, 18H, chain C//2), 0.89 (3H, dist. t, C//3). 
124 
2-Substituted-benzimidazoles, tetrahydrobenzimidazoles and imidazoles 
'^CNMR (100 MHz, CDCI3): 143.62, 136.06,131.33, 129.71, 123.44, 118.13, 34.19, 
31.41, 29.53, 28.99, 27.41, 22.32, 22.45, 14.15. 
MS (m/z, %): (M+l)^400 (20), M^399 (25), 286 (75), 190 (70), 162 (100). 
Anal. Calcd. for C24H37N3O2: C, 72.15; H, 9.33; N, 10.51. Found: C, 72.70; H, 9.28; 
N, 10.56%. 
2-{(8Z, llR)-ll-Hydroxyhepiadec-8-enylJ-S-nitro-lH-benzimidazole {4g) 
Yellow oily liquid; yield: 82%. 
IR (KBr): 3355, 1640, 1580 cm"'. 
'HNMR (400 MHz, CDCI3): 5 9.25 (s, IH, N-//), 7.13 (d, IH, Ai-H), 7.04 (m, IH, 
AT-H), 6.91 (m, IH, Ar-H), 5.45 (m, 2H, -CH=CH-), 3.68 (m, IH, -C//-OH), 2.33 (t, 
2H,J= 7.31 Hz , a to benzimidazole ring), 2.23 (m, IH, -OH), 2.04 (m, 4H, -CH2-
CH-CH-C//2-), 1.61 (m, 2H, p to benzimidazole ring), 1.36 (br.s, 18H, chain CH2), 
0.88 (3H, dist. t, CHi). 
"CA^Mi?(100MHz,CDCl3): 144.13,135.44,131.19,129.31,123.33, 117.71,37.11, 
34.26, 31.83, 29.61, 27.10,25.81,23.11,22.15,15.06. 
MS (m/z, %): (M+l)Ml6 (35), M^415 (70), 330 (100), 300 (70), 260 (20). 
Anal. Calcd. for C24H37N3O3: C, 69.37; H, 8.97; N, 10.11. Found: C, 69.79; H, 8.92; 
N, 10.16%. 
2-f(8R, llZ)-8-Hydroxyheptadec-ll-enyl]-5-nitro-lH-benzimidazole{Ah) 
Yellow oily liquid; yield: 80%. 
JR (KBr): 3390,1630,1584 cm"'. 
^HNMR (400 MHz, CDCI3): 6 9.20 (s, IH, N-//), 7.16 (d, IH, Ar-H), 7.04 (m, IH, 
Ax-H), 6.93 (m, IH, Av-H), 5.43 (m, 2H, -CH=CH-), 3.67 (m, IH, CH-OH), 2.36 (t, 
2H, J - 7.29 Hz, a to benzimidazole ring), 2.21 (m, IH, -OH), 2.04 (m, 4H, -C//2-
CH=CH-C//2-), 1.64 (m, 2H, p to benzimidazole ring), 1.42 (br.s, 18H, chain CH2I 
0.87 (3H, dist. t, C//3). 
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"CA^M/f(100MHz,CDCl3): 144.23, 135.64,131.39,129.41,123.83,117.71,37.51, 
34.66, 31.38, 29.51, 27.43,25.44,23.11, 22.15,15.16. 
M5(m/z, %): (M+l)^416 (10), M^415 (70), 344 (100), 290 (25), 246 (20). 
Anal. Calcd. for C24H37N3O3: C, 69.37; H, 8.97; N, 10.11. Found: C, 69.84; H, 8.92; 
N, 10.13%. 
2-(Dec-9-enyl)-5-chloro-lH-benzimidazole{4i) 
Colorless oily liquid; yield: 88%. 
IR (KBr): 3368,1640,1578 cm-'. 
'HNMR (400 MHz, CDCI3): 6 9.01(s, IH, N-//), 7.43-7.3l(m, 3H, Ar-H), 5.82 (tdd, 
IH, J^_.,.^^= 6.6 Hz, J„_„^ = 10.2 Hz, J„_„^= 17.1 Hz, CHj^C//-), 5.02 (dd, IH, 
j ^ ^ . ^ - 10.2 Hz, J„^.„^= 1.2 Hz, //zC=CH), 4.90 (dd, IH, J„^_„ = 17.1 Hz, 
J„^_„,^ = 1.2 Hz, //fC^CH-), 2.3l(t, 2H, J = 7.33 Hz, a to benzimidazole ring), 2.04 
(m, 2H, -C//2-CH=CH2), 1.63 (m, 2H, p to benzimidazole ring), 1.33 (br.s, lOH, chain 
C//2). 
"CiVM^ (100 MHz, CDCb): 142.81, 141.31,132.91,131.61,129.71, 128.91, 
124.71,123.46,29.71,28.36,27.91,23.91,22.45,14.81. 
MS (m/z, %): (M+1)^ 291 (10), M^290 (85), 263 (100), 179 (25), 151 (40). 
Anal. Calcd. for C,7H23C1N2: C, 70.22; H, 7.96; N, 9.63. Found: 70.80; H, 7.92; N, 
9.58%. 
2-(Heptadec-8-enyl)-5-chloro-lH'benzimidazole{A\) 
Light yellow oily liquid; yield: 87%. 
//f(KBr):3370,1655, 1589 cm-'. 
'HNMR (400 MHz, CDCI3): 5 9.12 (s, IH, N-//), 7.55-7.20 (m, 3H, Ax-H), 5.44 (m, 
2H, -C//=C//-), 2.24 (t, 2H, J= lAA Hz, a to benzimidazole ring), 2.04 (m, 4H, -C//2-
CH=CH-C//2-), 1.56 (m, 2H, P to benzimidazole ring), 1.29 (br.s, 18H, chain C//2), 
0.87 (3H, dist. t, C//3). 
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'^CNMR (100 MHz, CDCI3): 143.48, 133.85, 131.24, 129.57, 127.71, 121.61, 
117.81, 37.41, 34.21, 33.92,29.56,29.13,25.84,23.13,22.35,14.12. 
MS (m/z, %): (M+lf 389 (30), M^388 (75), 275 (15), 165 (100), 151 (80). 
Anal. Calcd. for C24H37CIN2: C, 74.11; H, 9.58; N, 7.20. Found: C, 74.68; H, 9.63; N, 
7.16%. 
2-[(8Z, llR)-ll-Hydroxyheptadec-8-enylJ-5-chloro-lH-benzimidazole (4k) 
Yellow oily liquid; yield: 87%. 
IR (KBr): 3412,1648,1572 cm"'. 
'HNMR (400 MHz, CDCI3): 6 9.25 (s, IH, N-//), 7.43-7.31 (m, 3H, Ai-H), 5.46 (m, 
2H, -CH=CH-), 3.67 (m, IH, -CHOH), 2.33 (t, 2H, J - 7.12 Hz, a to benzimidazole 
ring), 2.27 (m, IH, -OH), 2.02 (m, 4H, CH2-CU=CH-CH2), 1.57 (m, 2H, p to 
benzimidazole ring), 1.39 (br.s, 18H, chain CH2), 0.88 (3H, dist. t, C//3). 
'^CNMR (100 MHz, CDCI3): 142.98, 133.76,130.99,129.76,127.80, 121.53, 
119.01, 37.03, 34.12, 33.57,29.34,28.37,25.71,23.91,22.11,15.17. 
MS (m/z, %): (M+1)^ 405 (15), M M 0 4 (70), 319 (100), 249 (85), 207 (90). 
Anal. Calcd. for C24H37CIN2: C, 71.18; H, 9.20; N, 6.91. Found: C, 71.66; H, 9.23; N, 
6.87%. 
2-f(8R,llZ)-8-Hydroxyheptadec-ll-enylJ-5-chloro-lH-benzimidazole(4\) 
Yellow oily liquid; yield: 86%. 
/i?(KBr):3349, 1629,1590 cm-'. 
'HNMR (400 MHz, CDCI3): 5 9.29 (s, IH, N-TT), 7.46-7.33 (m, 3H, Ar-H), 5.45 (m, 
2H, -CH=CH-), 3.68 (m, IH, -CH-OH), 2.36(t, 2H, J= 7.23 Hz, a to benzimidazole 
ring), 2.29 (m, IH, -OH), 2.04 (m, 4H, -CHi-CH^CH-CHi-), 1.62 (m, 2H, p to 
benzimidazole ring), 1.28 (br.s, 18H, chain CH2), 0.88 (3H, dist. t, C//3). 
"CA^Mif(100MHz,CDCl3): 142.68, 133.67,130.89,129.67,127.82, 121.43, 
119.01, 37.53, 34.41, 33.51, 29.43,28.32,25.17, 23.22,22.13,15.19. 
MS (m/z, %): (M+1)'' 405 (10), M^404 (80), 333 (40), 279 (85), 179 (65). 
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AnaL Calcd. for C24H37CIN2O: C, 71.18; H, 9.20; N, 6.91. Found: C, 71.71; H, 9.16; 
N, 6.94%. 
2-(Dec-9-enyl)-4,5,6,7-tetrahydro-lH-benzimidazole (4m) 
Pale yellow oily liquid; yield: 90%. 
IR (KBr): 3338,1632,1580 cm-'. 
^HNMR (400 MHz, CDCI3): 6 9.01(s, IH, N-/f), 5.82 (tdd, IH, J„ , .„ = 6.6 Hz, 
J„_„.^= 10.2 Hz, J„_„^= 17.1 Hz, CH2=C7/-), 5.02 (dd, IH, J„^_„= 10.2 Hz, 
J^^.^ = 3.6 Hz, //zC=CH), 4.90 (dd, IH, J„^_„ = 17.1 Hz, J„^_„^= 3.6 Hz, 
HEC=CH-), 2.34 (t, 2H, J = 7.36 Hz, a to benzimidazole ring), 2.03 (m, 2H, -CH2-
CH=CH2), 1.87 (m, 2H, -CH- ring), 1.69 (m, 2H, p to imidazole ring), 1.50 (m, 8H, 
-CH2- ring), 1.30 (br.s, lOH, chain CH2). 
"CNMR{\OOMHz,C^Chy. 170.33,139.81,117.61,64.01,37.62,31.91,29.88, 
28.35,24.57,22.50,22.21. 
MS (m/z, %): (M+1)^  263 (30), M^262 (70), 235 (100), 179 (70), 123 (60). 
AnaL Calcd. for C17H30N2: C, 77.82; H, 11.51; N, 10.67. Found: C, 77.30; H, 11.47; 
N, 10.70%. 
2-(Heptadec-8-enyl)-4,5,6,7-tetrahydro-lH-benzimidazole(4n) 
Light yellow oily liquid; yield: 89%. 
IR (KBr): 3356,1641, 1593 cm"'. 
'HNMR (400 MHz, CDCI3): 6 9.12 (s, IH, N-/f), 5.38 (m, 2H, -CH=CH-), 2.34 (t, 
2H, J = 7.30 Hz, a to benzimidazole ring), 2.02 (m, 4H, -C//2-CH=CH-C//2-), 1.86 
(m, 2H, -CH- ring), 1.66 (m, 2H, p to imidazole ring), 1.50 (m, 8H, -CH2- ring), 1.32 
(br.s, 18H, chain C//2), 0.88 (3H, dist. t, C//3). 
'^CNMR (100 MHz, CDCis): 169.97, 63.91, 36.92, 31.88, 28.22, 27.36, 24.63,22.49, 
22.12,21.90,14.91. 
MS (m/z, % ) : (M+1)^ 361 (40), M^ 360 (85), 247 (45), 207 (50), 193 (67). 
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Anal. Calcd. for C24H44N2: C, 79.95; H, 12.29; N, 7.76. Found: C, 79.40; H, 12.36; N, 
7.72%. 
2-[(8Z, llR)-ll-Hydroxyheptadec-8-enyl]-4,5,6,7-tetrahydro-lH-benzimidazole (4o) 
Yellow oily liquid; yield: 88%. 
IR (KBr): 3350, 1620, 1592 cm-'. 
^HNMR (400 MHz, CDCI3): 5 9.25 (s, IH, N-/^, 5.42 (m, 2H, -CH=CH-), 3.66 (m, 
IH, -CH-OH), 2.32 (t, 2H, J = 7.28 Hz, a to benzimidazole ring), 2.27 (m, IH, -OH), 
2.02 (m, 4H, -CHj-CR^CH-CHi-), 1.88 (m, 2H, -CH- ring), 1.67 (m, 2H, p to 
imidazole ring), 1.50 (m, 8H, -CH2- ring), 1.39 (br.s, 18H, chain CH2), 0.88(3H, 
dist. t, C//3). 
, '^CNMR (100 MHz, CDCI3): 169.99, 71.72, 63.89, 36.98, 34.22, 33.63, 31.66,28.61, 
27.63, 24.56,22.91,22.11,21.81,14.73. 
MS (m/z %): (M+1)^  377 (15), M^ 376 (70), 291(10), 247 (85), 123 (100). 
Anal. Calcd. for C24H44N2O: C, 76.55; H, 11.77; N, 7.43. Found: C, 76.01; H, 11.82; 
N, 7.40%. 
2-f(8R, llZ)-8-HydroxyheptadeC'll-enyl]-4,5,6, J-tetrahydro-lH-benzimidazole (4p) 
Yellow oily liquid; yield: 87 %. 
//?(KBr):3358,1658,1577 cm-'. 
'HNMR (400 MHz, CDCI3): 5 9.72 (s, IH, N-/^, 5.44 (m, 2H, -CH=CH-), 3.68 (m, 
IH, -C//-OH), 2.28(t, 2H, J = 7.39 Hz, a to benzimidazole ring), 2.21 (m, IH, -OH), 
2.03 (m, 4H, -C//2-CH=CH-C//2-), 1.87 (m, 2H, -CH- ring), 1.69 (m, 2H, p to 
imidazole ring), 1.52 (m, 2H, -CH2- ring),1.36 (br.s, 18H, chain C//2), 0.88 (3H, dist. t, 
C//3). 
'^CNMR (100 MHz, CDCI3): 169.87, 71.73,64.01, 36.89, 34.32, 33.36, 31.66, 28.64, 
27.53, 24.65, 22.98, 22.11, 21.81, 14.69. 
MS (m/z, %): (M+1)^  377 (30), M*376 (50), 305 (10), 251 (75), 123 (100). 
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Anal: calcd. for C24H44N2O: C, 76.55; H, 11.77; N, 7.43. Found: C, 76.98; H, 11.72; 
N, 7.47%. 
2-(Dec-9-enyl)-l H-imidazole (4q) 
Colorless oily liquid: yield: 89%. 
IR (KBr): 3354, 1642,1598 cm-'. 
'HNMR (400 MHz, CDCI3): 6 9.81(s, IH, N-/^, 5.82 (tdd, 2H, J „ . „ = 6.6 Hz, 
J„_„^= 10.2 Hz, J„_ff^= 17.1 Hz, CH2=G//-), 5.02 (2H, dd, J/,^.^= 10.2 Hz, 
J^^_^^= 3.6 Hz, //zC=CH), 4.90 (2H, dd, J„^_„ = 17.1 Hz, J„^_„.^= 3.6 Hz, 
//£C=CH-), 2.31 (t, 2H, y = 7.16 Hz, a to imidazole ring), 2.04 (m, 2H, -CH2-
CH=CH2), 1.66 (m, p to imidazole ring), 1.36 (br.s, lOH, chain CHj). 
'^CNMR (100 MHz, CDCI3): 152.31, 130.96, 125.93, 33.66, 32.81, 30.14,23.26, 
14.31. 
MS (m/z, %): (M+1)^ 207 (20), M^208 (22), 176 (36), 109 (100), 81 (100). 
Anal. Calcd. for C13H22N2: C, 75.69; H, 10.74; N, 13.57. C, 75.22; H, 10.70; N, 
13.63%. 
2-(Heptadec-8-enyl)-l H-imidazole {4r) 
Pale yellow oily liquid: yield: 88%. 
IR (KBr): 3367, 1644, 1590 cm"'. 
'HNMR (400 MHz, CDCI3): 5 9.77 (s, IH, N-//), 5.62 (m, 2H, -CH=CH-), 2.33 (t, 2H, 
y - 7.35 Hz, a to imidazole ring), 2.05 (m, 4H, -C//2-CH-CH-C//2-), 1.62 (m, 2H, p to 
imidazole ring), 1.29 (br.s, 18H, chain CH2), 0.87 (3H, dist. t, C//3). 
'^C NMR (100 MHz, CDCI3): 152.71, 131.76, 126.83, 33.38, 32.25, 30.44, 23.62, 
14.38. 
MS (m/z, %): (M+1)^ 305 (40), M^304 (22), 191 (31), 165 (31), 67 (100). 
Anal. Calcd. for C20H36N2: C, 78.89; H, 11.91; N, 9.20. C, 78.35; H, 11.86; N, 9.15%. 
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2-[(8Z, llR)-ll-Hydroxyheptadec-8-enyl]-lH-imidazole (4s) 
Yellow oily liquid: yield: 86%. 
IR (KBr): 3378, 1655, 1597 cm"'. 
'HNMR (400 MHz, CDCI3): 6 9.81 (s, IH, N-/f), 5.66 (m, 2H, -CH=CH-), 3.59 (m, 
IH, -C//-OH), 2.36 (t, 2H, J = 7.39 Hz, a to imidazole ring), 2.32 (m, IH, -OH), 2.03 
(m, 4H, -CH2-CH=CH-CH2-), 1.62 (m, 2H, p to imidazole ring), 1.29 (br.s, 18H, chain 
C//2), 0.88 (3H, dist. t, CH^). 
'^C NMR (100 MHz, CDCI3): 152.91, 131.46, 126.57, 71.93, 36.97, 34.21, 33.62, 
31.64,28.51, 27.35,24.62,22.28,22.11,21.82,14.36. 
MS(m/z,%):(M+l)^321 (40), M^ 320 (22), 235 (100), 191 (31), 165(100). 
Anal. Calcd. for C20H36N2O: C, 74.96; H, 11.31; N, 8.74. C, 74.61; H, 11.37; N, 
8.70%. 
2-[(8R, llZ)-8-Hydroxyheptadec-ll-enyl]-lH-imidazole (4t) 
Yellow oily liquid: yield: 86%. 
IR (KBr): 3354, 1628, 1578 cm"'. 
'HNMR (400 MHz, CDCI3): 6 9.81 (s, IH, N-//), 5.59 (m, 2H, -CH=CH-), 3.61 (m, 
IH, -C//-OH), 2.41 (t, 2H,J= 7.44 Hz, a to imidazole ring), 2.33 (m, IH, -OH), 2.05 
(m, 4H, -C//2-CH=CH-C//2-), 1.65 (m, 2H, p to imidazole ring), 1.30 (br.s, 18H, chain 
C//2), 0.89 (3H, dist. t, CH3). 
" C NMR (100 MHz, CDCI3): 152.81, 131.32, 126.33, 71.64, 36.87, 34.58, 33.36, 
31.44,28.45,27.63,24.52, 22.91,22.27,21.73,14.34. 
MS(m/z, %): (M+1)^ 321 (38), M'"320 (46), 249 (100), 195 (18), 165 (73). 
Anal. Calcd. for C20H36N2O: C, 74.96; H, 11.31; N, 8.74. C, 74.48; H, 11.26; N, 
8.69 %. 
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6.1 Theoretical 
1,2,4-Triazines are an important class of compounds, which act as anti-
inflammatory'"^, and antimalarial'' agents. Some of them are used as antibacterial^"^ 
and antidiabetics*. 3-Sulfanilamido-5-dimethylethyI-l,2,4-triazine is manufactured 
and used as a drug'. 6-Azacytidine derivatives show antiviral effects on the 
adenovirus genome'", whereas some triazinone derivatives are used as antiulcer 
agents''. Fluorene containing substituted 3-thioxo-l,2,4-triazin-5-ones exhibit 
antihuman immune virus activity . 
The 1,2,4-triazine moiety plays a vital role in many biological activities 
including antiviral'^, antihypertensive' '''', blood-platelet aggregation inhibitory''*''^, 
analgesic'^, and antibacterial properties'^''* as well as some of new anti-HIV and 
anticancer agents'^. 
Microwave assisted organic synthesis (MAOS) continues to affect synthetic 
chemistry significantly by enabling rapid, reproducible and scalable chemistry 
development^". The use of microwave irradiation has been an established tool in 
organic synthesis for achieving better selectivity, rate enhancement and reduction of 
thermally degradative by products ' . However these procedures are practically 
limited as the solvents in microwave oven at elevated temperatures create high 
pressure, which may cause explosion. One of the advances to overcome this problem 
is the inorganic solid supported^ '^^ '' organic synthesis which attracted attention 
because of enhanced selectivity, milder reaction conditions and associated ease of 
manipulation. Moreover they also provide an opportunity to work with open vessels 
and enhanced possibility of upscaling the reactions on preparative scale ' . 
Numerous reactions including condensations, cycloadditions, heterocycle 
formation, metal catalyzed cross coupling have been explored under microwave 
conditions, some of which have been applied to medicinal chemistry and total 
11 
synthesis of natural products . 
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Safieh et al. have described novel method for the synthesis of a new series 
of 5-substituted 1,3-dimethyl pyrazolo-[4,3-e][l,2,4]-triazines (v) (Scheme 6.1). 
HaC NO, H,C NO, 
'/ W 
\ N 
I 
CH3 
(0 
NHjNHjHjO/EtOH JJ \ 
-CI ^\N-
I 
CH3 
(ii) 
RCOCl 
-NH 
1„, THF/OX-rt 
NH2 
H,C 
H3C N::^  
i.y/ PPA N 
I 
CH3 
(V) 
NH, 
l' \ /C 
R 
(iv) 
Scheme 6.1 
A number of 6-aryi and 3-substituted-6-aryl-l,2,4-triazines (ix) have been 
prepared by heating a mixture of a-haloacetophenone (vi) and two equivalent of acid 
hydrazide (vii) in alcohol or acetic acid in presence of slight excess of NaOAc, KOAc 
29 
or AgOAc for few minutes (Scheme 6.2). 
0 0 
•^  Rl NH 
(vi) (vii) 
= CI, Br, R = aryl, R, = H, 
? 
alkyl, aryl, 
J—NH 0 
-.^ R L 
N—NH 
0 
(viii) 
Scheme 6.2 
F 
-HP ^ N 
(ix) 
Synthesis of thiadiazine and triazino [3,4-b] thiadiazine derivatives were 
i30 
reported by Nami et al. The addition of dimethyl acetylenedicarboxylate (DMAD) 
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to dithizon (x) afforded dimethyl-2-methoxycarbonylmethyIene-4,8-diphenyl-1,2,4-
triazino[3,4-b]-l,3,4-thiadiazin-3-one-6,7-dicarboxylate (xi) (Scheme 6.3). 
/ 
Ph 
(X) 
S^N 
r 
=N 
NH 
/ 
—NH 
-Ph 
MeOOC. 
2 mole DMAD s 
M 
u 
1 1 
COOMe 
(xi) 
Scheme 6.3 
Ali^' has synthesized 4-(4-{[(6-Chloro-4-oxo-4H-chromen-3-yl)methylene] 
amino} phenyl)-5,6-dihydro-5-phenyl-3 -thioxo-1,2,4-triazine and 4-(4- {[(6-ChIoro-4-
oxo-4H-chromen-3-yi)methyiene]-amino}phenyl)-2,5-dihydro-5,6-diphenyl-3-thioxo-
1,2,4-triazine (xiii) as potential antifungal agents (Scheme 6.4). 
,NH ^SK 
PC ^NNH, N T ' ^ V ^ ^ ^ N ^ ' ^ ^ ^ ^ ^ ^ N ' ^ ^ N H 
(xii) (xiii) 
Scheme 6.4 
Heravi et aO^ have reported the synthesis of [l,3,4]thiadiazolo [2,3-
c][l,2,4]triazin-4-ones (xv) using sulfuric acid supported onto silica gel in 
solventless system (Scheme 6.5). 
Ri 
NH, \ _ 
^ " ^ ^ ^ ^ R'COOH S N . 0 
^^N\ < ^ Silica gel 
N R sulfiiric acid " x . ' : ? ^ ^ ^ 
N R 
(xiv) (xv) 
Scheme 6.5 
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Broadening the scope of 1,2,4-triazine synthesis by the appUcation of 
microwave technology Zhao et alr"^ have developed the rapid synthesis of diverse 
3,5,6-trisubstituted-l,2,4-triazines (xviii) in excellent yield and purity, including many 
previously unknown 3-heterocyclic-1,2,4-triazines (Scheme 6.6). 
0 Ph 
Ph O \ 
O Ph. N NHpAc( lOequiv.) \ ^ "^fg 
AcOH ' 
NH-NH2 180°C, MW Ph" ' ' ' ^N 
5 minutes 
(xvi) (xvii) (xviii) 
Scheme 6.6 
4-Amino-6-(/er^butyl)-3-methylthio-4,5-dihyd^o-l ,2,4-triazin-5-one (xix) was 
used in nucleophilic substitution reaction with carboxylic acid hydrazides^'' (Scheme 
6.7). 
H 
YT 
Me,C ^ N ^ 
MeaC N"^ 0 
Scheme 6.7 
In a one pot microwave reaction, an acyl hydrazide-tethered indole underwent 
a 3-component condensation to form a triazine (xxiii), followed by an inverse-electron 
demand Diels-Alder reaction and subsequent chelotropic expulsion of nitrogen to 
deliver novel, unnatural p-carboline alkaloids (xxiv) in good isolated yields 
(Scheme 6.8). 
35 
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Scheme 6.8 
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6.2 Microwave Assisted Efficient One-pot Synthesis of 3,5,6-
Trisubstituted-1,2,4-triazines from Fatty Acid Hydrazides Under 
Solvent-Free Conditions and their Antimicrobial Activity* 
1,2,4-Triazines are a representative class of heterocyclic compounds with a 
wide variety of interesting properties which are used in medicine and agriculture^ " . 
It has been associated with diverse pharmacological activities such as hypertension 
and inhibition of platelets''^, antileukemic'*', anti-inflammatory'*^ and potent 
neuroprotective agents'*''. The 1,2,4-triazine moiety is a structural element in 
antimalarial'*'*, anticancer'* ,^ antifungal'* ,^ anticonvulsant'*^, antibacterial'** and 
antiviral'*' compounds. Certain compounds containing 1,2,4-triazines nucleus have 
been reported to possess pesticidal^^, neuropharmacological^', analgesic and 
antidepressant^^ properties. Also some 1,2,4-triazine derivatives are used for the 
determination of metal ions and as dyes^'. The N-methyl derivatives of 1,2,4-
triazines are the naturally occurring antibiotics fervenulin (planomycin), toxoflavin 
(xanthothricin) and neomycin^'. 
In view of above mentioned pharmacological importance of heterocycles and 
our ongoing efforts to synthesize heterocycles from fatty acids^ "^^ ^ we now describe a 
expeditious ecofriendly solvent free microwave accelerated solid state approach for 
the rapid synthesis of 3,5,6-trisubstituted-1,2,4-triazines from saturated and olefinic 
fatty acid hydrazides wherein several disadvantages such as long reaction time and 
tedious work up has overcome. 
* Research paper entitled ''Microwave assisted efficient one-pot synthesis of 3,5,6-
trisubstituted-l,2,4-triazines from fatty acid hydrazides under solvent-free conditions and 
their antimicrobial activity" is published. (A. Rauf, S. Sharma, S. Gangal, ARKIVOC 2007 
(xvi) 137-147). 
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6.3 Results and discussion 
Considering that MW irradiations using commercial domestic ovens have 
been used to accelerate organic reactions, the high heating efficiency giving 
remarkable rate enhancement and dramatic reduction in reaction times and better 
yields, we became interested to synthesize heterocycles firom fatty acids imder 
microwave irradiations. We now report the synthesis of 3,5,6-trisubstituted-l,2,4-
triazine 3a-i by condensation of 1,2-diketone 2a-b with various saturated and olefmic 
(internal and terminal) fatty acids hydrazides la-f under MW and solvent free 
conditions in short time (Scheme 6.9). 
+ \_J NH,OAc, Et3N Y 1 
NH-NH2 R2 R3 Si02,MW ^ N " ^ ^ R 3 
la-f 2a-b 3a-l 
(a)Rj=R3=CH3 
(b) R2=R3=C6H5 
Scheme 6.9 Synthesis of 3,5,6-trisubstituted-l,2,4-triazines 
As can been seen from Table 6.1 and Table 6.2 the scope of the reaction using 
saturated, olefinic (internal and terminal) and hydroxy fatty acid hydrazides was found 
to be good. 
145 
3,5,6- Trisubstituted-1,2,4-thazmes 
Table 6.1 3,5,6-TnsubstUuted-l,2,4-triazines 
Entry Compound Ri R2 Ra^  
CHj 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
la,3a 
lb,3b 
lc,3c 
ld,3d 
le,3e 
lf,3f 
la,3g 
lb,3h 
lc,3i 
ld,3j 
le,3k 
13 
He 
'in 
OH 
3 6 
^ 13 
CHj 
HE 
.CH2 
6 - ' 5 
CH, 
12 lf,3I 
' 6H 
OH 
CH3 
CH3 
CH3 
CH3 
CH3 
CH3 
CeHs 
C6H5 
CeHs 
CeHs 
CeHs 
CeHs 
CH3 
CH3 
CH3 
CH3 
CH3 
CH3 
C6H5 
CeHs 
CeHs 
CeHs 
CfiHs 
CeHs 
The yield of 3,5,6-trisubstituted-l,2,4-triazine did not depend on the length of 
chain of fatty acid hydrazide and was found to be appreciable (Table 6.2). In order to 
determine the optimum conditions for the synthesis of triazines in faster and efficient 
way, molar ratios of reagents and the irradiation time and power level of microwave 
set-up was investigated. After some experimentation, we found a set of conditions 
that generally provides products in good yield. The optimum conditions employed 
are that the molar ratio of fatty acid hydrazides and 1,2-diketone is 1:1 and 
irradiation time and power level of microwaye set up are 10-15 minutes, 60 and 
100% power. 
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Table 6.2 Optimization for the reaction of fatty acid hydrazides with 1,2-diketones 
under microwave irradiation 
Entry 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
1 
la 
lb 
Ic 
Id 
le 
If 
la 
lb 
Ic 
Id 
le 
If 
2 
2a 
2a 
2a 
2a 
2a 
2a 
2b 
2b 
2b 
2b 
2b 
2b 
Ratio 
1/2" 
1:1 
1:1 
1:1 
1:1 
1:1 
1:1 
1:1 
1:1 
1:1 
1:1 
1:1 
1:1 
~" —rr— 
Microwave 
Equipment 
Multimode 
Multimode 
Multimode 
Multimode 
Multimode 
Multimode 
Multimode 
Multimode 
Multimode 
Multimode 
Multimode 
Multimode 
Power*^  
(%) 
60 
60 
60 
100 
100 
100 
60 
60 
60 
100 
100 
100 
Time'' 
(minutes) 
7 
7 
8 
8 
8 
9 
7 
8 
8 
10 
12 
12 
Product 
3a 
3b 
3c 
3d 
3e 
3f 
3g 
3h 
3i 
3j 
3k 
31 
Yield' 
(%) 
92 
92 
92 
89 
90 
89 
90 
91 
90 
89 
89 
88 
(a) All reactions were carried out using fatty acid hydrazides (leq) with respect to 1,3-diketone 
under microwave irradiation. 
(b) Microwave equipment multimode was used. 
(c) Full power is 1.35 kHz. 
(d) Monitored by TLC. 
(e) All yields refer to isolated products and the products were characterized by IR, 'HNMR, 
'^CNMR, MS and elemental analysis. 
'H N M R spectrum of 3-(heptadec-8-enyl)-5,6-dimethyl-l,2,4-triazine 3d 
showed characteristic signal of triplet for two hydrogens at 6 2.77 for methylene 
protons alpha to triazine ring.and multiplet of two hydrogens at 1.63 for -CH2 P to 
ring. The structure of 3d was further supported by its mass spectral studies, which 
showed molecular ion peak at m/z 345 consistent with its molecular formula 
C15H25N3. Base peak appears at m/z 108. Detailed spectra of titled compounds are 
given in the experimental section. 
To check the biological activity of the compounds, the series of the compounds 
(3a-l) were screened for the antimicrobial activity against bacteria (e.g. Escherichia 
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coli, Staphylococcus aureus, Bacillus subtilis, Salmonella typhimurium), fungus 
(Penicillium sp, Helminthosporum oryzae, Aspergillus niger) and Candida albicans. 
The results are shown in Table 6.3 and Table 6.4. The compounds showed good 
activity against H. oryzae, S. aureus, E. coli and better results were obtained against 
C. albicans, Penicillium, A. niger. The moderate activity of compounds was observed 
against S. typhimurium and B. subtilis. 
Table 6.3 In vitro antibacterial activity of3,5,6-trisubstituted-l,2,4-triazines 
S.No. 
3a 
3b 
3c 
3d 
3e 
3f 
3g 
3h 
3i 
3j 
3k 
31 
Control DMF 
Chloroamphenicol 
E.coli 
+ + 
+ + 
-H-
+ + 
+ 
+ 
+ + 
+ + 
+ + + 
+ + 
+ 
+ + 
— 
+ + + 
B.subtilis 
+ 
+ 
+ + 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
— 
+ + + 
S. aureus S.typhimurium 
+ + + 
+ + + 
+ + 
+ + 
+ + 
+ + 
+ + 
+ + 
+ + 
+ + 
+ + 
+ + 
— 
+ + + 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
• + 
+ 
+ 
+ 
— 
+ + + 
Table 6.4 In vitro antifungal activity of3,5,6-trisubstituted-l,2,4-triazines 
S. No. C. albicans 
3a 
3b 
3c 
3d 
3e 
3f 
3g 
3h 
3i 
3j 
3k 
31 
Control DMF 
Nystatin 
+++ 
+++ 
+++ 
+++ 
+++ 
+++ 
+++ 
++ 
++ 
++ 
+ 
+ 
..^. 
+++ 
Penicillium 
+++ 
+++ 
+++ 
++ 
++ 
++ 
++ 
++ 
+++ 
+ 
+ 
+ 
— 
+++ 
sp A. niger 
++ 
+++ 
+++ 
+++ 
+++ 
++ 
++ 
++ 
++ 
-H-
++ 
++ 
+++ 
H. oryzae 
++ 
+++ 
+++ 
+++ 
++ 
• H -
++ 
++ 
++ 
++ 
++ 
++ 
-H-+ 
Zone of diameter of of growth inhibition: Zone of diameter of growth inhibition; <10 mm (-), 10-12 
mm (+), 13-15 mm (++), 16-20 mm (+++). 
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6.4 Experimental 
The sources of all the fatty acids and instrumentation details are the same as 
given in Chapter 1 (page 38). The microwave irradiations were carried out using an 
unmodified domestic oven (LG, Model MC-808WAR, 1.35 KW, 2450MHz). 
General procedure for the synthesis of3,5,6-trisubstituted-l,2,4-triazines (3a-I) 
The hydrazides of corresponding fatty acids were prepared as reported earlier 
in Chapter 2 (page 38)^ .^ A mixture of fatty acid hydrazide la-f (2mmol), diketone 
2a-b (2mmol) and silica gel was ground with a pestle, NH4OAC and EtsN were added 
in catalytic amount and the prepared mixture was introduced into microwave 
irradiation in open pyrex beaker for appropriate time (Table 6.2). After complete 
conversion as indicated by TLC, the mixture was extracted with petroleum ether and 
washed with water. Then the solvent was extracted in vacuum and the product was 
purified by column chromatography (Hexane:EtOAc, v:v) 3a, (99:1); 3b, (99:1); 3c, 
(99:1), 3d, (98:2); 3e, (98:2); 3f, (98:2), 3g, (99:1); 3h, (99:1); 3i, (99:1); 3j, (98:2); 
3k, (97:3); 31, (97:3). 
A ntibacterial A ctivity 
The newly synthesized compounds were screened in vitro against an assortment of S. 
aureus MSSA 22, B. subtilis ATCC 6051, E. coli K12 and 5". typhimurium MTCC 98. 
Screening results are summarized in Table 6.3. All the synthesized compounds were 
dissolved in DMF. The antibacterial activity of test compounds and standard 
chloramphenicol was done by filter paper disc method . Media with DMF was set up 
as control. 
Antifungal Activity 
The standard agar disc diffusion method" was performed to evaluate the antifungal 
property of the test compounds and standard nystatin. The newly synthesized 
compounds were screened for A. niger (lab isolate), C. albicans IOA-109, Penicillium 
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sp. (lab isolate) and H. oryzae (2537 ICAR, Jaipur). The synthesized compounds were 
dissolved in DMF. Media with DMF was set up as control. 
Spectroscopic data 
3-Pentadecyl-5,6-dimethyl-l,2,4-triazine (3a) 
IR (KBr): 2930,2859,1594,778 cm"'. 
'HNMR (400 MHz, CDCI3): 5 2.88 (t, 2H, J - 6.84 Hz, -CH2 a to ring), 2.35 (m, 6H, 
ring CH3), 1.62 (m, 2H, -CH2 p to ring), 1.28 (br.s, 24H, chain CHi), 0.88 (3H, dist.t, 
CHs). 
'^C NMR (100 MHz, CDCI3): 178.71, 176.77, 174.62, 34.62, 33.99, 31.64, 29.32, 
28.01,25.47,23.42,14.17. 
MS{m/z, %): (M+1)^ 320 (12), M^ 319 (42), 150 (18), 136 (20), 122 (55), 108 (100). 
Anal: Calcd. for C20H37N3: C, 75.23; H, 11.59; N, 13.16. Found: C, 75.16; H, 11.60; 
N, 13.20%. 
3-Heptadecyl-5,6-dimethyl -1,2,4-triazine (3b) 
IR (KBr): 2930,2860,1590, 770 cm''. 
'HNMR (400 MHz, CDCI3): 5 2.80 (t, 2H, J= 6.80 Hz, -CH2 a to ring), 2.35 (m, 6H, 
ring CH3), 1.63 (m, 2H, -CH2 P to ring), 1.28 (28H, br.s, chain CH2), 0.88 (3H, dist.t, 
CHs). 
'^CNMR (100 MHz, CDCI3): 180.10, 179.41, 177.09, 34.09, 31.95, 29.42, 24.71, 
22.72,14.15. 
MS (m/z, %): (M+1)^ 348 (10), M^ 347 (32), 330 (66), 232 (36), 122 (48), 108 (100). 
Anal: Calcd. for C22H41N3: C, 76.08; H, 12.10; N, 11.81. Found: C, 76.11; H, 12.13; 
N, 11.89%. 
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3-(Dec-9-enyl)-5,6-dimethyl-l,2,4-triazine{ic) 
IR (KBr): 2928, 2866, 1580, 775 cm'. 
'HNMR (400 MHz, CDCI3): 5 5.82 (IH, tdd, J„_.CH,^ 6.6 Hz, J//_^^ = 10.2 Hz, 
JH^H^ 17.1 Hz, CH2=C//-), 5.02 (IH, dd, J«^_//= 10.2 Hz, JH^^H^= 1.2 Hz, 
//zC=CH-), 4.90 (IH, dd, J„^_fj = 17.1 Hz, J«^_/,^= 1.2 Hz, HEC=CH-), 2.80 (t, 
2H, J = 6.8 Hz, -CH2 a to ring), 2.36 (m, 6H, ring CH3), 2.03 (m, 2H, -CH2-
CH-CH2), 1.63 (m, 2H, -CH2 P to ring), 1.29 (br.s, lOH, chain CH2). 
^^CNMR (100 MHz, CDCI3): 180.64, 179.76, 178.45, 139.19, 114.22, 34.02, 29.15, 
24.72. 
MS (m/z, %): (M+l)^248 (15), M^ 247 (35), 220 (24), 139 (74), 108 (100). 
Anal: Calcd. for C15H25N3: C, 72.87; H, 10.12; N, 17.00. Found: C, 72.99; H, 10.16; 
N, 17.12% 
3-(Heptadec-8-enyl)-S,6-dimethyl-l,2,4-triazine{3d) 
IR (KBr): 2930,2856,1585, 775 cm"'. 
'HNMR (400 MHz, CDCI3): 5 5.35 (m, 2H, -CH=CH-), 2.77 (t, 2H, J = 6.52 Hz, -
CH2 a to ring), 2.34 (m, 6H, ring CH3), 2.03 (m, 4H, -Ci/2-CH=CH-C//2-), 1-63 (m, 
2H, -CH2 P to ring), 1.30 (br.s, 18H, chain CH2), 0.88 (3H, dist.t, CH3). 
'^CNMR (100 MHz, CDCI3): 179.76, 176.77, 174.37, 130.01, 129.72, 44.37, 34.00, 
31.64,29.39,27.13,25.54,24.74,14.17. 
MS {m/z, %): (M+1)* 346 (23), M^ 345 (75), 330 (63), 232 (46), 122 (29), 108 (100). 
Anal: Calcd. for C22H39N3: C, 76.52; H, 11.30; N, 12.17. Found: C, 76.50; H, 11.33; 
N, 12.19% 
3-f(8Z, llR)-ll-Hydroxyheptadec-8-enylJ-5,6-dimethyl-I,2,4-triazine(ie) 
IR (KBr): 2940,2866,1580, 778 cm"'. 
'HNMR (400 MHz, CDCI3): 8 5.38 (m, 2H, -C//=C//-), 3.64 (m, IH, -C//OH), 2.88 
(t, 2H, J = 6.82 Hz, -CH2 a to ring), 2.30 (m, IH, -CUOH), 2.21 (m, 6H, ring CH3), 
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2.03 (m, 4H, -C//2-CH=CH-C//2-), 1.54 (m, 2H, -CH2 p to ring), 1.37 (br.s, 18H, 
chain CH2), 0.88 (3H, dist.t, C//3). 
'^CNMR (100 MHz, CDCI3): 178.73, 177.0, 175.02, 127.98, 127.83, 77.67, 37.05, 
34.63,32.41,29.16,24.29,14.15. 
MS {m/z, %): (M+l)^362 (12), M^ 361 (24), 276 (82), 136 (78), 122 (64), 108 (108). 
Anal: Calcd. for C22H39 N3O: C, 73.13; H, 11.63; N, 10.80. Found: C, 73.11; H, 11.70; 
N, 10.89% 
3-[(8R, llZ)-8-Hydroxyheptadec-ll-enyl]-5,6-dimethyl-l,2,4-triazine{^f) 
IR (KBr): 2930,2859,1594, 778 cm-'. 
'HNMR (400 MHz, CDCI3): 8 5.38 (m, 2H, -CH=CH-), 3.64 (m, IH, -C//OH), 2.83 
(t, 2H,J= 6.82 Hz, -CH2 a to ring), 2.24 (m, 6H, ring CH3), 2.31 (m, IH, -CHOH), 
2.04 (m, 4H, -C//2-CH=CH-C//2-), 1.63 (m, 2H, -CH2 p to ring), 1.36 (br.s, 18H, 
chain CH2), 0.88 (3H, dist.t, CH3). 
'^CNMR (100 MHz, CDCI3): 178.71,176.77,174.62,130.04,129.67,127.86, 71.67, 
37.06, 34.60, 33.98,31.64,29.28,24.29,14.50. 
MS (m/z, %): (M+l)*362 (14), M* 361 (78), 236 (32), 136 (62), 122 (18), 108 (100). 
Anal: Calcd. for C22H39N3O: C, 73.13; H, 11.63; N, 10.80. Found: C, 73.19; H, 
11.80; N, 10.99%. 
3-Pentadecyl-S,6-diphenyl-l,2,4-triazine(3g) 
IR (KBr): 2930,1590,2860, 770 cm-'. 
'HNMR (300 MHz, CDCI3): 5 7.53-7.26 (m, 10 H, Ai-H), 2.52 (t, 2H, J = 7.2Hz, 
-CH2 a to ring), 1.96 (m, 2H, -CH2 p to ring), 1.47 (br.s, 18H, chain CHj), 0.88 (3H, 
dist.t, C//j). 
'^CNMR (100 MHz, CDCI3): 180.33, 179.76, 178.45, 134.94, 133.04, 129.51, 34.15, 
31.98,29.45,23.74,14.17. 
MS (m/z, %): (M+1)^ 444 (9), M^ 443 (12), 428 (82), 260 (80), 246 (34), 232 (100). 
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Anal: Calcd. for C30H41N3: C, 81.26; H, 9.25; N, 9.48. Found: C, 81.30; H, 11.70; N, 
9.09%. 
3-Heptadecyl-5,6-diphenyl-l,2,4-triazine (3h) 
IR (KBr): 2930, 2859, 1594, 778 cm"'. 
'HNMR (300 MHz, CDCI3): 5 7.53-7.26 (m, 10 H, Ai-H), 2.52 (t, 2H J = 6.9Hz, -
CH2 a to ring), 1.96 (m, 2H, -CH2 p to ring), 1.47 (br.s, 28H, chain C//2), 0.88 (3H, 
dist.t, CH3). 
'^CNMR (100 MHz, CDCI3): 180.10, 179.76, 173.83, 134.92, 133.01, 129.49, 34.09, 
31.95,29.42,23.71,14.15. 
MS (m/z, %): (M+l)^470 (12), M^471 (28), 456 (39), 260 (44), 246 (26), 232 (100). 
Anal: Calcd. for C32H45N3: C, 81.52; H, 9.55; N, 8.91. Found: C, 81.30; H, 9.66; N, 
8.70%. 
3-(Dec-9-enyl)-5,6-diphenyl-l,2,4-triazine (3i) 
IR (KBr): 2933,2856,1580, 776 cm-'. 
'HNMR (300 MHz, CDCI3): 8 8.03-7.25 (m, 10 H, Ar-/f), 5.82 (IH, tdd, J^ ,^ .^ ^ = 
6.6 Hz, J„_„,^ = 10.2 Hz, Jn_n^=\l.\ Hz, CH2=C//-), 5.02 (IH, dd, J„,^_„ = 10.2 
Hz, JH^^„^= 1.2 Hz,//zC=CH-),4.90(IH, dd, J„^_„ - 17.1 Hz, J„^,_„^ = 1.2 Hz, 
//£C=CH-), 2.81 (t, 2H, J = 7.6Hz, -CH2 a to ring), 2.02 (m, 2H, -C//2-CH=CH2), 
1.68 (m, 2H, -CH2 p to ring), 1.29 (br.s, lOH, chain CH2), 
'^CNMR (100 MHz, CDCI3): 178.71,176.77,174.62,130.56, 130.47,128.78, 
34.62, 33.99, 31.64,28.88,24.30. 
MS {m/z, %): (M+1)^ 374 (13), M^ 373 (35), 346 (66), 260 (70), 246 (82), 232 (100). 
Anal: Calcd. for C25H29N3: C, 80.42; H, 8.31; N, 11.26. Found: C, 80.36; H, 8.39; N, 
11.22%. 
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3-(Heptadec-8-enyl)-5,6-diphenyl-l,2,4-triazine(3]) 
IR (KBr): 2933, 2855, 1580, 770 cm-'. 
'HNMR (300 MHz, CDCb): 6 7.85-7.33 (m, 10 H, Av-H), 5.35 (m, 2H, -CH=CH-), 
2.79 (t, 2H, J = 7.2 Hz, -CH2 a to ring), 2.02 (m, 4H, -C//2-CH=CH-C//2-), 1.73 (m, 
2H, -CH2 P to ring), 1.26 (br.s, 20H, chain CHj), 0.88 (3H, dist.t, CH3). 
'^CNMR (100 MHz, CDCI3): 180.33, 178.95,176.77, 134.94, 133.04, 129.51, 34.15, 
31.98,29.45,23.74,14.17. 
MS" {m/z, %): (M+l)^470 (8), M^ 469 (48), 356 (15), 260 (38), 246 (23), 232 (100). 
Anal: Calcd. for C32H43N3: C, 81.87; H, 9.16; N, 8.95. Found: C, 81.36; H, 9.39; N, 
8.82%. 
3-f(8Z,llR)-ll-Hydroxyheptadec-8-enylJ-5,6-diphenyl-l,2,4-triazinei3k) 
IR (KBr): 2930,2850,1585, 776 cm-'. 
'HNMR (300 MHz, CDCI3): 6 8.03-7.21 (m, 10 H, Ai-H), 5.36 (m, 2H, -CH=CH-), 
3.89 (m, IH, -CHOE), 2.61 (t, 2H, J = 7.5 Hz, -CH2 a to ring), 2.27 (m, IH, -CHOH), 
2.04 (m, 4H, -C//2-CH-CH-C//2-), 1.51 (m, 2H, -CH2 p to ring), 1.25 (br.s, 18H, chain 
CH2), 0.86 (3H, dist.t, CH3). 
'^CNMR (100 MHz, CDCI3): 178.71, 177.09, 175.06, 130.56, 130.47, 128.78, 71.67, 
37.06, 34.30, 31.64,28.88,24.30,14.15. 
MS {m/z, %): (M+1)^ 486 (22), M^ 485 (38), 400 (28), 260 (44), 246 (23), 232 (100). 
Anal: Calcd. for C32H43N3O: C, 79.17; H, 8.86; N, 8.65. Found: C, 79.20; H, 8.89; N, 
8.60 %. 
3-[(8R,llZ)-8-Hydroxyheptadec-ll-enyl]-S,6-diphenyl-l,2,4-triazme{3\) 
IR (KBr): 2940, 2866, 1585, 778 cm-'. 
'HNMR (300 MHz, CDCI3): 8 7.35-7.00 (m, 10 H, Ar-H), 5.46 (m, 2H, -CH=CH-), 
3.91 (m, IH, -C//OH), 2.54 (t, 2H, J = 7.5 Hz, -CH2 a to ring), 2.36 (m, IH, -CHOH), 
2.02 (m, 4H, -C//2-CH=CH-C//2-), 1.73 (m, 2H, -CH2 p to ring), 1.38 (br.s, 18H, chain 
C//2), 0.88 (3H, dist.t, CH3). 
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'^CNMR (100 MHz, CDCI3): 178.71, 176.77, 174.62, 130.56, 130.47, 128.78, 71.67, 
37.06, 34.60, 33.96, 31.68,28.90,24.29,14.50. 
MS (m/z, %): (M+1)^ 486 (24), M^ 485 (34), 360 (56), 260 (67), 246 (82), 232 (100). 
Anal Calcd. for C32H43N3O: C, 79.17; H, 8.86; N, 8.65. Found: C, 79.16; H, 8.90; N, 
8.59 %. 
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Jsoxazoles and triazoles 
7.1 Theoretical 
The ever increasing demand for novel medicinally active compounds and the 
laborious process of lead discovery and optimization have resulted in the continuous 
search for simple and efficient compounds containing such useful scaffolds. Isoxazole 
derivatives have been reported to possess interesting biological activities and 
pharmacological activities such as analgesic, anti-inflammatory and hypoglycemic ' . The 
alkoxy carbonyl isoxazoles derivatives showed marked action as a diuretic^ Also, alkoxy 
carbonyl isoxazoles are important precursors for the synthesis of other compounds such 
as agrochemicals and microbicides''. In addition, 4,5-dihydroisoxazoles are recognized as 
useful intermediates in organic synthesis. For example they can be converted into various 
important synthetic units such as P-hydroxy ketones^, y-amino alcohols^, P, y-unsaturated 
ketones'' and P-hydroxy nitriles*. 
1,2,3-triazoles derivatives have received much attention because of their wide 
range of applications^ and biological activities such as anti-HIV'°, antimicrobial agents", 
P3- adrenergic receptor agonist and are important five-membered nitrogen heterocycles 
involved in a wide range of industrial applications'^ 1,3-Dipolar cycloaddition of azides 
and alkynes is one of the most useful method for the synthesis of 1,2,3-triazoles. 
Galactosides and lactosides bearing isoxazoles (iii), regiospecifically prepared by 
GigueVe et al}'^ by [l,3]-dipolar cycloadditions between alkynes (i), azides or nitrile 
oxides, provided specific galectin-1 and -3 inhibitors with potencies as low as 20 //M 
(Scheme 7.1). 
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^OAc 
AcO 
-j- O N ^ R O3, MeOH 
(MeO)2P(0)CHN2C(0)CH3, Na2C03, MeOH, 
AC2O 
H,C 
(i) (H) (Hi) 
Scheme 7.1 
1,3-Dipolar cycloaddition reactions of carbohydrate dipolarophiles (iv) with 
cerium (IV) ammonium nitrate CAN (IV) in acetone, acetophenone, or pinacolone 
yielded the corresponding 3,5-disubstituted-isoxazoles (v), stable pharmacophores for 
glycomimetic syntheses'^ (Scheme 7.2). 
OAc OAc 
H3C-~.\^^oO\ 
(iv) 
OAc OAc 
(V) 
Scheme 7.1 
Heteropolyanions (HPA) with different structures, including Keggin, Dawson, 
Preyssler, mixed addenda, and sandwich types, catalyzed the formation of 1,3- diphenyl-
isoxazole (viii) from the condensation of I,3-diphenyl-propane-l,3-dione (vi) and 
hydroxylamine hydrochloride (vii) in different solvents and under heating conditions 
(Scheme 7.3). The study indicates that H3PW11CUO40 is the catalyst of choice and could 
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selectivities'^. 
11 1 + NH.OH HPA 
R ^ ^ ^ R , 
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in high yields and good 
Ri 
(vi) (vii) (viii) 
Scheme 7.3 
The one-pot synthesis of 5-carboxyisoxazoles (x) from the cyclocondensation of 
P-alkoxyvinyl trichioromethyl ketones (ix) [CCl3C(0)C(R2)=C(Ri)OR, where Ri, R2=H, 
Me and R=Me, Et] and 2-trichloroacetyl cyclohexanone with hydroxylamine is 
reported'^. This work shows that the trichioromethyl group attached to p-alkoxyvinyl 
trichioromethyl ketones (a heterocyclic CCC building block) is an excellent carboxyl 
group precursor (Scheme 7.4) 
OR NHjOH. HCl, cone. H^SO^ 
R^OH, reflux, 8-12 h 
^. 
65-95 % 
(ix) (X) 
Scheme7.4 
A practical and efficient liquid-phase synthesis of 3,4,5-trisubstituted isoxazoles 
using poly(ethylene glycol) as support is described. Soluble polymer- supported nitrile 
oxide generated in situ reacted with chalcones to afford polymer-supported isoxazolines 
(xvi) which were cleaved by sodium methoxide to generate 3,4,5-trisubstituted 
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isoxazoles (xvii) (Scheme 7.5). This sequential process provided a novel method to 
synthesize 3,4,5-trisubstituted isoxazoles. 
"-0^° 
DCC, cat DMAP ">^-° 
NH,OH IICI 
» 
CI.N r\ 
(xi) (rii) (xiii) 
f\ 
N—OH 
(xiv) 
Scheme 7.5 
3-Hydroxy benzofuran substituted-isoxazoles (xx) were synthesized by Swamy 
and Agasimundin'^ by the reaction of 2-acetyl-3-hydroxybenzofuran (xviii) with different 
aromatic aldehydes in the presence of strong base, which undergoes cyclocondensation 
with hydroxylamine hydrochloride (Scheme 7.6). 
CH3 R. 
^ n^ 
NaOH 
= \ NHjOH. HCI 
(xviii) (xix) (XX) 
Scheme 7.6 
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7.2 Synthesis of Novel 3,5-Disubstituted-dihydroJsoxazoles, 
Isoxazoles, Triazole and Triazolo-tetrazole from Methyl undec-10-
enoate and Methyl undec-10-ynoate 
The azole ring has also attracted considerable attention in the design of 
biologically active molecules and advanced organic materials since it can be readily 
transformed into various bioactive agents^°. From this point of view, isoxazole appears 
well suited possessing three positions to be exploited for diversity. This scaffold (and the 
related isoxazoline) represents a pharmacophore itself as it has been observed in several 
substances showing activity against a broad range of therapeutic targets. Several methods 
have been reported for the synthesis of isoxazoles '^• '^'. The reaction of dipolarophiles 
(alkene and alkyne) with cerium (IV) ammonium nitrate, Ce(NH4)2(N03)6, in different 
ketones under reflux gave isoxazole derivatives containing alkoxy carbonyl. CAN (IV) 
has been used for a variety of oxidative transformations including a-nitration of ketones 
to nitrile oxides under acidic conditions. 
The synthesis of heterocyclic moieties from fatty acids under various conditions 
has been reported earlier^ .^ To further extend efforts towards this goal, the synthesis of 
isoxazole, bis-isoxazole, triazole and triazolo-tetrazole compounds from methyl undec-
10-enoate and methyl undec-10-ynoate utilizing CAN (IV) is described. 
7.3 Results and discussion 
In this chapter, the straightforward synthesis of 3,5-disubstituted-
dihydroisoxazoles possessing ester moiety by one-pot process is reported. The 
cycloaddition of dipolarophiles- methyl undec-10-enoate (1) and methyl undec-10-ynoate 
(4) with CAN (IV) and several ketones 2 under reflux gave the corresponding isoxazoles 
efficiently. On refluxing, 1 and CAN (IV) in acetone as solvent 3-acetyl-4,5-
dihydroxazole (3a) was obtained in appreciable yield (Scheme 7.7) (Table 7.1). Beside 
bands for normal fatty ester bond, IR spectra of 3a showed strong absorption bands at 
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1640 (C=N), 1587 (C-0) cm''. In 'H N M R spectrum appearance of signal at 8 3.14 
attributed to one methyne proton of dihydroisoxazole ring. The product formation 3a was 
further strengthened by characteristic signal in '^ C NMR at 167.98 and 66.71 for C-3 and 
C-5 respectively. When 2-chloro-3-butanone (2c) and alkenoate 1 was used in ratio of 2:1 
3c was obtained in 78% yield. The bis-isoxazole 3d was obtained in 70% yield as 
cycloaddition product of alkenoate 1, 1,4-diacetylbenzene (2d) and CAN (IV) in 
dichloromethane as solvent. The compound 3d was characterized by IR bands at 1657 
(C=N) and 1584 (C-0) cm"'. The M^ at 612 in mass spectrum and '^ C NMR values at 
168.45 and 65.78 for C-3 and C-5 establish the structure of 3d. The 'H NMR, mass 
spectra and elemental analysis data further support the synthesis. 
H j C ; ^ 
^•^^°^-' IK 
R = 2a, -CH3, 2b, -CsHs, 2c, -CHCI-CH3 
2d, -C6H4COCH3 
Scheme 7.7 Synthesis of3,S-disubstituted-dihydroisoxazoles and bis-isoxazole 
Moreover, in similar reactions using methyl undec-10-ynoate (4) and CAN (IV) in 
acetophenone the corresponding isoxazoles 5b was obtained (Scheme 7.8). On refluxing, 
4 and CAN (IV) in acetone as solvent 3-acetyl-4,5-isoxazole (5a) was obtained in 
appreciable yield (Table 7.1). The compound 5c was obtained in appreciable yield on 
refluxing 2-chloro-3-butanone (2c) and alkynoate 4 for 18 hours. The bands at 1642 
(C=N), 1590 (C-0) cm"' in IR and 8 5.41 for single proton of ring and signals at 148.12, 
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109.45, 158.85 in '^ C NMR established the structure of 5c. The IR spectra of 5d showed 
strong absorption bands at 1658 (C=N), 1585 (C-0) cm"'. The 'H NMR spectra peak at 5 
5.39 and '^ C NMR signal at 150.01, 105.54 and 158.45 for C-3, C-4 and C-5 support the 
formation of bis-isoxazole. The structure of 5d was further established by its mass 
spectral studies, which showed molecular ion peak at m/z 608 consistent with its 
molecular formula C34H44N2O8. 
H C ^ O . <-5^' 
6 II ^ H j C ^ ^ R 
0 
2a-d 
Scheme 7.8 Synthesis of 3,5-disubstituted-isoxazoles and bis-isoxazole 
Table 7.1 3,5-Disubstituted'isoxazoles 
Entry 
1 
2 
3 
4 
5 
6 
7 
8 
Dipolarophile 
1 
1 
I 
1 
4 
4 
4 
4 
Ketone (2a 
2a 
2b 
2c 
2d 
2a 
2b 
2c 
2d 
-d) Time (h) 
14 
16 
17 
19 
17 
18 
18 
20 
Product 
3a 
3b 
3c 
3d 
5a 
5b 
5c 
5d 
Yield {%) 
86 
80 
77 
70 
80 
76 
70 
72 
To enrich the scanty field of heterocycles from fatty acids by the synthesis of 
novel triazoles from medium-chain terminal alkyne fatty acid is carried out. The 
cycloaddition of azidoacetonitrile (6) with terminal alkyne gave corresponding triazole 7 
which on further reaction with sodium azide and ammonium chloride in DMF gave 
tetrazole 8 (Scheme 7.9). The 'H NMR value at 8 6.99, 4.09 was obtained for single 
proton at ring and -CH2CN respectively. The characteristic signals in CNMR at 8 
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139.01 (C-4), 133.56 (C-5), 114.14 (C-2"), 44.71(C-1") established the formation of 
triazole 7. The formation of tetrazole ring in compound 8 was exhibited by additional 
peak of (N-H) at 3381 cm'. The 'H NMR, '^CNMR, elemental analysis and mass spectral 
data further proved the synthesized compound. 
NC 
HC::^ 
•^ CHj + N,CH,CN 
.CH, 
\ ^ N 
Scheme 7.9 Synthesis ofl-cyanomethyl-4-(carbometho:qoctyl))-l,2,3-triazole and 
[l-(lH-tetrazol-5-yl-methyl)-4-carbomethoxyoctyl]-(l,2,3)-triazole 
One more representative of 1,2,3-tria2ole 10 was synthesized in appreciable yield 
by utilizing dipolarophile 4, benzyl chloride 9, sodium azide in DMF (Scheme 7.10). The 
synthesis of all the newly synthesized compounds was fully supported by mass spectral 
data and elemental analysis. The detailed spectra are given in experimental section. 
nc.$t- CH 
'3 + 
10 
Scheme 7.10 Synthesis ofl-benzyl-4-(carbomethoxyoctyl)-I,2,3-triazole 
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7.4 Experimental 
The source of undec-10-enoic acid and instrumentation details are the same as 
given in Chapter 1 (page 38). 
General procedure for the synthesis of3,5-disubstituted-dihydroisoxazole (3a-c) 
A mixture of methyl undec-10-enoate 1 (0.6 mmol) and ammonium cerium (IV) nitrate 
(0.6 mmol) in ketone (2a-b) (5 ml) was stirred under reflux for appropriate time. For the 
synthesis of 3d, alkenoate 1(0.6 mmol), diacetylbenzene 2d (1.2 mmol) and cerium (IV) 
ammonium nitrate (0.6 mmol) in CH2CI2 (5 ml) was stirred under reflux for 19 hours. 
The formation of product was analyzed by thin layer chromatography. The mixture was 
extracted with Et20 (10 x 3 ml) and washed with 10% aq. NaHCOa solution (2x2 ml), 
saturated aqueous NaCl ( 2 x 2 ml) and water. The ethereal solution was dried over 
anhydrous Na2S04 and concentrated in vacuum. The resulting oily crude product was 
further purified by column chromatography. 
Preparation of methyl undec-10-ynoate (4) 
To an acid solution of commercial 10-undecenoic acid (0.022 mole) in CCI4 (15 ml), 
bromine (O.OlSmole), was added dropwise. When the addition was over, the mixture was 
stirred for 3 hours and left overnight. Distillation of CCI4 and work up with Et20 
furnished 10, 11-dibromoundecanoic acid as a thick viscous liquid. Dibromide, KOH, 
water, ethanol were taken in a flask and refluxed for 10 hours. Most of the alcohol was 
removed under vacuum. The product was dissolved in water, acidified with cold dil. 
H2SO4, extracted with Et20. The extracts were washed with water and dried over 
anhydrous Na2S04 and concentrated in vacuum. The removal of solvent yields the 
product which was recrystallized from petroleum-ether. (M.p. 41-42 °C)^ .^ The acetylenic 
acid was esterified with dimethyl metherate to form methyl undec-10-ynoate 4. 
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General procedure for the synthesis of 3,5-disubstituted-isoxazole (5a-c) 
A mixture of alkynoate 4 (0.6 mmol) and CAN (IV) (0.6 mmoO in ketone (2a-b) (5 ml) 
was stirred under reflux for appropriate time. The 5d was obtained on refluxing 4 
(0.6mmol), CAN (IV) (0.6 mmol) and 2d (1.2 mmol) in CH2CI2 for 20 hours. The 
progress of reaction was monitored by thin layer chromatography. The mixture was 
extracted with EtaO and washed with aqueous 10% NaHCOs solution ( 2 x 2 ml), 
saturated aqueous NaCl ( 2 x 2 ml) and water. The ethereal solution was dried over 
anhydrous Na2S04 and concentrated in vacuum. The resulting oily crude product was 
further purified by column chromatography. 
Procedure for the synthesis of azidoacetonitrile (6) 
To an emulsion chloroacetonitrile (0.7 mmol) in 10 ml of water was added NaNs (0.8 
mmol) at vigorous stirring, and the mixture was slowly heated to 70°C then the reaction 
mixture was refluxed at 80-85°C for 2 hours. Then it was cooled to 20-25°C and poured 
into 5.ml EtOAc. The organic layer was separated, the water layer was extracted with 
EtOAc, and the extract was dried on anhydrous Na2S04 and concentrated in vacuum. 
Synthesis of l-cyanomethyl-4-(carbomethoxyoctyl))-l,2,3-triazole (7) 
A mixture of alkynoate 4 (0.4 mmol) and azidoacetonitrile 6 (0.6 mmol) in 5 ml of 
alcohol was stirred under reflux for 10 hours and product formation was detected by 
TLC. The crude product was concentrated in vacuum and purified by column 
chromatography as viscous oily compound in 70% yield. 
Synthesis of fl-(lH-tetrazol-5-yl-methyl)-4-carbomethoxyociylJ-(J,2,3)-triazole(S) 
A suspension of 4.5 mmol of NaNaand 4.5 mmol of ammonium chloride was dissolved at 
stirring and heating in 5 ml of DMF, then the solution was cooled, and 4mmol of 
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compound 7 was added. The mixture was stirred for 20 hours at 120°C. The reaction 
mixture was cooled, the precipitate was filtered off, and the filtrate was evaporated in 
vacuum. The residue after removal was poured in water and wash with ether, acidified 
with HCI till the pH becomes 2, then the solution was extracted with EtOAc dried on 
anhydrous Na2S04 and concentrated in vacuum and obtained in 61% yield as yellow oily 
compound. 
Synthesis ofl-benzyl-4-(carbomethoxyoctyl)-l,2,3-triazole (10) 
The alkynoate 4 (0.4 mmol), benzyl chloride (0.4 mmol), and NaNs (0.5 mmol), was 
taken in 5 ml DMF and stirred under refluxing for 16 hours and product formation was 
detected by TLC. Then it was cooled to 20-25 °C and poured into 5 ml CHCI3 and wash 
with water. The organic layer was separated, and the extract was dried on anhydrous 
Na2S04 and concentrated in vacuum. The crude product was purified by column 
chromatography and obtained as oily liquid in 64% yield. 
Spectroscopic data 
3-Aceiyl-5-(carbomethoxyoctyl))-4,5'difiydroisoxazole(3a) 
IR(KBr): 1739, 1710, 1640, 1587 cm"'. 
'HNMR (400 MHz, CDCI3): 6 3.66 (s, 3H, -COOC//3), 3.14 (m, IH, -CH- ring), 2.35 (t, 
2H, C//2-COOCH3), 2.12 (s, 3H, COC//3), 1.97-1.19 (br.s 16H chain and ring CH2). 
'^CNMR (100 MHz, CDCI3): 196.95, 172.31, 167.98, 66.71, 50.37, 34.00, 31.86, 29.70, 
29.50, 29.22,27.13,24.85,24.62,14.15. 
MS{m/z, %): (M+1)^ 284 (14), (M )^ 283 (60), 224 (14), 209 (48), 210 (26), 168 (63). 
Anal. Calcd. for C,5H25N04: C, 63.59; H, 8.88; N, 4.94. Found: C, 63.01; H, 8.83; N, 
4.98. 
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3-Benzoyl-5-(carbomethoxyoctyl))-4,5-dihydroisoxazole{ib) 
//f(KBr): 1740, 1712, 1655, 1580 cm"'. 
'HNMR (400 MHz, CDCI3): 5 7.83 (m, 2H, Av-H), 7.51 (m, 3H, Kv-H), 3.67 (s, 3H, -
COOC//3), 3.14 (m, IH, -CH- ring), 2.33 (t, 2H, C//2-COOCH3), 1.66-1.21 (br.s 16H, 
chain and ring CH2). 
'^CNMR (100 MHz, CDCI3): 194.60, 172.46, 167.83, 134.92, 133.01, 129.93, 129.05, 
67.10, 50.62, 34.09, 31.95, 29.72,29.09,22.72, 14.17. 
MS (m/z, %): (M+lf 346 (30), (M )^ 345 (12), 286 (86), 258 (40), 244 (55), 174 (48). 
Anal. Calcd. for C20H27NO4: C, 69.55; H, 7.87; N, 4.05. Found: C, 69.98; H, 7.81; N, 
4.09. 
3-(2 '-Chloropropanoyl)-5-(carbometho)^octyl))-4,5-dihydroisoxazole (3c) 
M(KBr): 1738, 1715, 1667, 1590 cm"'. 
'HNMR (400 MHz, CDCI3): 5 4.39 (q, IH, C//-CI), 3.66 (s, 3H, -COOC//3), 3.16 (m, 
IH, -CH- ring), 2.34 (t, 2H, -C//2-COOCH3), 1.86-1.20 (br.s, 19H, chain, ring CH2 and -
CH3). 
'^CNMR (100 MHz, CDCI3): 196. 67, 172.43, 167.98, 66.78, 54.71, 50.62, 34.39, 33.82, 
29.74,29.27,28.92,14.16. 
MS {m/z, %): (M+1)^ 333 (13), (M*) 332 (58), 245 (72), 231 (20), 203 (36), 175 (61). 
Anal. Calcd. for C,6H26C1N04: C, 57.92; H, 7.89; N, 4.22. Found: C, 57.21; H, 7.85; N, 
4.27. 
Bis-(3-Benzoyl-5-(carbomethoxyoctyl))-4,5-dihydroisoxazole (3d) 
//?(KBr): 1745, 1715, 1657, 1584 cm"'. 
'HNMR (400 MHz, CDCI3): 6 7.64-7.49 (m, 4H, kx-H), 3.67 (s, 6H, -COOC7/3), 3.26 
(m, 2H, -CH- ring), 2.33 (t, 4H, -C//2-COOCH3), 1.92-1.13 (br.s 32H, chain and ring 
CH2). 
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'^CNMR (100 MHz, CDCI3): 196.95, 180.10, 172.76, 168.45, 134.92, 133.01, 129.93, 
129.05, 65.78, 52.62, 34.09, 31.95, 29.72, 29.09, 22.72, 14.19. 
MS (m/z, %): (M+1)* 613 (17), (M"") 612 (22), 524 (34), 488 (28), 392 (10), 178 (29). 
Anal. Calcd. for C34H48N2O8: C, 66.87; H, 7.59; N, 4.58. Found: C, 66.50; H, 7.55; N, 
4.62. 
3-Acetyl-5-(carbontethoxyociyl))-isoxazole (Sa) 
IR (KBr): 1742, 1720, 1662, 1590 cm-'. 
'HNMR (400 MHz, CDCI3): 5 5.44 (s, IH, -CH- ring), 3.66 (s, 3H, -COOC//3), 2.14 (s, 
3H, -CO-C//3), 2.32 (t, 2H, -C//2-COOCH3), 1.78-1.08 (br.s 14H, chain CH2). 
'^C NMR (100 MHz, CDCI3): 196.95, 171.92, 159.07, 149.77, 106.43, 52.51, 34.25, 
33.77,29.05,28.88,24.73, 14. 17. 
MS {m/z, %): (M+1)^282 (13), (M )^ 281 (37), 222 (18), 207 (70), 199 (14), 166 (26). 
Anal. Calcd. for C,5H23N04: C, 64.04; H, 8.23; N, 4.98. Found: C, 64.68; H, 8.29; N, 
4.95. 
3-Benzoyl-5-(carbomethoxyoctyl)-isoxazole {Sb) 
M(KBr): 1744, 1718, 1646, 1593, cm"'. 
'HNMR (400 MHz, CDCI3): 6 7.82 (m, 2H, Ar-i^, 7.49 (m, 3H, Ax-H), 5.31 (s, IH-C//-
ring), 3.66 (s, 3H, COOCT/j), 2.34 (t, 2H, -C//2-COOCH3), 1.92-1.14 (br.s, 14H, chain 
CH2). 
'^CNMR (100 MHz, CDCI3): 196.96, 172.74, 159.96, 147.95, 133.58, 129.90, 127.77, 
121.05, 117.81, 102.29,52.62,34.45,31.41,29.65,29.09,28.99,22.45, 14.16. 
MS {m/z, %): (M+1)^344 (18), (M )^ 343 (25), 284 (52), 269 (74), 200 (39), 172 (44). 
Anal Calcd. for C20H25NO4: C, 69.96; H, 7.33; N, 4.07. Found: C, 69.31; H, 7.38; N, 
4.03. 
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3-(2 '-Chloropropanoyl)-5-(carbomethoxyoctyl))-isoxazole (5c) 
IR{KBr): MAI, 1722, 1642, 1590cm"'. 
'HNMR (400 MHz, CDCb): 6 5.41 (s, IH, -CH- ring), 4.32 (q, IH, -C//-C1), 3.66 (s, 
3H, -COOC//3), 2.33 (t, 2H, -C//2-COOCH3), 1.80-1.25 (br.s 17H, chain CHzand -CH3). 
'^C NMR (100 MHz, CDCI3): 189.20, 172.48, 158.85, 148.12, 109.45, 60.95, 37.22, 
34.12, 31.88, 29.16, 25.08, 23.13, 22.53, 14.76, 15.02. 
MS (m/z, %): (M+l)^331 (23), (M^) 330 (64), 256 (77), 242 (80), 186 (54), 158 (28). 
Anal. Calcd. for C16H24CINO4: C, 58.45; H, 7.35; N, 4.26. Found: C, 58.01; H, 7.39; N, 
4.21. 
Bis-(3-Benzoyl-5-(carbomethoxyociyl))-isoxazole(5d) 
//?(KBr): 1738, 1717, 1658, 1585 cm"'. 
'HNMR (400 MHz, CDCI3): 6 7.52-7.31 (m, 4H, Ar-H), 5.39 (s, 2H -Ci/ring), 3.66 (s, 
6H, COOC//3), 2.35 (t, 4H, C//2-COOCH3), 1.14 (br.s 28H, chain CH2). 
"CNMR (100 MHz, CDCI3): 190.21, 172.99, 158.45, 150.01, 134.66, 129.59, 128.32, 
105.54, 50.62, 33.31, 32.19, 29.7, 24.91, 15.13. 
MS (m/z, %): 609 ( M ^ l , 13), 608 (M )^ (88), 490 (49), 432 (88), 348 (67), 288 (72). 
Anal. Calcd. for C34H44N2O8: C, 67.09; H, 7.28; N, 4.60. Found: C, 67.56; H, 7.24; N, 
4.65. 
l-Cyanontethyl-4-(carbomeihoxyoctyl))-l,2,3-triazole{l) 
IR (KBr): 1740,1540 cm"'. 
'HNMR (400 MHz, CDCI3): 6 6.99 (s, IH, -C//ring), 4.09 (s, 2H, -C//2-CN), 3.66 (s, 
3H, -COOC//3), 2.34 (t, 2H, C//2-COOCH3), 2.51 (m, 2H, -CHjato ring), 1.23 (br.s, 12 
H, chain CHj). 
'^C NMR (100 MHz, CDCI3): 172.44, 139.01, 133.56, 114.14, 50.62, 44.71, 34.71, 
29.20,28.88,24.73. 14.01. 
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MS {m/z, %): (M+ir279 (23), (M )^ 278 (60), 219 (68), 204 (80), 191 (46), 121 (65). 
Anal. Calcd. for C14H22N4O2: C, 60.43; H, 7.96; N, 20.12. Found: C, 60.01; H, 7.92; N, 
20.17. 
[l-(lH-Tetrazol-S-yl-methyl)-4-carbomethoxyoctyl]-(l,2,3) triazole(S) 
/^(KBr):3381, 1745, 1538 cm-'. 
'HNMR (400 MHz, CDCI3): 5 8.31 (s, IH, N-/^, 6.89 (s, IH, -C//ring), 4.86 (s, 2H, 
C//2-Ar), 3.67 (s, 3H, COOC//3), 2.33 (t, 2H, C//2-COOCH3), 2.07 (m, 2H, -CH2 a to 
ring), 1.20 (br.s, 12 H, chain CHj). 
'^C NMR (100 MHz, CDCI3): 172.66, 144.31, 130.57, 130.49, 129.12, 128.53, 52.16, 
49.88, 37.22, 33.76, 31.88, 29.36, 25.68, 23.13. 15.12. 
MS (m/z, %): (M+1)^322 (17), (M^ 321 (30), 262 (49), 220 (66), 178 (38), 150 (33). 
Anal. Calcd. for C,4H23N702: C, 52.34.; H, 7.21; N, 30.49. Found: C, 52.71; H, 7, 26; N, 
30.01. 
l-Benzyl-4-(carbomethoxyoctyl)-l,2,3-triazole (10) 
/R(KBr): 1734, 1535 cm"'. 
'HNMR (400 MHz, CDCI3): 6 7.10-7.01 (m, 5H, kx-H), 6.88 (s, IH, -C//ring), 4.31 (s, 
2H, CH2-Ar), 3.67 (s, 3H, -COOC//3), 2.34 (t, 2H, Ci/2-COOCH3), 1.99 (m, 2H, -CH2 a 
to ring), 1.42 (br.s, 12 H, chain CHj). 
'^CNMR (100 MHz, CDCI3): 172.10, 141.80, 133.58, 129.90, 129.75, 127.89, 59.10, 
50.81, 33.76, 31.88, 29.36, 25.68, 23.13, 15.12. 
MS (m/z, %): (M+l)^330 (19), (M )^ 329 (47), 270 (67), 255 (79), 214 (41), 158 (26). 
Anal. Calcd. for C19H27N3O2: C, 69.28; H, 8.25; N, 12.75. Found: C, 69.70; H, 8.61; N, 
12.71. 
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